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Estrogen is a known risk factor for breast cancer and possible mechanisms of 
carcinogenesis may also be similar for various types of cancers. Estrogen is highly 
mitogenic in hormone-sensitive tissues, such as breast and uterus. Prolonged exposure 
of target tissues or cells to excessive mitogenic stimulation by estrogens has been 
considered an important etiological factor for the induction of estrogen-associated 
cancers. Thus, estrogens are considered to participate in tumor promotion. 
Estrogens have been reported to cause cancer through their genotoxic effects. 
Estradiol caused sister chromatids exchanges and chromosomal aberrations in human 
peripheral blood lymphocytes and metabolic activation enhanced these chromosomal 
lesions. The genotoxic effects of estradiol could result from accumulation of 
potentially carcinogenic metabolites. Estradiol undergoes cytochrome P-450-catalyzed 
hydroxylation to various catecholestrogens. 4-Hydroxyestradiol (4-OHE2) undergoes 
redox cycling during which free radicals such as superoxide and the chemically 
reactive estrogen semiquinone and quinone intermediates are produced. The estrogen 
quinone can react with DNA to form stable or depurinating adducts with the potential 
to cause mutations leading to tumorigenesis. Another mechanism by which mutations 
may be formed is by the free radicals generated during the metabolic redox cycling of 
catecholestrogens. 
2-Hydroxylation is a major pathway in the liver, whereas 4-hydroxylation 
dominates in extrahepatic organs susceptible to estrogen. 4-Hydroxyestradiol found to 
be more carcinogenic than 2-hydroxyestradiol (2-OHE2). This could be due to the fact 
that 2-OHE2 is more rapidly metabolized and excreted than 4-OHE2. 
Alterations in estrogen metabolism have been observed not only in 
carcinogenesis but also in systemic lupus erythematosus (SLE). SLE is a chronic 
inflammatory autoimmune disease characterized by the production of non-organ-
specific autoantibodies. Clinical consequences include renal failure, vasculitis, 
thrombosis and seizures and other neurologic complications. The female 
predominance of SLE and frequent exacerbation of disease during pregnancy or 
following oral contraceptive therapy strongly suggest the role of sex hormone 
(estrogen) in disease activity. In addition, increased 16 a-hydroxylation of estradiol 
have been reported in SLE patients. 
In the present study, plasmid pUC 18 was isolated and modified by synergistic 
action of 4-OHE2 and NO. The plasmid DNA was also modified with 4-OHE2 and 
Cu(II). Chemical alterations induced in plasmid DNA following modification weie 
studied by agarose gel electrophoresis, UV and fluorescence spectroscopy, circular 
dichroism, thermal denaturation, nuclease Si and restriction enzyme digestions. The 
damage to DNA by estrogen includes single and double strand breaks. 4-OHE2-NO-
DNA showed hyperchromicity at 260 nm as compared to native DNA, reflecting the 
presence of single stranded regions and alterations in the structure of DNA. 4-OHE2-
Cu(II)-DNA also showed mark increase in the absorbance at 260 nm as compared to 
native DNA. Decrease in ellipticity of the positive peaks in the CD spectra of the 
modified DNA reflected again generation of strand breaks in modified DNA. 
The Tm of 4-OHE2-NO-ctDNA was found to be 81.5 °C whereas ctDNA 
showed a Tm of 88 °C. 4-OHE2-Cu(Il)-ctDNA showed a Tm of 80.5 °C. A net 
decrease of 6.5 °C in the Tm value of 4-OHE2-NO-ctDNA and a net decrease of 7.5 
°C in the Tm value of 4-OHE2-Cu(lI)-ctDNA indicates alterations in the structure and 
single strand breaks in the modified DNA. Nuclease SI sensitivity assay fiirther 
substantiated the formation of single strand breaks. Estrogen modification includes 
DNA bases modification, which was, quantified by ion exchange chromatography on 
DEAE Sephadex A-25. In the case of 4-OHE2-NO-DNA, all the four bases were found 
to be modified. Thymine was modified the most (46.9%), followed by guanine 
(42.6%), adenine (21%) and cytosine (16.6%). In case of 4-OHE2-Cu(lI)-DNA, the 
modificafion of thymine was to the maximum extent (47.1%). 
Results with various scavengers show that DNA damage induced by 4-OHE2 
and NO can be inhibited by carboxy-PTIO and sodium azide, indicating that 
generation of NO and 'O2 is involved in DNA modification. NO and 02*" readily 
react with each other to form peroxynitrite, which is also scavenged by uric acid. The 
inhibitory effects of catalase and bathocuproine on DNA modification by 4-OHE2-
Cu(II) demonstrate that H2O2 and Cu(I) participate in DNA modification. 
4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA were used to induce antibodies in 
rabbits and were found to be immunogenic, inducing high titre antibodies. The 
antigenic specificity of the induced antibodies was studied by competition ELISA. The 
immunogen showed a high degree of specificity for the induced antibodies. Protein-A 
Agarose purified immune IgG showed higher specificity as compared to serum. 
Induced antibodies showed preferential recognition of 4-OHE2-NO and 4-OHE2-
Cu(II) modified conformers of DNA and nitrogenous bases. 
Cancer sera were screened for the presence of antibodies reactive with native 
and modified DNA. The study consisted of 64 active sera fi-om patients with various 
types of mahgnancies. Direct binding ELISA showed greater recognition for modified 
plasmid DNA as compared to the native form. Sera fi-om breast and ovarian cancer 
showed higher recognition of modified DNA than native DNA. Sera from cancer of 
uterus and prostrate also showed higher reactivity with modified DNA. Patients 
suffering firom cancer of lung and hepatocellular showed higher reactivity towards 4-
OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA. Sera from gall and urinary bladder also 
showed higher reactivity with modified DNA. The higher binding to modified DNA 
over native DNA of the serum samples suggest the involvement of estrogen modified 
DNA in the production of autoantibodies in cancer patients. 
Oxidative damage to human genomic DNA was detected immunochemically 
using anti-4-OHE2-NO-DNA and anti-4-OHE2-Cu(II)-DNA antibodies as a probe. 
DNA samples from different cancer patients inhibited antibodies binding to their 
respective antigen demonstrating the presence of oxidatively altered epitopes on DNA 
molecules isolated from cancer patients. Data obtained from our studies on serum 
antibodies and lymphocytes DNA isolates could be correlated. In addition the DNA 
isolates from different cancer sera inhibited antibody binding to greater extent in those 
sera of the patients that showed higher inhibition with modified DNA. 
Similarly, the binding specificity of SLE anti-DNA antibodies with native, 4-
OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA was analyzed by ELISA and gel 
retardation assay. Direct binding ELISA results showed preferential binding of SLE 
autoantibodies to modified DNA in comparison to native DNA. Inhibition ELISA 
111 
reiterated the direct binding results. Gel retardation assay fiirther substantiated the 
binding of native and modified plasmid DNA with anti-DNA antibodies. The retarded 
mobility of modified DNA complexed with SLE anti-DNA antibodies confirmed that 
the autoantibodies in SLE recognize the modified DNA more as compared to the 
native plasmid DNA. 
In conclusion, 4-OHE2-NO and 4-OHE2-Cu(II) caused substantial damage to 
plasmid DNA and render it highly immunogenic. Polyclonal antibodies generated 
against modified antigen showed preferential recognition to 4-OHE2-NO and 4-OHE2-
Cu(II) modified epitopes on DNA and bases. The induced antibodies have been 
demonstrated as a good probe to detect oxidative damage to the human genome. 
Higher recognition of estrogen modified DNA by antibodies in sera of patients with 
cancer and SLE suggest estrogen induced DNA damage in these patients. It is 
postulated that 4-hydroxyestradiol, a metabolite of estrogen, on interaction with NO 
and Cu(I) result in DNA modification and the modified epitopes might play a major 
role in the production of SLE anti-DNA autoantibodies and circulating antibodies in 
cancer. 
IV 
STUDIES ON DMA DAMAGED BY FEMALE 
SEX HORMONE AND NITRIC OXIDE 
THESIS SUBMITTED FOR THE DEGREE OF 
Boctor of $I)tIofi[op^p 
IN 
BIOCHEMISTRY 
BY 
WAHID Abl KHAN 
Dated 
Approved : 
Dr. Moinuddin (Supervisor) 
DEPARTMENT OF BIOCHEMISTRY 
FACULTY OF MEDICINE 
JAWAHARLAL NEHRU MEDICAL COLLEGE 
ALIGARH MUSLIM UNIVERSITY 
ALfGARH (INDIA) 
2006 
T6357 
DEPARTMENT OF BIOCHEMISTRY 
FACULTY OF MEDICINE 
J. N. MEDICAL COLLEGE, 
ALIGARH MUSLIM UNIVERISITY 
ALIGARH-202002 
CERTIFICATE 
I certify that the work presented in the following pages has been carried 
out by Mr. Wahid Ali Khan, under my direct supervision, and is suitable for the 
award of Ph.D. degree in Biochemistry of the Aligarh Muslim University, Aligarh. 
^^<M,_^ 
(Moinuddin) 
Lecturer 
Department of Biochemistry 
Faculty of medicine 
J.N. Medical College 
Aligarh Muslim University 
Aligarh-202002, 
U.P., India 
Dedicated 
To 
My Parents 
ACKNOWLEDGEMENTS 
I wish to acknowledge my profound sense of gratitude to my supervisor, Dr. 
Moinuddin, for his ungrudging guidance and constant encouragement and inspiration in 
completion of the present study. These words are the barest acknowledgement of his 
beneficence to me in my research endeavour under his competent supervision. 
Words fall short to express my deep sense of gratitude and immeasurable debt to 
Prof. Rashid Ali, for his guidance and encouragement in trying moments. I have 
benefited from his sound knowledge in the field of biochemistry which has greatly helped 
me in writing up this thesis. 
My sincere thanks are due to Prof Asif Ali, and Dr. Khursheed Alam and other 
faculty members of the Department for their continuing help and encouragement. 
A word of deep appreciation for Prof Abida Malik, Department of Microbiology, 
of this medical college for her sympathetic interest in the present work. She has been 
source of inspiration for me throughout my research carrier. 
I acknowledge my deep sense of gratitude to Prof Moganty R. Rajeswari, 
Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, for 
providing selfless help and necessary facilities to carry out valuable biophysical studies. 
I also have to acknowledge the help given by. Dr. Kiran Dixit, Dr. Farah 
Mansoor, Dr. Farina Khan, Dr. Safia Habib, Dr. Jalees Farhan and Dr. Fozia Khan for 
their helpful advice and suggestions. 
I am extremely gratefiil to my friends, Danish, Wajid, Rais, Zia, Javed, Zafar and 
Suraiya for their valuable suggestions, help and support throughout my research. 
I have to mention the help and cooperation extended to me by my juniors, 
Prashant, Nadeem, Asad, Shereen, Humera and Vikrant. 
I wish to express my gratitude towards my family members for all the help and 
moral support. I would be failing in my duties if I do not express my gratefulness towards 
my parents without whose blessings it would have been difficult to achieve this task. 
Co-operation of Lab assistants- Sabu Khan, Jumman and Ashfaque Ali is greatly 
appreciated. Thanks are also due to the non-teaching staff of the Department of 
Biochemistry and the technical staff of the Central Photography Section for their co-
operation and help. 
(Wahid Ali Khan) 
CONTENTS 
Page 
ABSTRACT i 
LIST OF FIGURE v 
LIST OF TABLES xii 
ABBREVIATION xiii 
INTRODUCTION 1 
EXPERIMENTAL 32 
RESULTS 47 
DISCUSSION 140 
REFERENCES 150 
ABSTRA CT 
Estrogen is a known risk factor for breast cancer and possible mechanisms of 
carcinogenesis may also be similar for various types of cancers. Estrogen is highly 
mitogenic in hormone-sensitive tissues, such as breast and uterus. Prolonged exposure 
of target tissues or cells to excessive mitogenic stimulation by estrogens has been 
considered an important etiological factor for the induction of estrogen-associated 
cancers. Thus, estrogens are considered to participate in tumor promotion. 
Estrogens have been reported to cause cancer through their genotoxic effects. 
Estradiol caused sister chromatids exchanges and chromosomal aberrations in human 
peripheral blood lymphocytes and metabolic activation enhanced these chromosomal 
lesions. The genotoxic effects of estradiol could result from accumulation of 
potentially carcinogenic metabolites. Estradiol undergoes cytochrome P-450-catalyzed 
hydroxylation to various catecholestrogens. 4-Hydroxyestradiol (4-OHE2) undergoes 
redox cycling during which free radicals such as superoxide and the chemically 
reactive estrogen semiquinone and quinone intermediates are produced. The estrogen 
quinone can react with DNA to form stable or depurinating adducts with the potential 
to cause mutations leading to tumorigenesis. Another mechanism by which mutations 
may be formed is by the free radicals generated during the metabolic redox cycling of 
catecholestrogens. 
2-Hydroxylation is a major pathway in the liver, whereas 4-hydroxylation 
dominates in extrahepatic organs susceptible to estrogen. 4-Hydroxyestradiol found to 
be more carcinogenic than 2-hydroxyestradiol (2-OHE2). This could be due to the fact 
that 2-OHE2 is more rapidly metabolized and excreted than 4-OHE2. 
Alterations in estrogen metabolism have been observed not only in 
carcinogenesis but also in systemic lupus erythematosus (SLE). SLE is a chronic 
inflammatory autoimmune disease characterized by the production of non-organ-
specific autoantibodies. Clinical consequences include renal failure, vasculitis, 
thrombosis and seizures and other neurologic complications. The female 
predominance of SLE and frequent exacerbation of disease during pregnancy or 
following oral contraceptive therapy strongly suggest the role of sex hormone 
(estrogen) in disease activity. In addition, increased 16 a-hydroxylation of estradiol 
have been reported in SLE patients. 
In the present study, plasmid pUC 18 was isolated and modified by synergistic 
action of 4-OHE2 and NO. The plasmid DNA was also modified with 4-OHE2 and 
Cu(II). Chemical alterations induced in plasmid DNA following modification were 
studied by agarose gel electrophoresis, UV and fluorescence spectroscopy, circular 
dichroism, thermal denaturation, nuclease SI and restriction enzyme digestions. The 
damage to DNA by estrogen includes single and double strand breaks. 4-OHE2-NO-
DNA showed hyperchromicity at 260 nm as compared to native DNA, reflecting the 
presence of single stranded regions and alterations in the structure of DNA. 4-OHE2-
Cu(II)-DNA also showed mark increase in the absorbance at 260 nm as compared to 
native DNA. Decrease in ellipticity of the positive peaks in the CD spectra of the 
modified DNA reflected again generation of strand breaks in modified DNA. 
The Tm of 4-OHE2-NO-ctDNA was found to be 81.5 °C whereas ctDNA 
showed a Tm of 88 °C. 4-OHE2-Cu(II)-ctDNA showed a Tm of 80.5 °C. A net 
decrease of 6.5 °C in the Tm value of 4-OHE2-NO-ctDNA and a net decrease of 7.5 
^C in the Tm value of 4-OHE2-Cu(II)-ctDNA indicates alterations in the structure and 
single strand breaks in the modified DNA. Nuclease SI sensitivity assay further 
substantiated the formation of single strand breaks. Estrogen modification includes 
DNA bases modification, which was, quantified by ion exchange chromatography on 
DEAE Sephadex A-25. In the case of 4-OHE2-NO-DNA, all the four bases were found 
to be modified. Thymine was modified the most (46.9%), followed by guanine 
(42.6%), adenine (21%) and cytosine (16.6%). In case of 4-OHE2-Cu(II)-DNA, the 
modification of thymine was to the maximum extent (47. l%o). 
Results with various scavengers show that DNA damage induced by 4-OHE2 
and NO can be inhibited by carboxy-PTIO and sodium azide, indicating that 
generation of NO and 'O2 is involved in DNA modification. NO and 02 '" readily 
react with each other to form peroxynitrite, which is also scavenged by uric acid. The 
inhibitory effects of catalase and bathocuproine on DNA modification by 4-OHE2-
Cu(II) demonstrate thai H2O2 and Cu(I) participate in DNA modification. 
4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA were used to induce antibodies in 
rabbits and were found to be immunogenic, inducing high titre antibodies. The 
antigenic specificity of the induced antibodies was studied by competition ELISA. The 
immunogen showed a high degree of specificity for the induced antibodies. Protein-A 
Agarose purified immune IgG showed higher specificity as compared to serum. 
Induced antibodies showed preferential recognition of 4-OHE2-NO and 4-OHE2-
Cu(II) modified conformers of DNA and nitrogenous bases. 
Cancer sera were screened for the presence of antibodies reactive with native 
and modified DNA. The study consisted of 64 active sera from patients with various 
types of maUgnancies. Direct binding ELISA showed greater recognition for modified 
plasmid DNA as compared to the native form. Sera from breast and ovarian cancer 
showed higher recognition of modified DNA than native DNA. Sera from cancer of 
uterus and prostrate also showed higher reactivity with modified DNA. Patients 
suffering from cancer of lung and hepatocellular showed higher reactivity towards 4-
OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA. Sera from gall and urinary bladder also 
showed higher reactivity with modified DNA. The higher binding to modified DNA 
over native DNA of the serum samples suggest the involvement of estrogen modified 
DNA in the production of autoantibodies in cancer patients. 
Oxidative damage to human genomic DNA was detected immunochemically 
using anti-4-OHE2-NO-DNA and anti-4-OHE2-Cu(II)-DNA antibodies as a probe. 
DNA samples from different cancer patients inhibited antibodies binding to their 
respective antigen demonstrating the presence of oxidatively altered epitopes on DNA 
molecules isolated from cancer patients. Data obtained from our studies on serum 
antibodies and lymphocytes DNA isolates could be correlated. In addition the DNA 
isolates from different cancer sera inhibited antibody binding to greater extent in those 
sera of the patients that showed higher inhibition with modified DNA. 
Similarly, the binding specificity of SLE anti-DNA antibodies with native, 4-
OHE2-NO-DNA and 4-OHE2-Cu(Il)-DNA was analyzed by ELISA and gel 
retardation assay. Direct binding ELISA results showed preferential binding of SLE 
autoantibodies to modified DNA in comparison to native DNA. Inhibition ELISA 
111 
reiterated the direct binding results. Gel retardation assay further substantiated the 
binding of native and modified plasmid DNA with anti-DNA antibodies. The retarded 
mobility of modified DNA complexed with SLE anti-DNA antibodies confirmed that 
the autoantibodies in SLE recognize the modified DNA more as compared to the 
native plasmid DNA. 
In conclusion, 4-OHE2-NO and 4-OHE2-Cu(II) caused substantial damage to 
plasmid DNA and render it highly immunogenic. Polyclonal antibodies generated 
against modified antigen showed preferential recognition to 4-OHE2-NO and 4-OHE2-
Cu(II) modified epitopes on DNA and bases. The induced antibodies have been 
demonstrated as a good probe to detect oxidative damage to the human genome. 
Higher recognition of estrogen modified DNA by antibodies in sera of patients with 
cancer and SLE suggest estrogen induced DNA damage in these patients. It is 
postulated that 4-hydroxyestradiol, a metabolite of estrogen, on interaction with NO 
and Cu(I) resuh in DNA modification and the modified epitopes might play a major 
role in the production of SLE anti-DNA autoantibodies and circulating antibodies in 
cancer. 
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Fig. 49 (a). Detection of antibodies against native, 4-OHE2-NO-DNA and 108 
4-OHE2-Cu(II)-DNA in the sera of patients with gall bladder 
cancer. 
(b). Detection of antibodies against native, 4-OHE2-NO-DNA and 
4-OHE2-Cu(II)-DNA in the sera of patients with gall bladder 
cancer. 
Fig. 50 (a). Detection of antibodies against native, 4-OHE2-NO-DNA and 109 
4-OHE2-Cu(II)-DNA in the sera of patients with gall and urinary 
VHl 
bladder cancer. 
(b). Detection of antibodies against native, 4-OHE2-NO-DNA and 
4-OHE2-Cu(II)-DNA in the sera of patients with urinary bladder 
cancer. 
Fig. 51 (a). Detection of antibodies against native, 4-OHE2-NO-DNA and 111 
4-OHE2-Cu(II)-DNA in the sera of patients with urinary bladder 
cancer. 
(b). Detection of antibodies against native, 4-OHE2-NO-DNA and 
4-OHE2-Cu(lI)-DNA in the sera of patients with urinary bladder 
cancer. 
Fig. 52. Elution profile of cancer IgG on Protein-A agarose column. 113 
Fig. 53. Band shift assay of breast cancer IgG binding to native and 4- 114 
OHE2-NO-DNA. 
Fig. 54. Band shift assay of breast cancer IgG binding to native and 4- 115 
0HE2-Cu(II)-DNA. 
Fig. 55 (a). Inhibition of anti-4-OHE2-NO-DNA IgG binding to 4-OHE2- 117 
NO-DNA by DNA isolated from lymphocytes of breast cancer 
patients. 
(b). Inhibition of anti-4-OHE2-NO-DNA IgG binding to 4-OHE2-
NO-DNA by DNA isolated from lymphocytes of ovarian 
carcinoma patients. 
Fig. 56 (a). Inhibition of anti-4-OHE2-NO-DNA IgG binding to 4-OHE2- 118 
NO-DNA by DNA isolated fi-om lymphocytes of uterus cancer 
patients. 
(b). Inhibition of anti-4-OHE2-NO-DNA IgG binding to 4-OHE2-
NO-DNA by DNA isolated from lymphocytes of prostrate cancer 
patients. 
Fig. 57 (a). Inhibition of anti-4-OHE2-NO-DNA IgG binding to 4-OHE2- 119 
NO-DNA by DNA isolated from lymphocytes of lung cancer 
patients. 
(b). Inhibition of anti-4-OHE2-NO-DNA IgG binding to 4-OHE2-
NO-DNA by DNA isolated from lymphocytes of patients with 
hepatocellular carcinoma. 
Fig. 58 (a). Inhibition of anti-4-OHE2-NO-DNA IgG binding to 4-OHE2- 120 
NO-DNA by DNA isolated from lymphocytes of gall bladder 
cancer patients. 
(b). Inhibition of anti-4-OHE2-NO-DNA IgG binding to 4-OHE2-
NO-DNA by DNA isolated from lymphocytes of urinary bladder 
cancer patients. 
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Fig. 59 (a). Inhibition of anti-4-OHE2-Cu(II)-DNA IgG binding to 4- 122 
0HE2-Cu(II)-DNA by DNA isolated from lymphocytes of breast 
cancer patients. 
(b). Inhibition of anti-4-OHE2-Cu(ll)-DNA IgG binding to 4-
0HE2-Cu(II)-DNA by DNA isolated from lymphocytes of ovarian 
carcinoma patients. 
Fig. 60 (a). Inhibition of anti-4-OHE2-Cu(II)-DNA IgG binding to 4- 125 
0HE2-Cu(II)-DNA by DNA isolated from lymphocytes of uterus 
cancer patients. 
(b). Inhibition of anti-4-OHE2-Cu(II)-DNA IgG binding to 4-
0HE2-Cu(II)-DNA by DNA isolated from lymphocytes of prostrat 
cancer patients. 
Fig. 61 (a).Inhibition of anti-4-OHE2-Cu(II)-DNA IgG binding to 4- 126 
0HE2-Cu(II)-DNA by DNA isolated from lymphocytes of lung 
cancer patients. 
(b). tohibition of anti-4-OHE2-Cu(II)-DNA IgG binding to 4-
0HE2-Cu(II)-DNA by DNA isolated from lymphocytes of patients 
with hepatocellular carcinoma. 
Fig. 62 (a), hihibition of anti-4-OHE2-Cu(II)-DNA IgG binding to 4- 127 
0HE2-Cu(II)-DNA by DNA isolated from lymphocytes of gall 
bladder cancer patients. 
(b). Inhibition of anti-4-OHE2-Cu(II)-DNA IgG binding to 4-
0HE2-Cu(II)-DNA by DNA isolated from lymphocytes of urinary 
bladder cancer patients. 
Fig. 63 (a). Direct binding ELISA of SLE anti-DNA autoantibodies to 129 
native, 4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA. 
(b). Direct binding ELISA of SLE anti-DNA autoantibodies to 130 
native, 4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA. 
Fig. 64 (a). Inhibition of SLE anti-DNA autoantibodies binding by native, 131 
4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA. 
(b). Inhibition of SLE anti-DNA autoantibodies binding by native, 
4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA 
Fig. 65 (a). Inhibition of SLE anti-DNA autoantibodies binding by native, 132 
4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA. 
(b). Inhibition of SLE anti-DNA autoantibodies binding by native, 
4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA. 
Fig. 66 (a). Inhibition of SLE anti-DNA autoantibodies binding by native, 133 
4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA. 
(b). Inhibition of SLE anti-DNA autoantibodies binding by native, 
4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA. 
Fig. 67 (a). Inhibition of SLE anti-DNA autoantibodies binding by native, 134 
4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA. 
(b). Inhibition of SLE anti-DNA autoantibodies binding by native, 
4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA. 
Fig. 68 (a). Inhibition of SLE anti-DNA autoantibodies binding by native, 135 
4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA. 
(b). Inhibition of SLE anti-DNA autoantibodies binding by native, 
4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA. 
Fig. 69. Elution profile of SLE IgG on Protein-A agarose column. 137 
Fig. 70. Band shift assay of SLE IgG binding to native and 4-OHE2-NO- 138 
DNA. 
Fig. 71. Band shift assay of SLE IgG binding to native and 4-OHE2-Cu(II)- 139 
DNA. 
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INTRODUCTION 
In 1953 American biochemist James Watson and British biophysicist Francis 
Crick pubHshed the first description of the structure of DNA which controls heredity 
on the molecular level. The hereditary information is stored as the sequence of bases 
along the polynucleotide chain-a message written in a language of only 4 letters, A, C, 
G and T. DNA both preserves this information and uses it. It does this through two 
properties: 
(a) DNA molecules can duplicate themselves, in a process called replication, in 
which the two halves of the helix separate and a new partner is fabricated to 
exactly match each half 
(b) DNA molecules control the synthesis of the proteins which characterize each type 
of organism. The structure of DNA directly controls the structure of proteins and 
the structure of protein directly determines the way in which they control living 
processes. 
DNA adopts different conformations but only the A, Z and B conformation are 
found in nature (Rich et al., 1984; Pechanaya, 1993). B- DNA is the most common 
form of DNA that is found in living cells. Z-DNA in which phosphate groups in the 
backbone are zig-zagged (Rich et al., 1984), turn strands about the helical axis like a 
mirror image of the B-form (Rich et al., 1984). 
Essential Features of Bacterial Plasmids 
Plasmids are extrachromosomal genetic elements frequently found in bacteria. 
They are circular molecules, ranging from 1 kb to 200 kb. Each has an origin of 
replication and usually contains several genes including those encoding antibiotic 
resistance. Conjugation or transformation is the processes by which they are 
transmitted from bacteria to bacteria. 
pUC 18 and pUC 19 vectors are small, high copy number, E. coli plasmids, 
2686 bp in length. They are identical except that they contain multiple cloning sites 
(MCS) arranged in opposite orientations. pUC 18/19 plasmids contain: (1) the pMBl 
replicon rep responsible for the replication of plasmid. The high copy number of pUC 
plasmids is a result of the lack of the rop gene and a single point mutation in rep of 
pMBl; (2) b/a gene, coding for beta-lactamase that confers resistance to ampicillin. It 
differs from that of pBR322 by two point mutations; (3) region of E. coli lac operon 
containing CAP protein binding sites, promoter Piac, lac repressor binding site and 5'-
terminal part of the lac Z gene encoding the N-terminal of beta-galactosidase 
(Yanisch-Perron et al., 1985). 
Antigenicity of DNA 
Among antibodies directed to biological macromolecules, antibodies to DNA 
(anti-DNA) are imique in their association with the pathological state. These 
antibodies are the serologic hallmark of systemic lupus erythematosus (SLE) and serve 
as markers for diagnosis and prognosis of the disease. The close association of anti-
DNA with SLE has implied that immune responses to DNA are an exclusive feature of 
autoimmune diseases (Emlen et al., 1986). 
Antibodies to DNA were first described in 1957 (Robbins et al., 1957). They 
constitute a subgroup of antinuclear antibodies that bind single-stranded DNA, double-
stranded DNA or both. They may be IgM antibodies or any of the subclasses of IgG 
antibodies. Antibodies that bind exclusively to single-stranded DNA, can bind its 
complement bases, nucleoside, nucleotide, oligonucleotide and ribose-phosphate 
backbone. In contrast, antibodies that bind double-stranded DNA bind to the ribose-
phosphate backbone, base pair or particular conformations of the double helix (Stollar, 
1994; Kalsi et al., 1996). Double-stranded DNA exists primarily in a right-handed 
helical form called B-DNA; there is also a left-handed helical form called Z-DNA. 
Some patients with systemic lupus erythematosus have antibodies that react 
preferentially with Z-DNA (Stollar, 1994; Herrman, 1995). Native DNA per se is a 
week immunogen while its modified forms have been shown to be highly 
immunogenic (Moinuddin and Ali, 1994; Ashok and Ali, 1998; Ashok and Ali, 1999; 
Dixit and Ali, 2001; Ali and Alam, 2002; Ahsan and Ali, 2003; Dixit and Ali, 2004; 
Dixit et al., 2005; Habib et al., 2005). 
The variable (V) regions of the antibody to DNA determine antigenic 
specificity (Putterman et al., 1997). V-regions of several human antibodies to DNA 
have been sequenced (Taki et al., 1992; Winkler et al., 1992; Mahmoudi et al., 1995). 
The clone of B cells that produce antibodies to DNA is some what limited, but 
probably no more so than that of normal B cells stimulated by external antigens (Radic 
and Weigert, 1994; Zouali, 1997;. In many antibodies to DNA, the ability to bind 
DNA residues predominantly in the heavy chain, but the light chains can enhance or 
prevent binding (Putterman et al., 1997; Mahmoudi et al., 1995). How a particular V-
region sequence permit DNA binding is not fiiUy understood; enrichment in certain 
amino acids, such as arginine, is critical to the binding of DNA in some, but not all 
molecules (Radic and Weigert, 1994; Putterman et al., 1997). 
Antigenicity of Plasmid DNA 
DNA immunization has usually been used to generate immunity against the 
antigens of infectious agents or tumors and both beneficial and detrimental effect on 
the course of autoimmune disease have occurred (Garren and Steinman, 2000). DNA 
in the form of DNA vaccines are known to stimulate the immune response. The basic 
form of the vaccine consists of the two components: (1) a mammalian expression 
cassette and (2) the bacterial plasmid backbone. The importance of the plasmid 
backbone during vaccination has been attributed to the presence of specific 
immunostimulatory CG dinuleotide sequences within the bacterial DNA, known as 
CpG motifs (Krieg, 2000). DNA sequences containing CpG motifs have been shown 
to activate T and B cells and promote maturation of dendritic cells, increasing their Ag 
presentation capacity. When the CpG sequence contained with in immunization 
plasmid were removed or methylated, the vaccine activity was dramatically reduced, 
supporting an important role for unmethylated CpG motifs in successful immunization 
by plasmid DNA vaccine (Sato et al., 1996; Klinman et al., 1997; Klirmian et al., 
2000). Sequence analysis of the ampicillin resistant gene of plasmid DNA vaccines 
indicated that it contained two repeats of a palindromic CpG hexamer 5'AACpGTT3' 
(Sato et al., 1996). This 6 base motif proved to be a potent adjuvant in mice. These 
immunostimulatory sequence (ISS) behave as an internal immunological adjuvant. 
They stimulate the production of cytokines, in particular gamma interferon and IL-12 
that favor a T-helper response (Kreig et al., 1995; Klinman et al., 1997; Klinman et al., 
1999). CpG motifs are about 20 times more common in the bacterial than in the 
mammalian genome. More over, less than 5% of the cytosine residues in the CpG 
dinucleotides of bacterial DNA are methylated as compared to 70-90% of the cytosine 
residues in eukaryotic DNA (Kreig et al., 1995; Klimnan et al., 1997; Tigh et al., 
1998; Lee and Siing, 1998). Methylation of cytosine residues in plasmid DNA results 
in the loss of the immunostimulatory effect (Kreig et al., 1995). Earlier studies showed 
that myocytes behaved as antigen presenting cells (APC) when the plasmid DNA was 
administered by the intra-muscular route (Wolff et al., 1990; Ulmer et al., 1996). 
However, monocytes express MHC class I molecules, but they do not express co-
stimulatory molecules that are needed to optimize CTL activation. Antigen-specific 
CTL responses could be induced by muscles cells only when the mice were vaccinated 
with plasmid DNA possessing an antigen and a B7 (co-stimulatory molecules) reporter 
genes (Agadjanyan et al., 1999). Furthermore, Klinman et al. (1998) were able to 
transfer immunization by transplanting skin within 12 hours following intra-dermal 
administration of plasmid DNA. DNA vaccines are now being tested in clinical trials, 
yet further safety studies should be undertaken and potential dangers should not be 
neglected. 
Estrogen 
Estrogens (also oestrogens) are a group of steroid compounds that function as 
the primary female sex hormone. While estrogens are present in both men and women, 
they are found in women in significantly higher quantities. They promote the 
development of female secondary sexual characteristices, such as breasts, and are also 
involved in the thickening of the endometrium and other aspects of regulating the 
menstrual cycle, which is why many oral contraceptives contain estrogens. The three 
naturally occurring estrogens are estradiol, estriol and estrone. In the body these are all 
produced from androgens through enzyme action. Estradiol is produced from 
testosterone and estrone from androstenedione. Estrone is weaker than estradiol and in 
post-menopausal women more estrone is present than estradiol. 
Estrogen known to be complete carcinogens in breast and various gynecologic 
tissues (Cavalieri, 2000; Yager, 2000; Clemons and Goss, 2001). There are various 
reports that establish a link between estrogen-induced cancer and oxidative stress 
(Cavalieri, 2000; Yager, and Liehr, 1996; Yager, 2000; Wani, et al., 1998). Prolonged 
exposure of target tissue or cell to excessive mitogen stimulation by natural or 
synthetic estrogen has long been considered an important etiological factor in the 
induction of estrogen-associated cancers in experimental animals (Nandi et al., 1995; 
Li and Li, 1996) and humans (Ziel and Finkle, 1975; Fiegelson and Henderson, 1996; 
Grady and Emster, 1996). A variety of estrogens are capable of acting as complete 
carcinogens through a mechanism that involves oxidative stress in the liver, kidney 
and breast tissues of various rodent models (Yager, and Liehr, 1996; Han and Liehr, 
1996). 
It has been hypothesized that the initiation of cancer may result from induction 
of DNA damage by estrogen metabolites, although progression may be facilitated by 
estrogen receptor-mediated upregulation of mitogenic genes. There are various reports 
that confirm that estrogen metabolites are tumorigenic in animal models (Liehr, 1997; 
Newbold and Liehr, 2000; Liehr, 2000). More recently, the direct action of estrogen 
has been shown by its ability to transform normal breast epithelial cells in culture 
(Russo et al., 2001). Estrogen in certain cell types (including both normal and breast 
cancer cell) may be oxidized by extra hepatic cytochrome P450 family (mainly 
CYPlAl and CYPIBI). These are major enzymes catalyzing P-nicotinamide adenine 
dinucleotide phosphate (NADPH) dependent oxidative metabolism of estrogen to 
multiple hydroxylated metabolites (Zhu and Conney, 1998; Spink et al., 1998; 
Jefcoate et al., 2000) (Table 1). 
Table 1 Hydroxylated metabolites of 17p-estradiol (estradiol and estrone). All 
estrogen metabolites listed were found in biological samples (e.g tissues, 
blood, bile, urine) or were formed by in vitro incubations of estrogen 
with enzyme preparations from animals or humans. 
Position of 
Oxidation 
C-l 
C-2 
C-4 
C-6 
C-7 
c-u 
C-14 
C-l 5 
C-16 
C-I7 
C-18 
Estrogen 
Systematic name 
1,3,5(10)-Estralrien-1,3-diol-17-one 
l,3,5(10)-Eslratrien-2,3-diol-17-one 
1,3,5( 10)-Estratrien-2,3,l 7p-triol 
1,3,5( 10>Estratrien-2,3,16al 7p-tetrol 
1,3,5( 10>Estratrien-l ,3-diol-l 7-one 
1,3.5( 10)-Estratrien-2.3,17P-triol 
l,3,5(IO)-Estratrien-2,3.16al7p-letrol 
1,3,5( 10)-Estratrien-3,6a-diol-l 7-one 
1,3,5(10)-Estratrien-3,6p-<liol-17-one 
1,3,5( 10)-Estratrien-3,6a, 17P-triol 
1,3,5(10)-Estratrien-3,6o, 17P-triol 
1,3,5( 10)-Estratrien-3,6a, 16al 7P-letro! 
1,3,5( 10)-Estratrien-3,7a-diol-17-one 
1,3,S( 10)-Estratrien-3,7Miol-17-one 
1,3,5( 10>Eslratrien-3,7a, 17p-triol 
l,3,5(10)-Estratrien-3,7p,17p-triol 
l,3,5(10>Estratrien-3,7a,I6al7p-tetrol 
l,3,5(10)-Estratrien-3,llMiol-n-one 
1,3,5( 10>Estratrien-3,11P, 17P-triol 
1,3,5( 10), 11 -Eslratrien-3,17a-diol* 
1,3,5( 10),9,11 -Estralrien-3ol-l 7-one' 
1,3,5( 10)-Estratrien-3,14a-diol-17-one 
1,3,5(10)-Estralrien-3,14a, 17p-triol 
1,3,5( 10)-Eslratrien-3,l 5a-<iiol-l 7-one 
1,3,5( 10)-Estralrien-3,15p-diol-17-one 
1,3,5( 10)-Estratrien-3,15a, 17P-lriol 
1,3,5( 10)-Estratrien-3,15a, 16a, 17P-tetrol 
1,3,5( 10)-Estra(rien-3,16a-diol-17-one 
l,3,5(10)-Estratrien-3,16p-<iiol-17-one 
l,3,5(10)-Estratrien-3,16a,I7p-triol 
1,3,5(10)-Estratrien-3,17a-diol 
1,3,5( 10>-Estratrien-3,160,17o-triol, 
1,3,5.( 10)-Estralrien-3,18-diol-l 7-one 
metabolites 
Common name 
l-Hydroxyeslrone 
2-Hydroxyestrone 
2-Hydroxyestradiol 
2-Hydroxyestriol 
4-Hydroxyestrone 
4-Hydroxyestradiol 
4-Hydroxyestriol 
6a-Hydroxyestrone 
6p-Hydroxyestrone 
6a-Hydroxyestradiol 
6p-Hydroxyestradiol 
6a-Hydroxyestriol 
7a-Hydroxyeslrone 
7p-Hydroxyestrone 
7a-Hydroxyestradiol 
7p-Hydroxyestradiol 
7a-Hydroxyestriol 
11 P-Hydroxyestionc 
1 ip-Hydroxyestradiol 
A( 11 )-Dehydroestradiol-17a 
A(9,l l)-Dehydroestrone 
14o-Hydroxyestrone 
14a-Hydroxyestradiol 
15a-Hydroxyestrone 
15|5-Hydroxyeslrone 
15a-Hydroxyestradiol 
15o-Hydroxyestriol (estetro!) 
16a-Hydroxyestrone 
16p-Hydroxyestrone 
16a-Hydroxyeslradiol (estriol) 
17a-Estradiol 
17-Epiestriol 
18-Hydroxyestrone 
Adapted from (Zhu et al., 1998) 
This metabolism is potentially harmful given that the quinone-catecholestrogen can 
bind to DNA and form DNA adduct. Furthermore, redox cycling between quinone and 
unstable semiquinone form causes hydroxyl radical formation that can lead to 
hydroxylated nucleotide bases and permanent mutation, if not repaired (Liehr, 1997; 
Liehr, 2000; Thibodeaus, and Paquette 1999). The estrogen and its metabolites can 
also be detoxified by conjugation to glucuronides and sulfates, although the 
significance of these processes in the breast is less clear (Raftogianis, 2000). The 
ability of qumone reductase (QR) to detoxify quinone-catechol estrogen by reduction 
of the reactive quinone-catechol estrogen back to the hydroxy-catecholestrogen has 
been shown for synthetic estrogen, diethylstilbestrol (Roy and Liehr, 1988) and 
hydroxyequlenin-o-quinone (Shen et al., 1997). Although research on estrogen, its 
hydroxylated metabolites, has been carried out for the last 25 years, the NADPH-
dependent hydroxylation of estrogen by multiple cytochrome P450 enzyme in target 
tissues or cell is largely unknown. During the oxidation of estrogen, specific enzymes 
in the target cell catalyze the formation of hydroxylated estrogen with subsequent 
formation of reactive oxygen species (ROS) and unstable catecholestrogen such as 
semiquinones (Yager and Liehr, 1996: Liehr, 1999; Yager, 2000) (Fig. 1). Redox 
cycling between the quinone and unstable semiquinone results in hydroxyl radical 
formation that can lead to DNA damage and cause cancer (Yager and Liehr, 1996; 
demons and Goss, 2001; Liehr, 1999). Furthermore, elevated serum concentration of 
16-hyclroxyestrone has been described in patient with SLE (Lahita et al., 1979) 
suggesting that abnormal pattern of estrogen metabolism may lead to increased 
estrogenic activity. Estrogen and their metabolites seem to play an important role in 
autoimmune rheumatic disease (Weidler et al., 2004). Increased I6-alpha-
hydroxylation of estradiol occurs in SLE (Lahita et al., 1979) and the 16-aIpha-
metabolites have been shown to be potent estrogens. Abnormal pattern of estrogen 
metabolites and increased hydroxylation of estradiol at C-16 in SLE suggest a role of 
hydroxylation of estrogen in the etiopathogenesis of SLE. 
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Fig. 1. Activating and deactivating (protecting) pathways of estrogen metabolism and 
formation of DNA adducts (Adapted from Cavalieri et al., 2000). 
Types of Estrogen Hydroxylation 
Estrogen can hydroxylated at multiple positions by NADPH-dependent 
cytochrome P450 enzymes. Liver microsomes from adult rats resulted in the formation 
of upto 20 detectable estrogen metabolites when incubated with [4-''*C] estradiol and 
NADPH (Suchar et al., 1995). Because catechol-0-methyl transferase detoxifies the 
hydroxycatechol estrogen by methylation (Liehr, 2000), several additional 
methoxyestrogen metabolites would have been formed if a methylating enzyme 
system had been included during the incubations. Extra hepatic cultured cells from 
target tissues express estrogen-hydroxylating enzyme activities (Haaf et al., 1992; 
Liehr et al., 1995; Liehr et al., 1996; Hammond et al., 1997). Mammary gland of 
female rat contains at least nine different isoforms of cytochromes P450 (Hellmold et 
al., 1995). Multiple cytochromes P450 are present and are selectively expressed in 
certain areas of brain (Wainer and Gustafsson, 1994; Stromstedt et al., 1994) but their 
role for metabolism of estrogen is largely unknown. Enzymes that catalyze the 
formation of catechol estrogens have been detected in the central nervous system of 
rats (Hersey and Weisz, 1983; Bui and Weisz, 1988) and their level are marked by 
increased in certain region of the brain (Hersey and Weisz, 1983). In addition to these 
enzymes, partial purified cytochrome P450 from rat brain shows high catalytic activity 
for the 6a-hydroxylation of estradiol (Sugita et al., 1987) and it is also catalyzed to 
lesser extent the 2-, 4-, 6(3-, 15a- and 16a-hydroxylation of estradiol (Sugita et al., 
1987). Human follicular fluid specimens contain high concentration of 6a-
hydroxyestradiol, 16a-hydroxyestradiol and 2-methoxyestradiol and several 
additional metabolites have also been observed (Dehennin et al., 1984). Multiple 
pathways for estrogen hydroxylation in liver and extrahepatic target tissues/cell are 
due to under regulatory control by endogenous factors such as sex hormone (Dannan 
et al., 1986; Hellmold et al., 1995) and by environmental agents such as drugs, 
pesticides, polycyclic aromatic hydrocarbons etc (Dannan et al., 1986; Suchar et al., 
1996). 
a) 2-Hydroxylation: 2-Hydroxylation is a major metabolic pathway in the liver, 
where as 4-hydroxylation dominates in extrahepatic organs susceptible to estrogen 
(Suchar et al., 1995; Zhu and Conney, 1998). In rats, cytochrome P450 1A2, 2B1/2B2, 
2C6, 2C11, C-M/F (one or more members of the 2D family) and the 3A family 
catalyzed hepatic 2-hydroxylation of estradiol (Zhu and Conney, 1998). In human, 
cytochrome P450, 1A2 and the 3A family are major enzymes for hepatic estrogen 2-
hydroxylation (Kerlan et al., 1992, Shou et al., 1997). 2-hydroxylation of estradiol 
and/or estrone has been observed with microsome prepared from various extrahepatic 
tissues such as placenta (Bui and Weisz, 1988; Liehr et al., 1995), breast (Liehr and 
Ricci, 1995; Hoffman et al., 1979), kidney (Zhu et al., 1994; Liehr and Ricci, 1995), 
uterus (Liehr and Ricci, 1995), brain (Hersey and Weisz, 1983) and pituitary (Bui and 
Weisz, 1988). In human placenta, formation of catecholestrogen by microsomal 
monooxygenase (s) was largely by 2-hydroxylation pathway while the 4-
hydroxylation is very minor metabolic pathway in this tissue (Liehr et al., 1995). The 
2-hydroxyIation of estradiol by MCF-7 human breast cells treated with 2, 3, 7, 8-
tetrachlorodibenzo-p-dioxin (TCDD) appears to be predominantly catalyzed by 
cytochrome P450 lAl/1 A2 (Spike et al., 1990). The organic hydroperoxide-dependent 
peroxidative pathway may also contribute significantly to the 2- and 4-hydroxylation 
on these estrogens in the liver (Bui et al., 1990) and estrogen target tissues (Weisz, et 
al., 1993). Cytochrome P450 enzymes predominantly catalyze catecholestrogen 
formation by peroxidative pathway (Bui et al., 1990). Inspite of extensively 2-
hydroxylated activity in liver and extrahepatic tissue, the concentration of 
unconjugated 2-hydroxyestradiol and 2-hydroxyestrone metabolite are very low in the 
systemic circulation (Emons et al., 1987) which is probably due to rapid metabolism 
followed by urinary excretion. 
b) 4-HydroxyIation: 2-hydroxylation of estradiol and estrone is the major pathway 
for catechol estrogen formation in liver microsomes but small amount of 4-
hydroxlated estradiol and estrone are also formed (Zhu and Liehr, 1993; Suchar et al., 
1995; Suchar et al., 1996; Hammond et al., 1997). 4-Hydroxylation of estradiol is 
catalyzed by cytochrome P450 1A2, 2B1/2 and the 3A family in rat liver microsomes 
(Pannan et al., 1986; Suchar et al., 1996) while in human hver microsomes the 
cytochrome P450 3A family play a major role in the 4-hydroxylation of estradiol 
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(Aoyama et al., 1990). Although 2-hydroxlation of estradiol and estrone is the 
dominant pathway for catechol estrogen formation but recent studies showed that 4-
hydroxlation of estradiol is a dominant pathway for catechol estrogen formation in 
several extrahepatic target tissues. For example, an estradiol 4-hydroxylase activity is 
expressed in rat pituitary which has little or no activity for 2-hydroxyestradiol 
formation (Bui and Weisz, 1988) but an estradiol 4-hydroylase activity with low Km 
(2-5|aM) was observed in human uterine myometrial and myoma tissues (Liehr et al., 
1995). Cytochrome P450 IBl is an enzyme for the 4-hydroxyIation of estradiol in 
human breast and uterus (Liehr et al., 1995; Hayes et al., 1996). An organic 
hydroperoxide-dependent peroxidatic pathway may also contribute significantly to the 
4- and 2-hydroxylation of estradiol and estrone in estrogen target organ (Weisz et al., 
1993) and liver (Bui et al., 1990). In microsomes from human uterine myoma or from 
MCF-7 human breast cancer cells treated with TCDD, estradiol 4-hydroxylation is 
catalyzed predominantly by cytochrome P450 IBl (Liehr et al., 1995; Savas et al., 
1993). Human cytochrome P450 IBl isolated from a yeast expression system 
catalyzes both 4- and 2-hydroxylation of estradiol with low Km (<1 mM) but the 
Vmax for the 4-hydroxylation of estradiol is ~ 4-fold higher than the Vmax for the 2-
hydroxylation of estradiol (Hayes et al., 1996). Cytochrome P450 IBl mRNA appears 
to be one of the major cytochrome P450 mRNA in uterine endometrium and 
mammary gland (Savas et al., 1994). In contrast, the mRNA for cytochrome P450 lAl 
is expressed mainly in the epithelial cell of mouse uterine endometrium and mammary 
gland (Savas et al., 1994). Treatment of TCDD or indolo [3,2-b] carbazole (Haynes et 
al., 1996) or a dietary derived Ah-receptor legend (Bjeldanes et al., 1991) stimulated 
the expression of cytochrome P450 IBl- dependent estradiol 4-hydroxylase activity in 
MCF-7 human breast cancer cells. 
c) 6-and 7-Hydroxylation: The cytochrome P450 2B1/2B2 in rat liver microsomes is a 
major enzyme responsible for the 6a- and 6P-hydroxylation of estradiol and 
cytochrome P450 1A1/1A2 also catalyzes the hepatic 6a- and 7a-hydroxylation 
reaction (Watanabe et al., 1991). S J^.dies have shown that phenobarbitol or 3-
methylcholantherene stimulated the hepatic 6a- and 6p - hydroxylation of estradiol in 
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female rats and 3-methylcholantherene stimulated the hepatic 6a- and 7a-hydroxylation 
of estradiol (Suchar et al., 1996). The major biotransformation product of estrone and 
estradiol in pig uterus is 6 a- and 7 a-hydroxylated metabolites (Adamski et al., 1994). 
6a- and 7a- hydroxylation of estrone was catalyzed by pig endometrial cell with 100 Km 
values (<l)xM) and these enzymes activities were inhibited by ketocanazole (Adamski et 
al., 1994), a cytochrome P450 inhibitors. Exposure of MCF-7 cells to TCDD markedly 
stimulated 6a-hydroxylation of estradiol by microsomes from MCF-7 human breast 
cancer cells (Spike et al., 1990). A partially purified cytociirome P450 enzyme from rat 
brain was shown to catalyze the 6a- and 6P-hydroxlation of estradiol and this enzyme 
preparation also catalyzed the formation of 4-hydroxyestradiol, 2-hydroxyestradiol, 6-
ketoestradiol, 15a-hydroxyestradiol and 16a-hydroxyestradiol (Sugita et al., 1987). 
d) 15a- and 16a-Hydroxylation: 15a-hydroxylase activity was observed in the 
human adrenal gland (Younglai and Solomon, 1968), in human fetal liver (Cantineau 
et al., 1985) and in certain microorganisms (Laskin et al., 1964). 15a-hydroxylation is 
predominant metabolic pathway in male rats which is carried out by male specific 
cytochrome P450 2C13 (Maggs et al., 1992). Male rats metabolize estradiol to 15a-
hydroxyestrone and 15a-hydroxyestradiol that are excreted into the bile in vivo. 
During pregnancy 15a-hydroxyestrone is present in large amounts in human feces 
(Adlercreutz and Martin, 1976). The 15a-hydroxylation of estradiol results in 
metabolites that have <1% of estradiol binding affinity for the classical estrogen 
receptor and little or no estrogenic activity (Fishman and Martucci, 1978). 
Cytochrome P-450 c-m/f, a new constitutive form of microsomal cytochrome 
P450 in male and female rat liver show high activity for the 2 and 16a-hydroxylation 
of estradiol and weak activity for 6a-, 6P- and 15a-hydroxylation of estradiol (Sugita 
et al., 1988). 16 a-hydroxylation of estrogen also catalyzed by cytochrome P450 2C11 
in male rat (Cheng and Schenkman, 1984). In human, cytochrome P450 3A4 has 
strong catalytic activity for estrone 16a-hydroxylation (Shou et al., 1997). Increased 
formation of 16 a-hydroxyestrogen metabolites may be associated with an increased 
risk for developing mammary cancer in mice and human (Bradlow et al., 1995; 
Fishman et al., 1995). Certain pesticides and polychlorinated biphenyls were reported 
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to increase the rate of 16a-hydroxylation of estrone in MCF- cells (Bradlow et al.. 
1995). 
In addition to the above described hydroxylation of estrogen, many other 
hydroxylated metabolites of estradiol and estrone have been identified during in vitro 
incubation of an estrogen with enzyme preparations from animals or humans and / or 
have been identified in urine, blood or tissue sample obtained during in vivo studies. 
Estradiol-Mediated Modulation of Immune Responses 
Estrogens not only induce ROS production, but can also modulate immune 
responses and immune mediated diseases, which can predispose to cancer (Cutolo et 
al., 1995). Physiologic doses of estradiol (E2) potently induce interleukin (IL)-la, a 
cytokine that can initiate a cascade of other cytokines, chemotactic and growth factors 
(Cutolo et al., 1995; Ansel et al., 1990). Chemotactic factors cause infiltration of 
phagocytes, which may be activated to secrete other cytokines, ROS, and reactive 
nitrogen species (RNS) (Kupper, 1990; Stadnyk, 1994; Griffiths and Lunec, 1998; 
Mor et al., 1998). On the other hand, E2 inhibits IL-1 a-induced IL-6 production. 
Therefore, by suppressing IL-6 formation, E2 increases human epithelial cell 
proliferation, a process important in tumor growth, while it also inhibits the activity of 
natural killer cells, thus allowing tumor growth (Ansel et al., 1990; Mor et al., 1998). 
E2 mediates macrophage proliferation and decreases cell differentiation (Cutolo et al., 
1995). Each of these affected processes, allow or encourage tumor cell development 
and growth. 
Effects of Estrogen on Macrophages 
In breast tumors the proliferation of macrophages increase tremendously, 
providing up to 50% of the tumor mass (Lewis et al., 1995; Santner et al., 1997). This 
increase in mass might be caused by estrogen-stimulating macrophage proliferation 
(Cutolo et al., 1995). Significant levels of estrogen are produced fi-om androgens 
within the female breast by the action of aromatase, a cytochrome P450 enzyme that is 
present in cells as well as in macrophages (Zhu and Cormey, 1998, Yue et al., 1998). 
Thus, estrogens cause macrophage proliferation and activation and, in turn, 
macrophages produce estrogens, which may act on other phagocytic cells. After 
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macrophage stimulation, inducible nitric oxide synthase is synthesized by the cells and 
mediates production of L-arginine-derived nitric oxide (NO), another radical species, 
which participates in signal transduction, numerous reactions, and cellular processes. 
02*" and NO may rapidly interact, to produce peroxynitrite, a much more potent 
oxidant (Esumi and Tannenbaum, 1994). Hence, macrophage activation may lead to 
ROS and RNS. 
Effects of Estrogen on PMN Function 
Estrogens known to affect the fiinction of PMNs (polymorphonuclear 
leukocytes, neutrophils, granulocytes), which are another group of phagocytic cells 
that produce copious amounts of ROS on their stimulation. PMNs express 
myeloperoxidase, an enzyme that catalyzes oxidation of chloride ions by H2O2 
(generated by NADPH oxidase) to hypochlorite/ hypochlorous acid (H0C1/0C1-), one 
of the most potent oxidants (Frenkel, 1992). This reaction is catalyzed by 
myeloperoxidase released from PMNs during their activation process. However, 
estrogens and some of their metabolites (i.e., E2, El, 16a-0HEi, and estriol) may 
induce myeloperoxidase release from the resting (inactivated) cells and stimulate 
generation of oxidants in the absence of pathogens (Jannson, 1991). In addition, 2-
hydroxylated estrogens act as powerful inhibitors of PMNs activity, possibly one of 
the protective properties of the 2-hydroxylated CE. The estrogen-mediated action 
causes HOCl/OCl" formation and ensuing oxidative cell damage. Moreover, estrogens 
can stimulate (by 10-fold) the activity of the released myeloperoxidase, thus 
compounding the damaging effects. Various interactions occur at physiological pH 
among reactive oxygen and nitrogen species generated by the phagocytic cells, 
macrophages and PMNs. These interactions lead to various types of DNA 
modification, many of which result in mutations. Therefore, estrogens, by modulating 
phagocytic cell proliferation and activation, have a pronounced effect on the DNA and 
mutagenesis. 
Immunomodulation by Estrogens 
Important properties of E2 include, not only its ability to differentiate T and B 
cells, but also irxrease immunoglobulin production, and aggravate immune complex-
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mediated diseases, such as systemic lupus erythematosus, which occur predominantly 
in females (Carlsten et al., 1996; Cooke et al., 1997). Women with well established 
breast cancer have significantly elevated anti-5-hydroxymethyl-2'-deoxyuridine 
(HMdU) autoantibodies (Frenkel et al., 1998). The levels of anti-HMdU 
autoantibodies are remarkably stable over a period of years. The presence of high anti-
HMdU autoantibody levels attests to the prooxidant conditions that have led to 
oxidation of bases in cellular DNA and have evoked an autoimmune response. These 
results also suggest that the oxidative DNA base damage (HMdU) and the biologic 
responses it evokes (anti-HMdU autoantibodies) start occurring early in the 
carcinogenic process. Such a conclusion is strengthened by data that showed that 
oxidative DNA base damage is evident in DNA of individuals at risk for hormone-
dependent cancers (Djuric et al., 1996; Frenkel et al., 1998). 
Estradiol-Induced Lipid Peroxidation and DNA Damage 
Estradiol induced ROS may also cause oxidation of cellular macromolecules 
other than DNA, which include proteins and lipids. Hence, E2-induced ROS may have 
a pronounced effect on cell maintenance and functioning. Lipids, particularly 
polyunsaturated lipids, are readily peroxidized, and the products often participate in a 
chain reaction propagating formation of various radical species (Aruoma, 1998). 
Again, like other carcinogens, estrogens induce lipid peroxidation during their 
metabolic activation (Liehr, 1997). The insidiousness of this process is demonstrated 
by the fact that lipid hydroperoxides formed during E2 metabolism may serve as 
cofactors in fiirther E2 (or other carcinogen) metabolism to hydroxylated products and 
in the oxidation of CE to quinone intermediates, which continuously amplify the 
formation of lipid hydroperoxides and cellular damage. Furthermore, lipid 
hydroperoxide-derived aldehydes, such as malondialdehyde and 4-hydroxynonenal, 
interact with bases in cellular DNA, thus increasing the burden of DNA modification 
(Wang and Liehr, 1995; Nath et al., 1998). Estrogen metabolites and oxidants lead to 
at least three types of DNA base damage: DNA base adducts produced by quinones, 
lipid hydroperoxide-derived aldehyde DNA adducts, as well as a plethora of oxidized 
DNA bases. The importance of ROS formation during estrogen metabolism is 
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underscored by the fact that H2O2 generated by the redox cycHng of the semiquinone-
quinone couple is readily reduced by cellular transition metal ion such Cu+, to 
hydroxy] radicals (•OH), the most potent oxidants (Hiraku et al., 2001). Hydroxyl 
radicals not only oxidize bases in DNA, but also cause lipid peroxidation. Lipid 
hydroperoxides then serve as cofactors in further estrogen metabolism, which leads to 
additional semiquinone-quinone redox cycling, ROS production, and so on. 
Antioxidants 
An antioxidant is a molecule stable enough to donate an electron to a 
rampaging free radical and neutralize it, thus reducing its capacity to damage. Some 
antioxidants, including glutathione, ubiquinol and uric acid are produced during 
normal metabolism in the body while other antioxidants are found in the diet. 
The role of antioxidants is to detoxify reactive oxygen species (ROS) in the 
body which play important role in carcinogenesis (Epe, 2002). Dietary antioxidants 
(e.g. vitamin E and C, selenium, p-carotene and other phytochemicals) as well as 
endogenous antioxidants (e.g. glutathione) that neutralize or trap ROS act as cancer 
preventing agents (Borek, 2004; Borek, 1997). These studies were further supported 
by the fact that oxidant stress increases with clinical progression of breast cancer 
(Khanzode et al., 2004) and that a diet rich in antioxidant-containing foods reduces the 
risk of certain cancer (Steinmetz and Potter, 1996). 
Some dietary antioxidants may have potential as adjuvants in cancer therapy 
by their ability to induce programmed cell death (apoptosis) (Zimmermann, 2001). 
Studies in cell cultures showed that vitamin E and C, selenium and some 
phytochemicals selectively induce apoptosis in cancer cells while sparing normal cells 
(Sigounas et al., 1997; Taper et al., 2004); other findings, in a model of metastatic 
growth, show that vitamin C is an angiostatic factor and may have potential in aiding 
host resistance to tumor growth and invasiveness (Ashino et al., 2003). Antioxidants 
also show promise in cancer therapy by their palliative action, reducing painful side 
effects associated vwth treatment (Kennedy et al., 2001). 
As a cancer-preventive agent, vitamin E acts in synergy with selenium, 
preventing cell transformation by x-irradiation, suggesting its use in protecting normal 
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cells against the potential late effects of secondary cancer following radiotherapy 
(Borek et al., 1986). Vitamin C given alone or in combination with y-rays, selectively 
induced mitotic accumulation in human cancer cells compared with normal fibroblasts 
and had a growth inhibitory effect on a variety cancer cells (Prasad et aJ., 2003). A 
combined treatment with vitamin E and C inhibited apoptosis in human endothelial 
cell more effectively than each alone, by upregulating the antiapoptotic protein Bcl-2 
and down regulating the proapoptotic Bax (Haendeler et al., 1996). By contrast, 
vitamin E induced apoptosis in human breast and prostate cancer cells as well as 
leukemia (Sigounas et al., 1997) and glioblastoma cells (Borek and Pardo, 1994). 
In the antisupplementation positions, antioxidants are found to be potentially 
harmful when included in a conventional drug protocol that causes oxidative damage 
for several reasons: 
a) First, even assuming that antioxidants might provide protection from the side 
effects of a treatment-related oxidant attack, their protective mechanisms may not 
distinguish between normal and malignant cell (Stewart et al., 1983). 
b) Second, some antioxidants can alter the coagulation cascades and potentially 
place one at greater risk for hemorrhage (Horwitt, 2001). 
c) Third, some classical antioxidants are known to cause toxicity on their own (Myhre 
et al., 2003). 
d) Finally, radiotherapy as well as a significant number of conventional cytotoxic 
agent in use today rely on oxidative mechanisms for their effect (Foksinski et al., 
1998). 
Cancer 
It is now accepted that cancer occurs in a stepwise fashion and a series of 
discrete complementary events must occur to convert a normal cell into a cancer cell 
(Bishop, 1991; Weinberg, 1989). These cancer cells act as the site of origin for yet 
another new or altered non-cancerous cell and with each step, the process shows an 
increased probability of evolving ultimately into a malignant tumor. 
It can be stated that tumor formation requires the following steps: (1) 
inactivation of Rb and p53 cellular pathways; (2) activation of Ras and/or other 
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growth promoting pathway; (3) inactivation of phosphatase 2A that causes changes in 
the phosphorylation and activity of several cellular proteins; (4) evasion of apoptosis; 
(5) telomerase activation or alternative mechanisms of cellular immortalization; (6) 
angiogenic activity and (7) the ability to invade surroimding tissue and to metastasize 
(Boccheth and Carbone, 2004). The development of cancer in humans involves a 
complex interplay of genetic events that usually occur over many decades. During this 
multistep process of malignant transformation, cell acquire mutant alleles of 
oncogerie, tumor suppressor gene and other genes that control cell proliferation in 
order to become cancer cells (Hunter, 1997; Hanahan and Weinberg, 2000). 
Furthermore, an ever increasing number of genes have been shown to contribute to the 
phenotype of malignant transformation and changes in the expression of thousands of 
genes have been demonstrated, as normal cells imdergo neoplastic transformation 
(Baylin and Bestor, 2002). Therefore, the process of malignant transformation from 
normal human somatic cells to immortal tumor cells appears to be a very complex 
system of genetic alteration (Hunter, 1997). 
Earlier studies in transgenic mice confirmed that pairs of collaborating 
oncogenes capable to transform cells in vitro could also drive tumor formation in vivo 
(Thompson et al., 1989; Sharpless et al., 2002). However, it is clear that these models 
do not perfectly recapitulate human cancer development. In contrast to these 
observations in animal models, kinetic analyses have shown that in case of most 
human tumors, four to six rate-limiting events were required for cancer promotion 
(Armitage and Doll, 2004). 
Indication that the process of malignant transformation can also be simplified 
to a few disrupted molecule circuits come from biochemical and molecular analyses of 
the regulatory pathways involved in most type of human cancer. In recent years, such 
studies have determined that alterations in regulatory mechanism disrupting the 
dependence of normal cell on mitogenic stimulation, most frequently through the ras 
signaling pathway (Hahn and Weinberg, 2002), in addition to the pathways important 
in cellular immortalization as pRB, p53 and the maintenance of telomeres, are 
required for the malignant transformation from normal to tumor cells. Cancer cells 
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have a markedly reduced dependence on external mitogenic stimulation (McCrmick, 
1999). This acquired interdependence derives from the activities of oncogenes 
(Shields et al., 2000). In human cancer, multiple proteins have been found to be 
altered, providing constitutive growth stimulatory signals (Ellis and Clark, 2000). 
It is generally acknowledged that gene mutations are at the core of the 
carcinogenesis. Infact, increasing number of skeptics are voicing their doubts about 
the value of the somatic mutation theory (SMT) (Jaffe, 2003; Soto and Sonnenschein, 
2004; Van Regenmortel, 2004; Fukino et al., 2004). Two main forces fuel this 
revisionist process: the first is that, despite the aggressive effort by laboratories around 
the world to vindicate the SMT and its ancient and modem variations (aneuploidy, 
oncogene/repressor gene balance, etc), the bill of goods promised after the dawn of the 
molecular biology revolution has not been delivered (Hahn and Weinberg, 2002; 
Rangarajan and Weinberg, 2003). The second force is the increasing accumulation of 
data emphasizing the role of tissue interaction in carcinogenesis (Barcellos-Hoff and 
Ravani, 2000; Maffini et al., 2004). This almost imperceptible switch of targets from a 
cell to a tissue-based etiopathogenesis does not fit easily into the expectation 
anticipated by the SMT. Pragmatic tissue-based models have been incorporated into 
the mix of options to explain both carcinogenesis and metastasis. An increasing 
number of researchers are favouring hybrid theory of carcinogenesis that incorporates 
element of the original SMT (mutations are the cause of cancer) and a role of 
stroma/epithelial interactions on this process (Bissell and Radisky, 2001). The later 
has also been dubbed the epigenetic theory of carcinogenesis, implying that tissue-
based phenomena are due to epigenetic gene expression modifications. 
DNA damage plays a major role in mutagenesis and has been demonstrated to 
posses a potential role in the initiation, promotion and malignant conversion 
(progression) stages of carcinogenesis (Bont and Larebeke, 2004). In living cells ROS 
are formed continuously as a consequence of metabolic and other biochemical 
reactions as well as external factors. These ROS can oxidize DNA, which can lead to 
several types of DNA damage, including oxidized bases and single and double-strand 
breaks. Oxidatively modified DNA, despite extensive DNA repair, was found to be 
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abundant in many human tissues, especially in tumors (lida et al., 2001; Li et al., 
2002). Oxidative stress occurs when the production of ROS exceeds the body's natural 
antioxidant defense mechanism, causing damage to macromolecules such as DNA, 
proteins and lipid. ROS also inactivate antioxidant enzymes (Tabatabaie and Floyed, 
1994). Any change in the endogenous generation of ROS or cellular antioxidant or in 
the efficiency of DNA repair should cause a corresponding modulation of the steady-
state levels of oxidative DNA modification, which in turn should modulate the 
mutation rate and ultimately the cancer incidence (Epe, 2002). 
Levels of oxidative bases in DNA are the consequences of a balance between 
lesion induction from radical processes and repair capacity has been seen as a potential 
marker of cancer susceptibility. Earlier evidence showed that exposure of cell to H2O2 
and perhaps other oxidants, may actually suppress DNA repair in addition to induce 
DNA damage (Hu et al., 1995). Human OGGl (hOGGl) removed 8-OH-Gua from 
DNA and plays a major role in the prevention of ROS-induced carcinogenesis. 
Therefore, inactivation of the hOGGl gene could increase the likelihood of malignant 
transformation. Although levels of hOGGl mRNA were normal in all tumors 
examined, sequencing studies revealed that 3 of 40 tumors possessed homozygous 
mutations, all of which result in an amino acid change in hOGGl protein (Chevillard 
et al., 1998). Kohno et al. (1998) described a genetic polymorphism at codon 326 in 
the hOGGl gene that led to differing activities between the isoform. Interindividual 
variability in 8-OH-Gua repair could derive from a polymorphic hOGGl genotype 
(Kohno et al., 1998). This suggestion is supported by a report of polymorphisms and 
alternative splicing of the hOGGl gene in human clear cell carcinoma of kidney, some 
of which resulted in an impaired or inactive form of hOGGl(Audebert et al., 2000). 
However, comparison of hOGGl genotype and 8-OH-Gua levels in lung cancer 
specimens failed to show that polymorphic variation could affect tissue 8-OH-Gua 
(Hardie et al., 2000). 
It is a well known fact that viruses can cause cancer tumors. Viruses are 
associated with a variety of human malignancies. Both hepatitis B virus (HBV) and 
hepatitis C virus (HCV) cause hepatocellular carcinoma (HCC) (Robinson, 1999; 
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Tanaka and Tsukuma, 1999); Epstein-Barr virus (EBV) is etiologically linked to 
burkitt's lymphomas, nasopharyngeal carcinoma (NPC), post-transplant lymphomas, 
Hodgkin's disease and possibly other tumors (Jeannel et al., 1999; Brook et al., 1999); 
human papilloma virus are the cause of cervical cancer, skin cancer in patients with 
epidermodysplasia verruciforms and possibly head and neck cancer and other 
anogenital cancer (Howley and Munger, 1999; Zur Hausen, 1999). It is estimated that 
-15% of all human tumors have a viral etiology (Parkin et al., 1999). The percentage 
of virus-related cancers is ~3 fold higher in developing countries than developed 
countries (Parkin et al., 1999), reflecting the prevalence of infection by the causative 
viruses and exposure to cooperating cofactors. 
Various endogenous and exogenous agents have been investigated as possible 
cooperating component in virus-mediated carcinogenesis. Most Burkitt's lymphoma 
are EBV-positive and also show characteristic chromosomal translocation between the 
c-myc gene and immunoglobin loci, leading to the constitutive activation of myc 
expression (Imreh et al., 1997). Long-term consimiption of sahed or dried fish, known 
to contain high levels of nitrosamines, has been implicated as a dietary cofactor in 
EBV-related NCP (Jeannel et al., 1999). Dietary exposure to another carcinogen, 
aflatoxin, has been proposed as a cofactor (Buendia, 1992; Montesano et al., 1997). 
Exactly how dietary carcinogens cooperate with viral infection to increase cancer 
development is not known. However, it has been concluded that selected groups of 
individuals are likely to suffer greater risk from exposure to environment carcinogens 
than the general population (Perera, 1996). 
There are multitudes of factors involved in cancer etiology (Gourley et al., 
1992). Envirormiental factors such as radiations, sunlight, pesticides and medications 
are knovm to increase cancer (Anathaswamy and Pierceall, 1990; Liehr, 1997). There 
were instance in which the relative risk of cancer increased significantly (>10%) 
following exposure to exogenous agents, such as skin cancer caused by UV light 
(Nakazaw et al., 1994), lung cancer due to cigarette smoking and bladder cancer due 
to aromatic amines (Lutz et al., 1998). In addition, several estrogen metabolites are 
known to play important role in tumor promotion (Hiraku et al., 2001), through redox 
21 
cycling processes that generate ROS (Yager and Liehr, 1996). In estrogen-induced 
carcinogenesis, estrogen metabolites, particular catechol oestrogen (CEs), are involved 
in the initiation process through oxidative DNA damage and oestrogen themselves 
enhances cell proliferation, leading to tumor promotion (Hiraku et al., 2001). 
Role of Different Hydroxylated Estrogen in the Etiopathogenesis of Cancer 
As describe above, estrogen undergo multiple pathway NADPH-dependent 
estrogen hydroxylation (Zhu and Conney, 1998). Aromatic hydroxylation of estradiols 
occurs primarily at C-2 and to a lesser extent at C-4, to form the 2, 3- and 3, 4-
catechol estrogen (CES) respectively. These metabolites are intermediate for the 
generation of the reactive semiquinones and quinones. Both semiquinone and 
quinones have the ability to DNA damage (Cavalieri et al., 1997; Cavalieri, 2000) and 
protein directly or indirectly through redox cycling and generation of reactive oxygen 
species (ROS). They have been implicated as potential initiator of tumor formation 
(Cavalieri et al., 2000; Yager, 2000). 2-hydroxyestradiol and 2-hydroxyestrone can 
undergo metabolic redox cycling to generate free radical such as superoxide and the 
chemically-reactive estrogen semiquinone/quinone intermediates (Liehr and Roy, 
1990) which may damage DNA and other cellular intermediates (Han and Liehr, 
1994). Inspite of that, 2-hydroxyestradiol and 2-hydroxyestrone have little or no 
tiunarigenic activity towards the male syrium hamster kidney (Li and Li, 1987). The 
lack of carcinogenic activity of 2-hydroxyestradiol and 2-hydroxyestrone is possible 
due to its faster rate of metabolism by catech-o-methyl transferase catalyzed o-
methylation (Roy et al., 1990), more rapid clearance in vivo (Emons et al., 1987) and 
posses weak hormonal potency in estrogen target tissue (Schutz et al., 1994). In 
addition, 2-methoxyestradiol is very potent inhibitor of tumor cell proliferation 
(Hamel et al., 1996) and angiogenesis (Klauber et al., 1997), which may be an 
important reason for the lack of carcinogenicity of 2-hydroxy estradiol in vivo. 
4-Hydroxyestradiol had greater carcinogenicity than 2-hydroyestradiol in 
Syrian hamster kidney and mouse uterine tumor models (Yager, 2000; Liehr, 1999). 
Moreover, the catechol estrogens, like the parent molecules, bind to the estrogen 
receptor and have been shown to be estrogenic, with 4-hydroxyestradiol reported to 
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have greater affinity and effect than 2-hydroxyestradio) (Villalobos et al., 1996). 
Studies show that 4-hydroxyestradiol is a major catechol estrogen capable of 
producing the oxidative damage because 2-hydroxyestradiol has no effect on the 
system. These data support other in vivo and in vitro studies showing 4-
hydroxyestradiol to be the more mutagenic and carcinogenic metabolite (Liehr, 2000; 
Cavalieri et al., 2000). This may be due to increased ability of the 4-OHE2 metabolites 
to consiune oxygen and generate DNA strand breaks in the presence of Cu(ll) 
(Thibodeau et al., 2002) or decreased level of inactivating conjugation compared with 
2-OHE2 (Zhu and Conney, 1998). These studies suggest that atleast in some system, 2-
hydroxyestradiol and 4-hydroxyestradiol have similar potential to participate in redox 
cycling processes and cause oxidative damage. Thus difference observed in the 
carcinogenicity of 2-hydroxyesterdial and 4-hydroxyestradiol may be attributed at 
least in part, to differences in their inactivation in vivo (Lavigne et al., 2001). 
Both rat (Zhu and Liehr, 1993) and human (Goodman et al., 2001) catechol-o-
methyltransferase have been shown to have a higher catalytic activity toward 2-
hydroxyestradiol compared with 4-hydroxyestradiol which may contribute to the 
comparatively weaker carcinogenicity of 2-hydroxyestradiol. 2-methoxyestradiol 
which is formed by catechol-o-methyltransferase has been shown to increase 
apoptosis, inhibit growth and angiogenesis (Zhu and Conney, 1998; Purohit et al., 
2000). Moreover, catechol-o-methyltransferase catalyzed o-methylation of 4-
hydroxyestradiol is inhibited by 2-hydroxyestradiol, whereas the o-methylation of 2-
hydroxyestradiol is not inhibited by 4-hydroxyestradiol (Roy et al., 1990). This may 
result in the accumulation of this metabolite in these target tissue due to inhibition of 
its o-methylation. 4-hydroxyestradiol was found to be strong carcinogen towards the 
hamster kidney than 2-hydroxyestradiol under same condition (Li and Li, 1987). High 
4-hydroxylase activity is expressed in the uterus of CD-I mice (Bui and Weisz, 1998), 
the kidney of male Syrian hamsters (Zhu et al., 1994) and the pituitary of rats (Bui and 
Weisz, 1988), which are all target organs susceptible to estrogen-induced 
carcinogenesis (Li and Li, 1987). Similarly elevated estradiol 4-hydroxylase activity 
has also been observed in human breast cancer tissue compared to normal tissue (Liehr 
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and Ricci, 1996). These studies show that 4-hydroxyestradiol is strong carcinogen that 
must have possible role in the etiopathogenesis of estrogen-associated cancers. 
The increased formation of 16a-hydroxyestrogen metabolites may be 
associated with an increased risk for developing mammary cancer in mice and humans 
(Fishman et al., 1995). 16a-hydroxyestrone enhanced the carcinogen-inhibited growth 
stimulation of cultured mouse mammary epithelial cells (Suto et al., 1993). The extent 
of 16a-hydroxylation of estradiol was positively correlated with their mammary tumor 
incidence in several different strains of mice with varying incidence of spontaneous 
mammary tumors (Bradlow et al., 1985). Certain pesticides and polychlorinated 
biphenyl were reported to increase the role of 16a-hydroxylation of estrone and 
decrease the rate of 2-hydroxylation of estrone (Bradlow et al., 1995) in MCF-7 cells, 
a human breast cancer cell lines. 16a-hydroxyestrone and 16a-hydroxyestradiol are 
only very weak carcinogens in the estrogen-induced hamster kidney tumor under 
experimental conditions that produced a 100% tumor incidence (Warner and 
Gustafsson, 1994). Pregnant women produce very large amounts of 16a-
hydroxyestradiol and 16a-hydroxyestrone during normal pregnancy and full term 
pregnancy actually decreases their risk of breast cancer (Fotsis, 1987). Although above 
studies suggest that increased formation of 16a-hydroxylated estrogen metabolites 
may be associated with an elevated risk of breast cancer, it should be noted that these 
studies have not yet received sufficient confirmation by other investigators using 
different experimental setting and that the evidence is not sufficiently strong to 
support the hypothesis of an etiological role of 16a-hydroxylated estrogen in cancer 
development. 
Systemic Lupus Erythematosus 
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease 
characterized by production of autoantibodies against many different autoantigens, 
typically including nucleic acid and associated protein (Mok and Lau, 2003). 
Significant health consequences include renal failure, vasculitis, thrombosis, seizures 
and other neurologic complications (Mills, 1994). Almost all autoimmune diseases are 
more common in women, but the female predominance in SLE is particularly strong. 
24 
At least 85% of patients with SLE are women (Jacobson et al., 1997). The central 
immunological disturbance in patients with SLE is autoantibody production. These are 
directed at several self molecules found in nucleus, cytoplasm and cell surface (Harada 
et al., 1994). In addition, autoantibodies are also directed against platelets, 
lymphocytes, polysaccharides (Kashihara et al., 1993), phospholipids (Tiikainem et 
al., 1991), cell membrane structure (Jacob et al., 1986) and nucleoproteins (DNA-
histone, nuclear ribonucleoproteins like Sm and Mo, cytoplasmic ribonucleoproteins ) 
(StoUar, 1981). The most remarkable feature of anti-DNA antibodies is their 
association with glomerulonephritis. Anti-DNA antibodies can be isolated in an 
enriched form from glomerular elutes of patients with active lupus nephritis and anti-
DNA antibodies can induce nephritis in normal and immunodeficient mice (Ehrenstein 
et al., 1995). Anti-DNA antibodies differ in their properties, including isotype, ability 
to fix complement and capacity to bind to the glomeruli causing pathogenicity 
(Vlahakos et al., 1992). Only certain types of anti-DNA antibodies are pathogenic 
(Hahn, 1998). First, clinical observation in most patients indicate that active nephritis 
is associated with raised anti-DNA antibody titres and reduced total haemolytic 
complement values (Bootsma et al., 1995). Second, anti-DNA antibodies show 
preferential deposition m the kidneys, suggesting that DNA-anti-DNA antibody 
immune complexes are the main mediators of inflammation (Foster et al., 1993). 
SLE is characterized by a myriad of immune system aberrations that involve 
B cells, T cells and cells of the monocytes lineage, resulting in polyclonal B cell 
activation, increased number of antibody producing cells, hypergamma globulinaemia, 
autoantibody production and immune complex formation (Mok and Lau, 2003). The 
activation of B and T cells requires stimulation by specific antigens. Chemicals such 
as pristine, bacterial DNA and cell wall phospholipids and viral antigens can induce 
anti-DNA antibodies in mice (Hahn, 1998). Moreover, self antigens, such as DNA-
protein and RNA-protein complexes may induce autoantibody production (James et 
al., 1995). B cell activation is abnormal m patient witii SLE. The number of B cells at 
all stages of activation is increased in the peripheral blood of patients with SLE 
(Klinman et al., 1991). These B cell abnormalities can precede the development of 
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SLE. Activated lupus B cells have higher intracytoplasmic calcium responses than 
controls (Liossis et al., 1996). There is also evidence that B cells in patients with SLE 
are more sensitive to the stimulatory effects of cytokines such as IL-6 than non-SLE B 
cells (Linker-Isreali et al., 1991). More over, the phenomenon of epitope spreading has 
been demonstrated in both human and murine SLE (Monneaux and Mullar, 2002). 
Abnormalities in T cell function are also evident in patient with SLE. The total 
number of penpheral blood T cells is usually reduced, probably because of the effects 
of anti-lymphocyte antibodies (Bakke et al., 1983). There is a skewing of T cell 
function toward B cell help, leading to enhanced antibody production (Linker-Isreali 
et al., 1991). Experiments have shown that the early events of T cell activation are 
defective in patients with SLE compared to controls (Portales-Perez et al., 1997). 
Down regulation by excessive Th 2 cytokines, defective interaction between APCs 
and T cells, the suppressive effects of CD8 T cells and natural killer (NK) cells, the 
presence of IL-2 inhibitors and the down regulation of IL-2 receptor are possible 
mechanisms (Lauwerys and Houssiau, 1998). 
Many cytokines have been implicated in regulating disease activity and in the 
involvement of different organs in patients with SLE (Dean et al., 2000). Lupus T cells 
are less responsive to IL-2 stimulation than normal T cells (Warrington, 1988). 
However, the expression of IL-2 in freshly prepared SLE peripheral blood 
mononuclear cells (PBMCs) was increased compared with control PBMCs (Horwitz et 
al., 1994). Lupus T cells are capable of producing normal amount of IL-2 in response 
to optimal stimulation with phytohaemagglutin combined with phorbol esters or with 
anti-CD 28 antibodies (Garcia-Cozar et al., 1996). IL-10 played important role in the 
pathogenesis of SLE. Earlier studies have shown that spontaneous production of IL-10 
from SLE peripheral blood B cells and monocytes is significantly higher than controls 
(Llorente et al., 1994). The expression of IL-10 transcripts was significantly increased 
in the non-T cell population of PBMCs from patients with SLE compared with 
controls (Csiszar et al., 2000). Moreover, serum IL-10 concentration are higher in 
patients with SLE than in controls and are correlated with clinical and serological 
disease activity and anti-DNA antibody litres (Grondal et al., 2000). Similarly IL-12 
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production was found to be impaired in stimulated PBMCs from patients with SLE 
compared with match controls (Lui and Jones, 1998). IL-12 promotes cell mediated 
immune responses but exerts some inhibitory activities on humoral responses 
(Trinchieri, 1994). The results from these studies suggest that dysregulation of the IL-
lO/IL-12 balance play a crucial role in the impaired cellular immune responses seen in 
patients with SLE. 
Defective immune regulatory mechanisms, such as the clearance of apoptotic 
cell and complexes, were important contributors to the development of SLE (Mok and 
Lau, 2003). MRL/Ipr mice are characterized by the presence of the Ipr gene, which is 
associated v^th Fas (CD95) receptors on the surface of lymphocytes. The interaction 
of Fas and Fas ligand (Fas L) transduces an active signal for cellular apoptosis (Suzuki 
et al., 1998). Defective Fas mediated apoptosis in MRL/Ipr mice results in massive 
lymphoproliferation and the development of a severe lupus-like disease with immune 
glomerulonephrities (Theofilopoulos and Dixon, 1981). Gld/gld mice, characterized 
by a mutation in the Fas L gene leading to a non-functional Fas L molecule, also 
develop lymphoproliferation, hypergamma globulinaemia and immunoglobulin 
deposits in the kidney (Takahashi et al., 1994). Patients or mice with homozygous Clq 
deficiency develop autoantibodies and lupus-like syndrome apparently because of the 
inability to eliminate apoptotic cells effectively, which leads to an increase in the 
exposure of antigens to the immune system (Walport and Davies, 1998). Mice with a 
targeted deletion of Clq show glomerulonephritis with deposits of immune complexes 
and apoptotic cell in the glomeruli. 
In addition, environmental factors, such as chemicals and drugs, UV light, 
dietary factors, viruses and estrogen are probably required to participate the onset of 
the disease. 
Role of Hydroxylated Estrogen in the Etiopathogenesis of SLE 
Estrogen (mainly 17p-estradiol, estradiol) and their metabolites seem to play 
important role in systemic lupus erythematosus (SLE) and autoimmune rheumatic 
disease (Weidler et al., 2004). A role for estrogens in the pathogenesis of SLE has 
been suspected for many years (Chapel and Bums, 1971; Fine et ah, 1981). SLE is 
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nine times more common in woman than men and fifteen time more common during 
the child bearing years. Patients with Klienfelters syndrome (i.e male with 47 
chromosomes and an XXY complement by karyotype analysis) are hyperestrogenic 
and have an increased incidence of SLE (Stem et al., 1977). Studies have revealed an 
abnormal pattern of estrogen metabolism among SLE patients where by the 16a-
hydroxylation pathway is used as the major catabolic route. (Lahita et al., 1979; 
Bradlow et al., 1982; Lahita et al, 1985; Bucala et al., 1985; Weidler et al., 2004). 
This pathway generates metabolic intermediate which fiinction as reactive haptens 
capable of forming covalent adducts with epsilon amino groups of lysine residues via 
a Heyns-types rearrangement (Bucala et al., 1987). These conjugated products are 
thought to elicit the production of anti-estrogen antibodies. Numerous case reports 
may be found in the literattire demonstrating an association between the administration 
of certain synthetic estrogen which are largely catabolized by the 16a-hydroxyIation 
route, e.g. ethyl- estradiol and the onset of a drug-induced lupus like syndrome (Lahita 
et al., 1979; 1981; Barret et al., 1986). 
16a-hydroxyestrone is a mitogenic and proliferative endogenous hormone that 
covalently binds to the estrogen receptor leading to nuclear translocation (Telang et 
al., 1992). Conversion products of estrone and estradiol are the 2-hydroxylated 
estrogens such as 2-hydroxyestrone and 2-hydroxyestradiol. In contrast to 16-
hydroxylated estrogens, the 2-hydroxylated forms inhibit growth promoting effect of 
estradiol (Bradlow et al., 1996). The study shows that urinary concentrations of the 2-
hydroxylated estrogens were 10 times lower in patients with rheumatoid arthritis and 
SLE than in healthy control, where as the rate of 16-hydroxyestrone/2-
hydroxyestrogens was 20 times higher in rheumatoid arthritis (RA) and SLE than in 
controls (Weidler et al., 2004). In a patient with RA and SLE, the magnitude of 
conversion to the mitogenic 16a-hydroxyestrone is greatly up regulated, which likely 
contributes to maintenance of the proliferative state in these diseases. Elevated serum 
concentration of 16a-hydroxyestrone have been described in the patients with SLE 
(Lahita et al., 1979) suggesting that abnormal patterns of estradiol metabolism may 
lead to increased estrogenic activity. Similarly there was a significantly higher 
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concentration of 16-hydroxyestrone/4-hydroxyestradiol in the synovial fluids of 
patients with RA as compared with control fluids (Castagnetta et al., 2003). The 
alterations in estrogen metabolism have been reported in both male and female 
patients (Cutolo et al., 2003; McMurray and May, 2003). Peripheral estrogen 
hydroxylation found to be increased in both man and women with SLE and estrogenic 
metabolite were reported to increase B cell differentiation and activate T cells (I.ahita, 
1996). 
Estradiol was formed to increase IgG and IgM production by peripheral blood 
mononuclear cell from patients with SLE which lead to elevated levels of polyclonal 
IgG, including IgG anti-double strand DNA, by enhancing B cell activity via IL-10 
(Kanda et al., 1999). These later result should also be replicated in the presence of 16-
hydroxyestrone, as well as with the naturally occuring 2-hydroxylated antiestrogen. 
Although Weidler et al (2004) showed that disease activity in SLE was negatively 
correlated to urinary concentration of 2-hydroxylated estrogen. These studies show 
that hydroxylated estrogen might have a role in the etiopathogenesis of SLE and other 
autoimmune disease. 
Hydroxylated Estrogen, Metal ions and Nitric oxide 
Estradiol undergoes cytochrome P-450-catalyzed hydroxylation to various 
catechol estrogens (Zhu and Conney, 1998). These catechol estrogens have been 
reported to be easily oxidized to their quinones enzymatically by phenol oxides 
(Kalyanaraman et al., 1985), prostaglandin H (Degen, 1990), Horseradish peroxidase/ 
H2O2 and cytochrome P450 oxidase (Liehr et al., 1985). In addition to cytochrome 
P450 oxidase/ reduction, there is alternative non-enzymatic mechanism which can 
mediate the metabolism of xenobiotices to oxidized intermediates (Trush and Kensler, 
1991). Studies have demonstrated that catechol estrogen have been easily oxidized to 
their quinones non enzymatically by copper (Hiraku et al., 2001). This non enzymatic 
oxidation of catechol estrogen (2-hydroxy and 4-hydroxyestradiol) by copper result in 
the generation of reactive oxygen species that can cause DNA damage (Thibodeau and 
Paquette, 1999). Catechol estrogen under Cu(II)-mediated autoxidation resulted in the 
formation of corresponding radicals and quinones. The formation of the semiquinone 
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radicals has been confirmed by an electron spin resonance study (Seacat et al., 1997). 
4-Hydroxyestradiol shown to be major carcinogenic metabolite capable of producing 
oxidative damage than 2-hydroxyestradiol (Bianco et al., 2003). This may be due to an 
increased ability of the 4-hydroxyestradiol to consume oxygen and generate DNA 
strand breaks in the presence of Cu (Thibodeau et al., 2002). Studies have showed that 
2-hydroxyestradiol and 4-hydroxyestradioI in the presence of copper caused similar 
amount of DNA strand break (Li et al., 1994), although electron spin studies indicated 
that in the presence of copper, 4-h}'droxyestradiol generated somewhat greater amount 
of hydroxy radical than 2-hydroxyestradiol (Seacat et al., 1997). In addition 
carcinogenic catechol estrogens type compounds such as catechol, flavonoids also 
induced oxidative DNA damage through H2O2 generation (Oikawa et al., 2001) in 
presence of Cu (II). Catechol did not cause DNA damage in the presence of other 
metals ions (Fe^^, Co^* Ni^^ Mn^ ^ or Mg ^ )^ (Oikawa et al., 2001). In order to inhibit 
these estrogen-mediated biological effects, it may be important to develop different 
strategies to block the production of reactive oxygen species by catechol estrogen-
redox cycle. 
In audition to the above described copper mediated non-enzymatic oxidation 
of catechol estrogen, catechol estrogen can also be oxidized in the presence nitric 
oxide (Yoshie and Ohshima, 1998). Nitric oxide (NO), a multifaceted bioregulatory 
agent (vasodilators, neurotransmitter) produced by many types of cells is known to 
play a critical role in both regulatory process and cell defence. It also participates in 
various collateral reactions, leading to DNA damage (Dixit and Ali, 2004). Quinone 
derivatives of catechol-estrogen produced by NO-mediated oxidation may form DNA 
adduct covalent binding with nucleophilic groups of nucleic acid (Abdul-Haji et al., 
199.'>; Stack et al., 1996). As catechol-estrogens are structurally similar to catechol and 
catecholamines these structurally similar compound are also oxidised in the presence 
of nitric oxides (Oikawa et al., 2001). Retrospective studies have suggested a role of 
NO in the pathogenesis of SLE by demonstrating elevated levels of NO in these 
patients (Wanchu et al., 1998). Elevated levels of NO in SLE correlate with disease 
activity (Gilkeson et aJ., 1999). 
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Objectives of the Present Study 
Estrogens are known to be complete carcinogen in estrogen susceptible tissue. 
Possible mechanisms may include differential metabolism with subsequent formation 
of reactive oxygen species, which may also involve indirect modulation of 
intracellular redox state. Estrogen-mediated oxidative DNA damage includes the 
formation of 8-oxo-2-deoxyguanosine, both in vitro and in vivo, thereby suggesting a 
role for oxidative stress in the initiation and/or progression of cancer. 4-
hydroxyestradiol is more carcinogenic than 2-hydroxyestradiol. In addition, estrogen 
can modulate immune response and play role in various autoimmune diseases 
including SLE. Abnormal estrogen metabolism has been demonstrated in SLE 
suggesting significantly raised 16-a hydroxyestrone concentration. In the present 
study, the following aspects have been studied. 
1. pUC 18 plasmid DNA was isolated from E. coli by using_Qiagen plasmid Mega kit 
and modified with 4-OHE2 and NO. 
2. Native plasmid DNA was also subjected to 4-OHE2 and Cu(II) modification. 
3. The modifications on DNA were studied by UV spectroscopy, fluorescence 
spectroscopy, circular dichroism, thermal denaturation studies, nuclease SI 
susceptibilty and restriction enzyme digestion. 
4. DEAE Sephadex A-25 was used to quantify base modification in the modified 
DNA. 
5. Polyclonal antibodies against 4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA were 
generated in experimental animals. The repertoire of specificities of induced 
antibodies was evaluated by their binding to various nucleic acid polymers. 
6. These antibodies were used as an immunochemical probe to detect oxidative 
damage in the DNA, isolated from cancer patients. 
7. In order to asses the possible role of 4-OHE2-NO and 4-OHE2-Cu(II) modified 
epitopes in the etiology of cancer, sera from various cancer patients were studied 
for their recognition of native and modified DNA. The recognition of native and 
modified DNA samples by autoantibodies in the sera of SLE patients has also been 
investigated. 
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EXPERIMENTAL 
MATERIALS 
Calf thymus DNA, nuclease SI, 4-hydroxyestradiol (4-OHE2), sodium 
nitroprusside (SNP), catalase, Protein-A Agarose (2.5 ml pre-packed column), 
proteinase K, mannitol, uric acid, superoxide dismutase, restriction enzymes (Pvu I, II, 
Ssp I), cuprous chloride (CUCI2), DNase I (RNase free), bovine serum albumin, anti-
human/anti-rabbit IgG-alkaline phosphatase conjugate, p-nitrophenyl phosphate, 
ethidium bromide, Coomassie Brilliant Blue G-250 and R-250, sodium dodecyl 
sulphate, Tween 20, Millipore filter (0.45 i^m pore size), Freund's complete and 
incomplete adjuvants, polydeoxyribonucleotides, and agarose were from Sigma 
Chemical Company, USA. Synthetic polynucleotides, Ficoll 400, xylene cyanol FF, 
DEAE Sephadex A-25 were purchased from Pharmacia Fine Chemicals, Sweden. 
Folin-Ciocalteau reagent and Blue Dextran 2000 were purchased from Centre for 
Biochemical Technology, New Delhi. Absolute ethanol was obtained from BDH 
Laboratory Supplies, England. Polystyrene microtitre flat bottom ELISA plates having 
96 wells (7 mm diameter) were purchased from NUNC, Dermiark. Acrylamide, 
ammonium persulphate, bisacrylamide, N, N, N'N'-tetramethylethylenediamine 
(TEMED) were from Bio-Rad Laboratory U.S.A. EDTA (disodiimi salt), sucrose, 
chloroform, isoamyl alcohol, methanol, phenol, glacial acetic acid were from 
Qualigens, India. Plasmid (pUC 18) was isolated from £ coli (TBI) by QIAGEN 
plasmid Mega kit (USA). Diphenylamine was chemically pure. All other 
reagents/chemicals were of the highest analytical grade available. 
Equipments 
Shiraadzu UV-240 spectrophotometer equipped with thermoprogrammer and 
controller, JASCO J-810 spectropolarimeter, spectroflurometer (Hitachi F2000, Japan), 
ELISA microplate reader (Labsystem Multiskan EX, Finland), Elico pH meter LI-120, 
Ultraviolet transilluminator (Vilber Lourmat, France), Avanti 30 table top high speed 
refrigerated centrifuge (Beckman, USA), Agarose gel electrophoresis assembly GNA-
100 (Pharmacia, Sweden), polyacrylamide gel electrophoresis assembly (Bio-Rad, 
USA) were the major e*^uipments used in this study. 
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Collection of Sera and Blood Samples 
Normal human sera were obtained from healthy subjects. SLE and cancer sera 
were obtained from outdoor and indoor patients of J. N. Medical College Aligarh 
Muslim University, Aligarh and Department of Medicine, All India Institute of 
Medical Sciences, New Delhi. The SLE sera showed high anti-DNA antibodies and 
fulfilled the American College of Rheumatology revised criteria for the classification 
ofSLE(Amettatal., 1988). 
METHODS 
Determination of DNA Concentration 
DNA concentration was estimated colorimetrically by the method of Burton 
(1956) using diphenylamine reagent. 
(a) Crystallization of diphenylamine 
Diphenylamine (2 gm) was dissolved in 200 ml boiling hexane. After adding 
0.5 gm of activated charcoal, the hot mixture was passed through Whatman No. 1 
filter paper and the filtrate was kept overnight at 4 °C and dried at room temperature 
before use. 
(b) Preparation of diphenylamine reagent 
750 mg of recrystallized diphenylamine was mixed with 50 ml of glacial acetic 
acid and 0.75 ml concentrated sulphuric acid. The reagent was prepared fresh before 
use. 
(c) Procedure 
One ml of DNA sample was mixed with 1.0 ml of IN perchloric acid and 
incubated at 70 °C for 15 min. One hundred |il of 5.43 mM acetaldehyde was added 
followed by 2 ml of fi-eshly prepared diphenylamine reagent. The contents were mixed 
and incubated at room temperature for 16-20 hr. Absorbance was read at 600 nm and 
the concentration of DNA in unknown samples was determined from a standard plot 
of calf thymus DNA purified free of RNA and proteins. 
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Determination of Protein Concentration 
Protein was estimated by methods of Lowry et al (1951) and Bradford (1976). 
Protein estimation by Folin's-phenol reagent 
The protein estimation by this method utilizes alkali (to keep the pH high), 
Cu^ "^  ions (to chelate proteins) and tartarate (to keep the Cu^ "^  ions in solution at high 
pH). 
(a) Folin-Ciocalteau reagent 
The reagent was purchased from Centre for Biochemical Technology, New 
Delhi and diluted 1:4 with distilled water before use. 
(b) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as follows: 
(i) 2 percent sodium carbonate in 100 mM sodium hydroxide 
(ii) 0.5 percent copper sulphate in 1.0 percent sodium potassium tartarate. 
The working reagent was prepared fresh before use by mixing components (i) 
and (ii) in 50:1 ratio. 
(c) Procedure 
To 1.0 ml of protein sample was added 5.0 ml of alkaline copper reagent and 
incubated for 10 min at room temperature. One ml of working Folin-Ciocalteau 
reagent was added and the tubes were read at 660 nm after 30 min. The concentration 
of protein in unknown sample was determined from a standard plot of bovine serum 
albumin. 
Protein Estimation by Dye Binding Method 
This assay is based on color change when Coomassie Brilliant Blue G-250, in 
acidic medium, binds strongly to protein hydrophobically at positively charged groups 
(Bradford, 1976). In the environment of these positively charged groups, protonation 
is suppressed and a blue color is observed (Amax-595 nm). 
(a) Dye preparation 
One hundred mg Coomassie Brilliant Blue G-250 was dissolved in 50 ml of 
95% ethanol and 100 ml of 85% (v/v) orthophosphoric acid was added. The resulting 
solution was diluted to a final volume of 1 litre and filtered through Whatman No. 1 
filter paper to remove undissolved particles. 
(b) Protein assay 
To 1 ml of solutions containing 10-100 jig protein was added 5 ml of dye 
solution and contents mixed by vortexing. The absorbance was read at 595 nm after 5 
min against a reagent blank. 
Purification of Calf Thymus DNA 
Commercially available calf thymus DNA was purified free of proteins and 
single stranded regions as described by Ali et al. (1985). DNA (2 mg/ml) was 
dissolved in 0.1 X SSC buffer (15 mM sodium citrate and 150 mM sodium chloride, 
pH 7.3) and extracted with an equal volume of chloroform isoamyl alcohol (24:1) in a 
stoppered container for 1 hr. The aqueous layer containing DNA was separated from 
the organic layer and re-extracted with chloroform-isoamyl alcohol. The DNA was 
precipitated with two volume of cold absolute ethanol and collected on a glass rod. 
After drying in air, the DNA was dissolved in acetate buffer (30 mM sodium acetate 
containing 30 mM zinc chloride, pH 5.0) and treated with nuclease SI (150 units/mg 
DNA) at 37 °C for 30 min to remove single stranded regions. The reaction was 
stopped by adding one-tenth volume of 200 mM EDTA, pH 8.0. Nuclease SI treated 
DNA was extracted twice with chloroform: isoamyl alcohol as before and finally 
precipitated with two volumes of cold ethanol. The precipitate was dissolved in 
phosphate-buffered saline (10 mM sodium phosphate containing 150 mM sodium 
chloride), pH 7.4. 
Polyacrylamide Gel Electrophoresis of Proteins 
PAGE was performed as described by Laemmli (1970). 
(i) Acrylamide-bisacrylamide (30:0.8) 
A stock solution was prepared by dissolving 30 gm of acrylamide and 0.8 gm 
bisacrylamide in distilled water to a final volume of 100 ml. 
(ii) Resolving gel buffer 
A stock solution was prepared by dissolving 36.3 gm Tris base in 48.0 ml of 
IN HCl. The contents were mixed, pH adjusted to 8.8 and the final volume brought to 
100 ml with distilled water. 
(iii) Stacking gel buffer 
6.05 gm Tris was dissolved in 40 ml distilled water, pH titrated to 6.8 with IN 
HCl and the final volume adjusts to 100 ml with distilled water. 
(iv) Electrode buffer 
3.03 gm Tris, 14.4 gm glycine and 1.0 gm SDS were dissolved in distilled 
water pH adjusted to 8.3 and final volume made up to one litre. 
(v) Procedure 
Glass plates, separated by 1.5 mm thick spacer were sealed with 1% agarose. 
The resolving gel mixture was prepared by mixing the components in the appropriate 
volume and poured into the space between the glass plates leaving sufficient space at 
the top for the stacking gel. After the polymerization of separating gel, stacking gel 
mixture was poured and allowed to solidify. Protein samples containing 10% glycerol 
and 0.002% bromophenol blue were applied and electrophoresis was carried out at 
60V for 6-8 hr. Staining of the gel was achieved with 0.1% Coomassie Brilliant Blue 
R-250 (in 25% isopropanol and 10% glacial acetic acid). Destaining was carried out in 
a mixture of 10% acetic acid and 10% methanol. 
Recipe for 7.5% SDS-PAGE 
Solutions 
Acrylamide-bisacrylamide 
Stacking gel buffer 
Resolving gel buffer 
Distilled water 
10% SDS 
1.5% ammonium persulphate 
Stacking gel 
1.25 ml 
2.5 m} 
— 
5.65 ml 
0.1ml 
0.5 ml 
Resolving gel 
7.5 ml 
3.75 ml 
16.95 ml 
0.3 ml 
i.5ml 
TEMED 0.75^1 15^1 
Isolation of Plasmid DNA 
Plasmid (pUC 18) was isolated from E. coli TBI by using QIAGEN plasmid 
Mega kit (USA). 
(a) Material used 
E. coli strain TBI was used throughout the study. Luria Broth was used for 
growth and ampicillin was added at a concentration of 100 |ag/ml. RNase A solution 
was added to buffer PI to give a final concentration of 100 i^g/ml supplied with the 
kit. 
(b) Composition of buffers in the kit 
Buffer Composition Storage 
Buffer PI (Resuspension Buffer) 
Buffer P2 (Lysis Buffer) 
Buffer P3 (Neutralization Buffer) 
Buffer FWB (QIAfilter Wash Buffer) 
Buffer QBT (Equilibration Buffer) 
Buffer QC (Wash Buffer) 
50 mM Tris-Cl, pH 8.0, 4 °C, after 
lOmMEDTA, addition of 
100 ^g/ml RNase A RNase. 
200 mM NaOH, 1 % SDS Room temp. 
3.0 M Potassium acetate, Room temp. 
pH5.5 or4°C 
750 mM NaCl; Room temp. 
50 mM MOPS, pH 7.0, Room temp. 
15%Isopropanol 
750 mM NaCl; Room temp. 
50 mM MOPS, pH 7.0, 
I5%Isopropanol, 
0.15% Triton X-100 
1.0 M NaCl, Room temp. 
50 mM MOPS, pH 7.0, 
37 
Buffer QF (Elution Buffer) 
Buffer QN (Elution Buffer) 
TE 
STE 
15% lisopropanol 
1.25MNaCl, 
50 mM Tris-HCl, pH 8.5, 
15%Isopropanol 
1.6MNaCl, 
50 mM MOPS, pH 7.0 
15%lsopropanol 
10 mM Tris-HCl, pH 8.0 
1 mM EDTA 
lOOmMNaCl, 
10 mM Tris-HCl, pH 8.0, 
1 mM EDTA 
Room temp. 
Room temp. 
Room temp. 
Room temp. 
(c) Isolation procedure 
Plasmid containing E. coli cells were grown in 10 ml L-broth containing 100 
)ig/ml ampicillin. After ~8 hr incubation at 37 °C, with vigorous shaking (-300 rpm) 
the culture was transferred to 500 ml L-broth containing 100 |ig/ml ampicillin and 
further incubated for 12-16 hr at 37 °C. Cells were harvested by centrifugation at 6000 
X g for 15 min at 4 °C and the supernatant was discarded off. The open centrifuge tube 
was left in an inverted position to allow all of the supernatant to drain away. The 
bacterial cell pellet was resuspended in 50 ml of Buffer PI containing RNase A. The 
bacteria should be resuspended completely by vortexing or pipetting up and dovra 
imtil no cell clumps remain. 50 ml of Buffer P2 was added and mixed gently but 
thoroughly by inverting 4-6 times and incubated at room temperature for 5 min. Then 
added 50 ml of chilled Buffer P3, mixed immediately but gently by inverting 4-6 times 
and incubated on ice for 30 min. The sample was mixed several times during ice-
incubation. The sample was centrifuged at >20,000 x g for 30 min at 4 °C. The 
supernatant was re-centrifiiged at >20,000 x g for 15 min at 4 °C. Supernatant 
containing plasmid DNA was promptly removed. Equilibrated a QIAGEN-tip 2500 by 
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applying 35 ml Buffer QBT and allowed the column to run on gravity flow. The 
supernatant was applied to the QIAGEN-tip and allowed it to enter the resin. Washed 
the Qiagen-tip with 2 x 100 ml Buffer QC and the DNA was eluted with 35 ml Buffer 
QF. The eluted DNA was precipitated by adding 24.5 ml (0.7 volumes) isopropanol. 
Mixed and centrifugeJ immediately at >15,000 x g for 30 min at 4 °C. The 
supernatant was carefully decanted off. DNA pellet was washed with 7 ml of 70% 
ethanol and centrifuged again at > 15,000 x g for 10 min. Carefully decanted the 
supernatant without disturbing the pellet. Air-dried the pellet for 10-20 min and 
redissolved the DNA in a suitable volume of TE, pH 8.0. DNA concentration was 
determined by UV spectrophotometry. 
Modification of Plasmid DNA by 4-OHE2 and NO 
Native plasmid DNA was modified with 4-hydroxyestradiol (4-OHE2) and NO 
as described by Yoshie et al (1998) with slight modification. pUC-18 DNA (0.152 
mM base pair) in 100 mM sodium phosphate buffer pH 7.4, containing 1.01 mM 
diethylenetriamine pentacetic acid (DTPA) was incubated with 0.505 mM 4-OHE2 and 
1.01 mM SNP at 37° C for 2 hr. Estrogen was dissolved in N, N-dimethylformamide 
(DMF), and the final concentration of DMF in the reaction mixture was 0.1%. After 
incubation, excess 4-hydroxyestradiol and SNP were removed by extensive dialysis 
against PBS pH 7.4. DNA exposed to 4-OHE2 or NO alone under similar experimental 
conditions served as controls. 
Modification of Plasmid DNA by 4-OHE2 and Cu(II) 
Native plasmid DNA was modified with 4-hydroxyestradioI (4-OHE2) and 
CuCl2 as described by Hiraku et al (2001), with slight modificafions. pUC-18 plasmid 
DNA (0.152 mM bp) in 10 mM sodium phosphate buffer (pH 7.4) was incubated with 
1.013 mM 4-OHE2 and 0.354 mM CuCb containing 1.013 mM DTP A. After 2 hr 
incubation at 37°C excess 4-hydroxyestradiol and CuCb were removed by extensive 
dialysis against PBS, pH 7.4. Estrogen was dissolved in N, N-dimethylformamide 
(DMF), and the final concentration of DMF in the reaction mixture was 0.1 %. DNA 
sample exposed to 4-OHE2 or CuCb alone under similar experimental conditions 
served as controls along with the untreated DNA. 
Spectroscopic Analysis 
The ultraviolet spectra of modified and unmodified DNA samples were 
recorded in the wavelength range of 200-400 nm on a Shimadzu UV-240 
spectrophotometer. 
Fluorescence spectroscopy of native and modified DNA samples using 
ethidium bromide was also performed. Excitation wavelength was 520 nm and spectra 
were recorded in the wavelength range of 490-700 rmi on a Hitachi F2000 
spectroflurometer. 
Circular Dichroism Measurements 
Circular dichroism (CD) measurements of native and modified plasmid DNA 
samples in PBS, pH 7.4 were performed at a constant temperature of 25 °C in the 
wavelength range from 200 nm to 320 nm. Scans were recorded at 0.2 nm intervals 
and three spectra of each sample were recorded and average determined. A scan of 
buffer alone was recorded to adjust the base line. The concentration of the plasmid 
DNA used was 0.048 mM base pair. Molar ellipticity [9] were calculated in terms of 
the base pair concentration according to the following equation 
[9] - _ - e 
10 cl 
where, 0 is the measured ellipticity (mdeg), c is the molar concentration of plasmid 
DNA per base pair and 1 is the path length in cm. 
Absorption-Temperature Scan 
Thermal denaturation analysis of DNA was performed in order to ascertain the 
degree of modification incurred on the DNA by determining mid point melting 
temperature (Tm). Native and modified DNA samples were subjected to heat 
denaturation on a Shimadzu UV-240 spectrophotometer coupled with a temperature 
programmer and controller assembly (Hasan and Ali, 1990). All the samples were 
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melted from 30 °C to 95 °C at a rate of 1.5 °C / min after 10 min equilibration at 30 
°C. The change in absorbance at 260 nm was recorded with increasing temperature. 
Percent denaturation was calculated as follows: 
A T - A30 
Percent denaturation = x 100 
A - A-^ 
Where, AT = Absorbance at a temperature T °C. 
Amax = Final maximum absorbance on the completion of 
denaturation (95 °C). 
A30 = Initial absorbance at 30 °C. 
Nuclease SI Digestibility and Gel Electrophoresis 
Native and modified DNA were characterized by nuclease SI (Matsuo and 
Ross, 1987). One microgram each of native and modified DNA in acetate buffer (30 
mM each of sodium acetate and zinc chloride, pH 5.0) were treated with nuclease SI 
(2.8 units/fig DNA) for 30 min. at 37 °C. The reaction v/as stopped by adding one 
tenth volume of 200 mM EDTA, pH 8.0. The digested and control samples were 
subjected to agarose gel electrophoresis. 
(i) Gel preparation 
Agarose (1%) in TAE buffer (40 mM Tris-acetate, pH 8.0 containing 2 mM 
EDTA) was dissolved by heating. The solution was cooled to about 50 °C and then 
poured into gel tray and allowed to solidify at room temperature. 
(ii) Sample preparation and loading 
Native and modified DNA samples treated with nuclease Si were mixed with 
one-tenth volume of sample buffer (0.125% bromophenol blue, 30% Ficoll 400,-^00 
mM EDTA in lOX electrophoresis buffer). The samples were loaded in the wells and 
electrophoresed for 2 hr at 30 mA. The gels were stained with ethidium bromide (0.5\ 
|ag/ml), viewed by illumination under UV light and photographed. 
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Restriction Enzyme Digestions 
Restriction digestions of native and modified DNA (4-OHE2-NO-DNA and 4-
0HE2-Cu(II)-DNA) were done with enzymes Pvu I, Pvu II and Ssp I. Native and 
modified DNA (0.5 fig each) was incubated with 1 unit of the respective enzyme in a 
total volume 40 ^1 for 8 hr at 37 °C. The reaction was stopped by extracting into 
phenol: chloroform: isoamylalcohol mixture (25:24:1). DNA was precipitated by the 
addition of one-tenth volume of 3 M sodium acetate and two volumes of chilled 
absolute alcohol (-20 °C) for 6-8 hr. The precipitate was obtained by hard spin at 
16,000 rpm for 30 min at 4°C and subsequently washed with 70% ethanol, air dried 
and dissolved in a minimum volume of TE buffer, pH 8.0. The digestions were 
analyzed by 1% agarose gel electrophoresis. 
Separation and Quantitation of DNA Bases 
The separation and quantitation of bases in modified and unmodified DNA was 
done according to the method described by Hasan and Ali (1990). 
(a) Acid hydrolysis of DNA samples 
Native, modified DNA and unmodified DNA samples were precipitated with 
two volumes of cold ethanol and dissolved in 70°'b perchloric acid. The samples were 
heated at 100 °C for 1 hr to release the bases. The hydrolysate was neutralized and 
chromatographed on DEAE Sephadex A-25 matrix. 
(b) DEAE Sephadex Chromatography 
The swollen ion exchanger was suspended in the equilibrating buffer (1 mM 
Tris-HCl, pH 7.6) and poured in a column. The column was extensively equilibrated 
and 3 ml of sample was applied and eluted with a linear gradient of 1-20 mM Tris-
HCl, pH 7.6 at a flow rate of 40 ml/hr. Fractions of 3 ml were collected and 
absorbance recorded at 260 nm. Elution profiles of individual bases and hydrolyzed 
native DNA served as standards. 
Immunization Schedule 
Modified DNA (50 jig) were emulsified with an equal volume of complete 
Freund's adjuvant and injected intramuscularly in female rabbits. Subsequent 
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injections were given in incomplete Freund's adjuvant. Each animal received a total of 
400 ^g of antigen in the course of 8 injections. Blood was collected from marginal 
vein of the ear. Serum was separated and decomplemented by heating at 56 °C for 30 
min. Pre-immune serum was collected prior to immunization. The sera were stored in 
small aliquots at -20 °C with 0.1% sodium azide as preservative. 
Isolation of IgG by Protein-A Agarose 
Serum IgG was isolated by affinity chromatography on Protein-A Agarose 
column. Serum (0.3 ml), diluted witli equal volume of PBS pH 7.4, was applied to 
column (12 mm X 45 mm) equilibrated with the same buffer. The wash through was 
recycled 2-3 times. Unbound IgG was removed by extensive washing with PBS, pH 
7.4. The bound IgG was eluted with 0.58% acetic acid in 0.85% sodium chloride 
(Goding, 1976) and neutralized with 1 ml of IM Tris-HCl, pH 8.5. Three ml fractions 
were collected and read at 251 and 278 nm. IgG concentration was determined 
considering 1.40 ODago = 1.0 mg/ml. 
Immunological Detection of Antibodies 
Sera were tested for antibodies by enzyme linked immunosorbent assay and gel 
retardation assay. 
(a) Enzyme linked immunosorbent assay 
The following reagents were prepared in distilled water and used in enzyme 
immimoassay. 
(i) Buffers and reagents 
Tris buffered saline (TBS) 
10 mM Tris, 150 mM NaCl, pH 7.4 
Tris buffered saline-Tween 20 (TBS-T) 
20 mM Tris, 144 mM NaCl, 2.68 mM KCl, pH 7.4, containing 500 ^1 Tween 
20/L. 
Carbonate-bicarbonate buffer 
15 mM sodium carbonate, 35 mM sodium bicarbonate, pH 9.6, containing 2 
mM magnesium chloride. 
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Citrate-phosphate buffer 
15 mM citric acid, 50 mM Na2HP04, pH 5.0. 
Substrate 
500 Jig p-nitrophenyl phosphate (p-NPP)/ml of carbonate-bicarbonate 
buffer. 
(ii) Procedure 
Antibodies were detected by ELISA using polystyrene microtitre plates as 
solid support. One hundred microlitre of 2.5 |ig/ml antigen in TBS, pH 7.4 was coated 
in test well of microtitre plates, incubated for 2 hr at 37 °C and overnight at 4 °C. The 
antigen coated wells were washed three times with TBS-T to remove the unbound 
antigen. Unoccupied sites were blocked with 150 |il of 1.5% BSA in TBS for 4-5 hr at 
room temperature. The plates were washed once with TBS-T and antibody (100 
Hl/well) to be tested, were diluted in TBS and added to each well. After 2 hr 
incubation at 37 °C and overnight at 4 °C, the plates were washed thrice with TBS-T 
and an appropriate anti-immunoglobulin alkaline phosphatase conjugate was added to 
each well. After incubation at 37 °C for 2 hr, the plates were again washed three times 
with TBS-T and twice with distilled water and developed using p-nitrophenyl 
phosphate as substrate and absorbance recorded at 410 rmi on an automatic microplate 
reader. Each sample was run in duplicate. The control wells were treated similarly but 
were devoid of antigen. Results were expressed as a mean of Atest~Acontroi-
(b) Competition ELISA 
The antigenic specificity of the antibodies was determined by competition 
ELISA (Hasan et al., 1991). Varying amounts of inhibitors (0-20 |ig/ml) were mixed 
with a constant amount of antiserum or IgG. The mixture was incubated at room 
temperature for 2 hr and ovemight at 4 °C. The immune complex thus formed was 
coated in the wells instead of the serum/IgG. The remaining steps were same as in 
direct binding ELISA. Percent inhibition was calculated using the formula: 
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•^inhibited 
Percent inhibition = 1 — X 100 
-'^uninhibited 
(c) Band shift assay 
For the visual detection of antigen-antibody binding and immune complex 
formation, gel retardation assay was performed (Sandford et al., 1988). A constant 
amount of antigen (native and modified DNA) was incubated with varying amounts of 
IgG in PBS, pH 7.4 for 2 hr at 37 °C and overnight at 4 °C. One-tenth volume of 'stop 
mix' dye was added to the mixture and electrophoresed on 1% agarose for 2 hr at 30 
mA in TAE buffer, pH 7.9. The gels were stained with ethidium bromide (0.5 |ig/ml), 
visualized under UV light and photographed. 
Isolation of Human DNA from Lymphocytes 
(i) Isolation of lymphocytes 
Blood was collected in EDTA from cancer patients and normal healthy 
individuals. Lymphocytes were harvested by lysing red blood cells using red blood 
cell lysing solution (155 mM NH4CI, 10 mM NaOHCOa, 0.1 mM EDTA pH 7.4). 
The blood samples were cooled to 4 °C and 10 volumes of RBC lysis solution 
was added and swirled for 5-10 min. The sample was centrifuged at 2000 rpm at 4 °C 
for 10 min to harvest the lymphocytes. This process was repeated 3-4 times, until a 
clear white pellet of lymphocytes was obtained. 
(b) Isolation of DNA 
Human DNA was isolated from lymphocytes as described by Ashok and Ali 
(1998). The lymphocytes were lysed by lymphocyte lysis buffer (10 mM Tris, 2 mM 
EDTA, 400 mM NaCl, containing 1% SDS and I mg/ml proteinase K, pH 7.4). 
(c) Procedure 
The lymphocytes were resuspended in lymphocyte lysis buffer, incubated at 
50°C for 1 hr and overnight at 37°C with constant shaking. Equal volume of 
chloroform-isoamyl alcohol (24:1) was added and the sample extracted for 15 min and 
allowed to stand for another 30 min. The aqueous layer was removed carefully and the 
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extraction step repeated 2-3 times. To the aqueous layer was added one-tenth volume 
of 3 N sodium acetate, pH 5.2 and 2 volumes of cold absolute ethanol to precipitate 
DNA. The DNA was collected by centrifugation, washed once with 70% ethanol, 
allowed to dry and subsequently dissolved in PBS, pH 7.4. Absorbance of DNA 
solution was monitored at 260 nm and 280 nm to ascertain its purity and 
concentration. 
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RESULTS 
Agarose gel electrophoresis of native and modified DNA 
Gel electrophoresis of native and 4-OHE2-NO-DNA was performed on 1% 
agarose gel (Fig. 2). Plasmid pUC 18 was incubated with either catechol estrogen (4-
OHE2), an NO-releasing compound (SNP) alone or the NO-releasing compound and 4-
OHE2 in combination. Incubation of the plasmid DNA with 4-OHE2 alone did not 
cause conversion of the covalently closed circular double-stranded supercoiled DNA 
(form I) to a relaxed open circle (form III) (Fig. 2; lane 2), relative to the untreated 
plasmid (lane 1). SNP at 0.2 mM also did not increase the formation of relaxed open 
circle form. However, when the plasmid was incubated in the presence of both SNP 
(0.2 mM) and 4-OHE2 (0.02, 0.1, 0.2 and 0.4 mM), significant conversion of 
covalently closed circular double-stranded supercoiled DNA to relaxed open circular 
form was observed (lanes 4-7), suggesting that the conversion is due to the generation 
of single strand breaks in DNA upon NO and 4-OHE2 modification. 
The electrophoretic pattern of DNA modified individually by 4-OHE2 and CUCI2 
[Cu(II)] as well as their combined action is shown in Figure 2. DNA treated 
individually to 4-OHE2 and Cu(II) showed similar migration band as native DNA (Fig. 
3; lanes 1-3). However, when the plasmid was incubated with 4-OHE2 plus Cu(II), 
covalently closed circular double-stranded supercoiled DNA (form I) get converted to 
relaxed open circular form (form III) as well as linear form (form II) as depicted in 
Figure 3 (lanes 4-8). Increase intensity of linear form as compared to native DNA and 
generation of relaxed open circular form, indicate that modification of DNA induce 
single-strand and double-strand breaks on treatment 4-OHE2-Cu(II). 
Spectroscopic analysis of modified DNA 
Ultraviolet absorption spectral studies 
The ultraviolet absorption characteristics of 4-OHE2-NO-DNA, when compared 
with native plasmid DNA, exhibited around 26.9% increase in absorbance at 260 nm, 
the Xmax (Fig. 4). 
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Fig. 2. Agarose gel electrophoresis of native plasmid DNA and 4-OHE2-NO-DNA. 
Lane: (1) native plasmid; (2) DNA modified with 0.4 mM 4-hydroxyestradiol 
(4-OHE2); (3) DNA modified with 0.2 mM sodium nitroprusside (SNP); (4-7) 
DNA modified with 0.02,0.1,0.2 and 0.4 mM 4-OHE2 in presence of 0.2 mM 
SNP in each lane. The concentration of DNA was 0.5 ng in all the lanes. 
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Fig. 3. Agarose gel electrophoresis of native plasmid DNA and 4-OHE2-Cu(II)-DNA. 
Lane: (1) native plasmid; (2) DNA modified with 0.8 mM 4-hydroxyestradiol 
(4-OHE2); (3) DNA modified with 0.07 mM CuCb; (4-8) DNA modified with 
O.I, 0.2, 0.4, 0.6, and 0.8 mM 4-OHE2 in presence of 0.07 mM CUCI2 in each 
lane. The concentration of DNA was 0.5 ^g in all the lanes. 
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Fig. 4. UV absorption spectra of native plasmid DNA (—) and 4-OHE2-NO-DNA (—-). 
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The UV absorption spectra of 4-OHE2-Cu(II)-DNA showed an increase in absorption 
over the entire UV range, with 33% hyperchromicity at 260 nm (Fig. 5). 
Fluorescence spectroscopy 
Fluorescence spectra of native and 4-OHE2-NO-DNA were taken using 
ethidium bromide as external fluorophore with excitation wavelength at 520 nm (Fig. 
6). A marginal increase in the fluorescence intensity was seen in case of 4-OHE2-NO-
DNA as compared to its native form. 
Fluorescence spectra of 4-OHE2-Cu(II)-DNA showed a decrease in the 
fluorescence intensity as compared to native DNA indicating the generation of strand 
breaks and perturbation in the double helix as a result of modification. 
Circular dichroism of native and modified DNA 
The CD spectra of native and modified DNA showed characteristics change in 
ellipticity. The spectra were measured from 200 to 320 nm at room temperature. The 
CD spectrum of native plasmid shows a positive peak at 274 nm, a cross over at about 
259 rmi and the two negative peaks centered at 246 and 210 nm (Fig. 7). The CD 
profile of 4-OHE2-NO-DNA have two negative peaks at about 242 and 210 rmi, cross 
over at about 262 nm and two broad positive peak at 278 and 268 nm. 4-OHE2-NO-
DNA when compared with native plasmid DNA showed a change in ellipticity from 
0.77 mdeg to 0.26 mdeg for the positive peak and from -1.3 to -0.83 for the negative 
peak. 
The CD profile of 4-OHE2-Cu(II)-DNA shows a positive peak at 273 nm, a 
cross over at about 256 nm and the two negative peaks centered at 244 nm and 208 
nm. 4-OHE2-Cu(II)-DNA showed change in ellipticity fi-om 0.77 mdeg to 0.52 mdeg 
for the positive peak and from -1.3 to -0.76 for the negative peak. The results show 
66% and 32.4% decrease in ellipticity of native plasmid after modification with 4-
OHE2-NO and 4-OHE2-Cu(II). 
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Fig. 5. UV absorption spectra of native plasmid DNA (—) and 4-OHE2 -Cu(Il)-DNA 
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Fig. 6. Fluorescence spectra of native plasmid DNA ( ), 4-OHE2-NO-DNA 
( ), 4-OHE2-Cu(II)-DNA (- • — -) in presence ethidium bromide and 
ethidium bromide alone ( ). Excitation wavelength was 520 nm. 
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Fig. 7. Circular dichroism spectra of native DNA ( ), 4-OHE2-NO-DNA ( ) 
and 4-OHE2-Cu(II)-DNA ( ). 
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Thermal denaturation of native and modified DNA 
Thermally induced transitions were measured spectrophotometrically at 260 
run by heating nucleic acid samples at a rate of 1.5 °C/min. Melting curves were 
obtained at temperatures from 30 °C to 95 °C. The increase in absorbance at 260 nm 
was taken as a measure of denaturation. The process was characterized by determining 
the percent DNA in denatured state as a function of temperature and by computing the 
melting temperature (Tm). 
Figure 8 shows thermal denaturation profile of native calf thymus DNA, 4-
0HE2-N0-calf thymus DNA and 4-OHE2-NO plasmid DNA. The melting temperature 
of native calf thymus DNA at which 50% of the structural organization is lost was found 
to be 88°C, while in case of 4-OHE2-NO-calf thymus DNA, it was found to be 81.5 °C, 
a net decrease of 6.5 °C in the Tm value of 4-OHE2-NO-calf thymus DNA was observed 
when compared to its unmodified native analogue. Tm value for 4-OHE2-NO plasmid 
DNA (4-OHE2-NO-DNA) was found to be 90.5 °C and the melting was initiated at 88.5 
°C. 
Figure 9 shows thermal denaturation profile of native calf thymus DNA, 4-
0HE2-Cu(II)-calf thymus DNA and 4-OHE2-Cu(II) plasmid DNA. In case of 4-OHE2-
Cu(II)-calf thymus DNA, Tm was found to be 80.5 °C, a net decrease of 7.5 °C in the 
Tm value of 4-OHE2-Cu(II)-calf thymus DNA was observed when compared to native 
DNA. Tm value for 4-OHE2-Cu(II)-DNA was found to be 90 °C. These findings point 
out structural alterations in DNA and a partial destruction of the secondary structure of 
DNA upon modification. Thermal denaturation characteristics of native and modified 
DNA are summarized in Table 2. 
Nuclease SI digestibility of native and modified DNA 
Native and modified DNA (4-OPffi2-NO-DNA and 4-OHE2-Cu(II)-DNA) were 
digested with nuclease SI (2.8 units/^g DNA) for 30 min at 37 °C, the controls were 
native and modified DNA without digestion with nuclease SI. Samples were run on 1% 
agarose gel. Figure 10 shows nuclease SI digestibility of native, 4-OHE2-NO-DNA and 4-
0HE2-Cu(II)-DNA. 
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Fig. 8. Thermal denaturation profile of native calf thymus DNA (O), 4-OHE2-NO-
calf thymus DNA (•) and 4-OHE2-NO plasmid DNA (A). 
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Fig. 9. Thermal denaturation profile of native calf thymus DNA (O), 4-OHE2-Cu(II)-
calf thymus DNA (•) and 4-OHE2-Cu(II) plasmid DNA (•). 
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TABLE 2 
UV Absorption and Thermal Denaturation Characteristics of Native, 
4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA 
Parameter Native DNA 4-OHE2-NO-DNA 4-OHE2-Cu(II)-DNA 
Absorbance ratio 2.15(1.86) 2.0(1.5) 1.95(1.50) 
(A260/ A280) 
Hyperchromicity 36 20.5 21.5 
at 95 °C 
Melting Temperature 88 81.5(90.5) 80.5(90) 
(Tm), °C 
Onset of duplex 
melting 82.5 68(88.5) 65.5(88) 
The values obtained with plasmid DNA are given in parentheses. 
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(a) 
(b) 
Fig. 10. Nuclease SI digestibility of native plasmid, (a) 4-OHE2-NO-DNA and (b) 4-
0HE2-Cu(II)-DNA. Lane (1) native plasmid DNA, (2) native DNA treated 
v^th nuclease SI, (3) modified DNA, and (4) modified DNA treated with 
nuclease SI. Electrophoresis was carried out on 1% agarose gel for 2 hr at 30 
mA. 
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The results showed substantially decreased fluorescence in case of both of the modified 
samples. However, such a loss of fluorescence signal was not found in the case of SI 
treated native DNA. 
Restriction enzyme digestions 
Restriction digestions were done with enzymes Pvu II, Pvu I and Ssp I. Pvu II 
and Pvu I recognize sequence CAGjCTG and CGATjCG, respectively and each has 
two cleavage site on pUC 18. Ssp I have an A-T rich recognition sequence 
(AATJ.ATT) and has a single site on pUC 18. Pvu II digestion of native and 4-OHE2-
NO-DNA shows an altered pattern of digestion. Similarly, Ssp I digestion linearised 
the native plasmid which is quite different from characteristic stretch exhibited by 4-
OHE2-NO-DNA (Fig. 11). However, Pvu I digestion of native and modified DNA 
exhibit same pattern of digestion. These findings indicate that GC and TA sites have 
been modified extensively after 4-OHE2-NO treatment. Either multiple bands or 
appearance of a stretch on digestion with Ssp I might be due to incomplete digestion 
because modification with 4-OHE2-NO may not be 100% and some GC or TA sites 
which are not modified might be accessible to the enzyme. 
Figure 12 shows characteristic pattern of digestion of native and 4-OHE2-
Cu(II)-DNA with Pvu I, Pvu II and Ssp I. An altered pattern of digestion is seen in the 
case of modified DNA digested with Pvu I and Pvu II indicating TC and GC sites have 
been modified extensively after modification. Ssp I digestion linearised the plasmid 
and a single band is obtained in both the native as well as in the 4-OHE2-Cu(II)-DNA 
indicating that modification of 4-OHE2-Cu(II) is not TA specific. 
Quantitative base modification in DNA by 4-OHE2-NO and 4-OHE2-
Cu(II) 
In order to separate and quantify the modification of bases, modified DNA 
solutions were subjected to acid hydrolysis. The neutralized hydrolysate was applied 
on a DEAE Sephadex A-25 column and eluted with a linear gradient of 1-20 mM Tris-
HCl, pH 7.6. The elution profile of individual standard bases is shown in Figure 13. 
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Fig. 11. Pvu II, Ssp I and Pvu I digestion of native plasmid and 4-OHE2-NO-DNA. 
Lane 1 contained 100 bp ladder. Lane 2 contained native plasmid DNA 
while lane 3 contained 4-OHE2-NO-DNA. Lanes 4, 5 and 6 contained 
native plasmid DNA digested with Pvu II, Ssp I and Pvu I, respectively. 
Lanes 7, 8 and 9 contained 4-OHE2-NO-DNA digested with Pvu II, Ssp I 
and Pvu I, respectively. Electrophoresis was performed on 1% agarose for 
3.5 hr at 30 mA. Amount of DNA used for the electrophoresis was 0.5 jig. 
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Fig. 12. Pvu I, Pvu II and Ssp I digestion of native plasmid and 4-OHE2-Cu(II)-DNA. 
Lane 1 contained 100 bp ladder. Lane 2 contained native plasmid DNA while 
lane 3 contained 4-OHE2-Cu(II)-DNA. Lanes 4, 5 and 6 contained native 
plasmid DNA digested with Pvu I, Pvu II and Ssp I, respectively. Lanes 7, 8 
and 9 contained 4-OHE2-Cu(II)-DNA digested with Pvu I, Pvu II and Ssp I, 
respectively. Electrophoresis was performed on 1% agarose for 3.5 hr at 30 
mA. Amount of DNA used for the electrophoresis was 0.5 ^g. 
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Fig. 13. Elution profile of standard individual. DNA bases on DEAE-Sephadex A-25 
column. Cytosine (a), thymine (b), adenine (c) and guanine (d). 
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Elution profile pattern of native or unmodified and hydrolysed DNA was 
similar to that obtained with mixture of individual bases (Fig. 14). 
Figure 15 shows the elution profile of acid hydrolyzate of 4-OHE2-NO-DNA. 
The peaks obtained were identified by comparing with the chromatographic pattern of 
the standard bases as well as hydrolysed native DNA. The first and second peaks 
represent modified and unmodified cytosine, while the third and fourth peaks 
represent modified and unmodified thymine. Adenine also eluted as two peaks 
(numbers 5 and 6) as also guanine (numbers 7 and 8) representing the modified and 
unmodified base. The extent of modification of bases by 4-OHE2-NO was determined 
by measuring the peak areas of the modified and the correiiponding unmodified bases. 
Among the bases modified, thymine was modified to the maximum of 46.9%, 
followed by guanine (42.6%), adenine (21%) and cytosine (16.6%) (Table 3). A 
similar elution profile of modified and unmodified bases were obtained with the acid 
hydrolyzate of 4-OHE2-Cu(II)-DNA (Fig. 16). In this case too, thymine was the 
maximum modified base, to an extent of 47.1%), while guanine, adenine and cytosine 
were modified to an extent of 45.5%), 16.9% and 12.6%), respectively (Table 3). 
Quenching studies 
To identify the compound(s) responsible for strand breaks induced by 4-OHE2 
plus NO, we examined the effects on straind breaks of various "OH scavengers 
(DMSO, ethanol and mannitol), NO-trapping agent (carboxy-PTIO), antioxidant 
(ascorbic acid) and other compounds (sodium azide, uric acid). As shown in Fig. 17, 
carboxy-PTIO and uric acid strongly (~ 80%) inhibited the modification by 4-OHE2 
plus NO, whereas sodium azide, an scavenger of singlet oxygen, had moderate effect 
(> 50% inhibition). Ascorbic acid and SOD caused small decreased in the 
modification of DNA (49% and 38%» inhibition), whereas "OH scavenger have no 
effect on DNA modification induced by 4-OHE2-NO. 
Figure 18 shows the modification of plasmid DNA induced by 4-OHE2 and 
Cu(II) in presence of different quenchers. Among the tested compounds, catalase and 
bathocuproine strongly (~ 80%) inhibited the modification by 4-OHE2 plus Cu(II) 
indicating the involvement of H2O2 and Cu(I) during the modification. 
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Fig. 14. Fractionation of acid hydrolyzed native DNA on DEAE-Sephadex A-25 column. 
Peaks 1,2, 3 and 4 represent cytosine, thymine, adenine and guanine, respectively. 
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Fig. 15. Elution profile of bases from acid hydrolyzed 4-OHE2-NO-DNA on DEAE-
Sephadex A-25 column. Peaks 1 and 2 represent modified and unmodified 
cytosine, peaks 3 and 4 represent modified and unmodified thymine, peaks 5 
and 6 represent modified and unmodified adenine, peaks 7 and 8 represent 
modified and unmodified guanine. 
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Fig. 16. Elution profile of bases from acid hydrolyzed 4-OHE2-Cu(II)-DNA on DEAE-
Sephadex A-25 column. Peaks 1 and 2 represent modified and unmodified 
cytosine, peaks 3 and 4 represent modified and unmodified thymine, peaks 5 and 
6 represent modified and unmodified adenine, peaks 7 and 8 represent modified 
and unmodified guanine. 
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TABLE 3 
Level of Modification of DNA Bases in Native DNA Modified with 4-
OHE2-NO and 4-OHE2-Cu(II) 
Base Percent Modification 
4-OHErNO-DNA 4-OHE2-Cu(II)-DNA 
Adenine 21 16.9 
Guanine 42.6 45.5 
Cytosine 16.6 12.6 
Thymine 46.9 47.1 
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Fig. 17. Effect of free radical scavenger, antioxidants and NO-trapping agent on the 
modification of DNA induced by 4-OHE2 and NO. The NO-trapping agent 
(carboxy-PTIO), "OH scavengers (DMSO, ethanol and mannitol), antioxidant 
(ascorbic acid) and other compounds (sodium azide, uric acid) were used at 5 
mM. SOD and catalase were used at a concentration of 700 units/ml. The data 
represent the arithmetic of three individual determinates. 
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Fig. 18. Effect of free radical scavenger, antioxidants and bathocuproine on the 
modification of DNA induced by 4-OHE2 and Cu(II). The "OH scavengers 
(DMSO, ethanol and mannitol), antioxidant (ascorbic acid) and bathocuproine 
were used at 5 mM. SOD and catalase were used at a concentration of 700 
units/ml. The data represent the arithmetic of three individual determinates. 
70 
Ascorbic acid and sodium azide were less effective, inhibiting the modification of 
DNA to an extent of about 35% and 31%. "OH scavenger had no effect on DNA 
modification indicating that free hydroxyl radical is not involved in the reaction. 
Antigenicity of modiHed DNA 
The antigenicity of modified DNA samples (4-OHE2-NO-DNA and 4-OHE2-
Cu(II)-DNA) was determined by inducing antibodies in rabbits against them. The 
antigenic specificity of induced antibodies was assayed by direct binding and 
competition ELISA. The binding of these antibodies to the immunogens and native 
DNA (nDNA) was also probed by band shift assay. 
(a) Antibodies against 4-OHE2-NO-DNA 
Direct binding ELISA was used to characterize the immune response in rabbit 
following immunization with 4-OHE2-NO-DNA. The antigen was found to be highly 
immunogenic. Antiserum showed a high titre antibodies (> 1:12800) in direct binding 
ELISA (Fig. 19). Pre-immune serum, used as a negative control, did not show any 
appreciable binding to 4-OHE2-NO-DNA. The specificity of anti-4-OHE2-NO-DNA 
antibodies was evaluated by competition ELISA. A maximum of 71.9% inhibition in 
antibody activity was obtained at an immunogen concentration of 20 |ig/ml. The 
concentration of immunogen required for 50% inhibition was 12.4 ^g/ml (Fig. 20). 
(b) Antibodies against 4-OHE2-Cu(II)-DNA 
The antiserum showed a very high titre antibodies (> 1:12800) in direct 
binding ELISA. The binding of pre-immune serum was of low magnitude (Fig. 21). In 
competition ELISA, a maximum of 73.8% inhibition was observed at 20 |ig/ml and 
50% inhibition was achieved at 8.75 fig/ml of immunogen (Fig. 22). 
Purification and characterization of immune IgG 
Immunoglobulin G was isolated from pre-immune and immune rabbit serum by 
affinity chromatography on Protein-A Agarose column (Fig. 23, 26). The purity of IgG 
was evaluated by SDS-polyacrylamide gel electrophoresis in the absence of a reducing 
agent. 
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Fig. 19. Direct binding ELISA of 4-OHE2-NO-DNA with preimmune (•) and immune 
sera (•). Microtitre plates were coated with 4-OHE2-NO-DNA (2.5 ^g/ml). 
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Fig. 20. Inhibition ELISA of anti-4-OHE2-NO-DNA immune (A) and preimmune 
(•) sera with 4-OHE2-NO-DNA. Microtire plates were coated with 4-
OHE2-NO-DNA (2.5 tig/ml). 
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Fig. 21. Direct binding ELISA of 4-OHE2-Cu(II)-DNA with preimmune (•) and immune 
sera (•). Microtitre plates were coated with 4-OHE2-Cu(II)-DNA (2.5 i^g/ml). 
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Fig. 22. Inhibition ELISA of anti-4-OHE2-Cu(II)-DNA immune (A) and pre-immune 
(•) sera with 4-OHE2-Cu(II)-DNA. Microtire plates were coated with 4-
0HE2-Cu(II)-DNA (2.5 ixg/ml). 
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Fig. 23. Elution profile of anti-4-OHE2-NO-DNA IgG on Protein-A Agarose affinity 
column. Inset: SDS-PAGE of purified IgG on 7.5% polyacrylamide gel. 
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The purified IgG migrated as a single band upon electrophoresis (Figs. 23, 26 inset). 
Direct binding ELISA of the purified IgGs showed strong recognition with the 
immunogen (Figs. 24, 27). Pre-immune IgG as negative control showed negligible 
binding. The specificity of purified IgG was also evaluated by competitive inhibition 
assays. 
Band shift assay 
The binding of 4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA to their immune 
IgG was further ascertained by band shift assay. Constant amounts of im.munogen 
were incubated with variable amount of respective immune and pre-immune IgG for 2 
hr at 37 °C and overnight at 4 °C. The immune complexes were then electrophoresed 
on 1% agarose for 2 hr at 30 mA. Figure 25 shows the formation of complexes 
between 4-OHE2-NO-DNA and anti-4-OHE2-NO-DNA IgG. An increase in the 
amount of IgG caused a proportional increase in the formation of high molecular 
weight immune complexes resulting in retarded mobility and increased fluorescence 
intensity of the immune complex. Whereas, the amount of unbound DNA showed a 
proportional decrease in intensity. No appreciable change was observed with pre-
immune IgG. Figure 28 shows the formation of immune complexes between anti-4-
0HE2-Cu(II)-DNA IgG and 4-OHE2-Cu(II)-DNA. Pre-immune IgG showed 
negligible binding. 
Immuno-cross reactivity of anti-4-OHE2-NO-DNA antibodies 
The antigenic specificity of the induced anti-4-OHE2-NO-DNA IgG was 
characterized by competitive inhibition assay using the immunogen, nucleic acids, 
synthetic polymers and bases as inhibitors. A maximum of 91.3% inhibifion of IgG 
with immunogen as inhibitor was observed (Fig. 29a). The induced antibodies were 
highly specific for 4-OHE2-NO-DNA with only 2.7 ^g/ml inhibitor required to inhibit 
50% antibody activity (Table 4). The antibodies showed a broad spectrum of reactivity 
as observed by the binding to a variety of nucleic acid antigens. Native DNA showed 
an inhibition of around 35% at 20 ug/ml. Competifion assays with 4-OHE2-NO-human 
DNA showed a considerable inhibifion of anfibody acfivity (65.3%). 
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Fig. 24. Binding of affinity purified anti-4-OHE2-NO-DNA immune IgG (•) and preimmune 
IgG (•) to 4-OHE2-NO-DNA. Microtitre plates were coated with 4-OHE2-NO-DNA 
(2.5 i^g/ml). 
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Fig. 25. Band shift assay of immune IgG (a) and preimmune IgG (b) binding to 4-
OHE2-NO DNA. DNA (0.5 i^g each) was incubated with buffer (lane 2) and 
5, 10, 15, 20, 30 and 40 ^g IgG through lanes 3 to 8 respectively, for 2 hr at 
37° C and overnight at 4° C. Electrophoresis was performed on 1% agarose 
for two hr at 30 mA. Lane 1 contains 100 base pair ladder. 
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Fig. 26. Elution profile of anti-4-OHE2-Cu(II)-DNA IgG on Protein-A Agarose affinity 
column. Inset: SDS-PAGE of purified IgG on 7.5% polyacrylamide gel. 
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Fig. 27. Binding of purified anti-4-OHE2-Cu(II)-DNA immune IgG (•) and preimmune 
IgG (•) to 4-OHE2-Cu(II)-DNA. Microtitre plates were coated with 4-OHE2-
Cu(II)-DNA (2.5 ^g/mi). 
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Fig. 28. Band shift assay of immune IgG (a) and preimmune IgG binding to 4-OHE2-
Cu(II)- DNA. DNA (0.5 i^g each) was incubated with buffer (lane 2) and 5, 
10,15, 20, 30 and 40 ^g IgG through lanes 3 to 8 respectively, for 2 hr at 37° 
C and overnight at 4° C. Electrophoresis was performed on 1% agarose for 
two hr at 30 mA. Lane 1 contains 100 base pair ladder. 
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Fig. 29. Inhibition of anti-4-OHE2-NO-DNA IgG binding to 4-OHE2-NO-DNA. 
Microtitre plates were coated with 4-OHE2-NO-DNA (2.5 )ig/ml). The 
competitors were (a) 4-OHE2-NO-DNA (•), native plasmid DNA (D) and (b) 
4-OHE2-NO human DNA (•), native human DNA (o), 4-OHE2-NO ctDNA 
(•), and native ctDNA (D). 
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Fifty percent inhibition was achieved with 15 ^g/ml of 4-OHE2-NO-human DNA. 
Native human DNA exhibited 38.5% inhibition of binding of immune IgG to the 
immunogen. 4-OHE2-NO-calf thymus DNA showed a maximum of 62% inhibition 
with 9 |J.g/ml required to attain 50% depletion in antibody binding to the solid phase 
coated antigen (Table 4). Native calf thymus DNA at 20 ^g/ml showed 38.2% 
inhibition (Fig. 29b). 
Adenine, guanine, cytosine, thymine and their 4-OHE2-NO-modified forms 
were used as inhibitors of antibody activity. Adenine, guanine, cytosine, thymine, 4-
0HE2-N0-adenine and 4-OHE2-NO-cytosine showed inhibition of 26.4%, 27.8%, 
38.9%, 42.4%, 46.7% and 41.7%, respectively (Fig. 30). In contrast, 4-OHE2-NO-
guanine and 4-OHE2-NO-thymine showed a maximum of 75.3% and 62.9%) inhibition 
with 7.5 yig/ml and 7.9 i^g/ml required to attain 50% inhibition in antibody binding to 
the antigen. 
Synthetic homopolymes such as poly(dA), poly(dT) and poly(dC) showed 
lower inhibitions of 34%, 33.7% and 25.7%, respectively at 20 i^g/ml inhibitor 
concentration (Fig. 31a). Mitochondrial DNA (mtDNA) and 4-OHE2-NO mtDNA 
caused 37.6% and 38% inhibition of binding of immune IgG to 4-OHE2-NO-DNA 
(Fig. 31b). 
Immuno-cross reactivity of anti-4-OHE2-Cu(II)-DNA antibodies 
Figures 32, 33, 34 show inhibition studies of anti-4-OHE2-Cu(II)-DNA IgG 
with various inhibitors. A maximum of 92.3% inhibition in the binding of antibodies 
was observed with immunogen as inhibitor. The concentration required for fifty 
percent inhibition was 3.75 fig/ml. Native DNA showed an inhibition of around 30.2% 
at 20 i^g/rnl (Fig. 32a). 4-OHE2-Cu(II)-human DNA and 4-OHE2-Cu(II)-calf thymus 
DNA respectively showed a maximum of 67.7% and 68.7% inhibition with 8.5 [ig/ml 
and 17.5 |ig/ml required to attain 50% inhibition in antibody activity (Fig. 32b). 
Native human DNA and calf thymus DNA showed an inhibition of 34.4% and 42.2%, 
respectively. 
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Fig. 30. Inhibition of anti-4-OHE2-NO-DNA IgG binding to 4-OHE2-NO-DNA. Microtitre 
plates were coated with 4-OHE2-NO-DNA (2.5 )ig/ml).The competitors were (a) 
4-OHE2-NO-adenine (•), adenine (o), 4-OHE2-NO-guanine (•), and guanine (D), 
(b) 4-OHE2-NO-cytosine (•) cytosine (o), 4-OHE2-NO-thymine (•) and thymine 
(D). 
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Fig. 31. Inhibition of anti-4-OHE2-NO-DNA IgG binding to 4-OHE2-NO-DNA. 
Microtitre plates were coated with 4-OHE2-NO-DNA (2.5 ^g/ml).The 
competitors were (a) polydA (•), polydT (•), and polydC (A) and (b) 
native mtDNA (•) and 4-OHE2-NO- mtDNA (A). 
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TABLE 4 
Inhibition of Anti-4-OHE2-NO-DNA IgG Binding to 4-OHE2-NO-
DNA by a Variety of Nucleic Acid Polymers 
Inhibitors Maximum % inhibition Concentration for Percent relative 
at 20 \ig/m\ 50% inhibition (ng/m!) affinity 
2.7 100 4-OHE2-NO-DNA 
Native plasmid DNA 
4-OHE2-NO human DNA 
Human DNA 
4-OHE2-NO ctDNA 
Calf thymus DNA 
4-OHE2-NO-adenine 
Adenine 
4-OHE2-NO-guanine 
Guanine 
4-OHE2-NO-cytosine 
Cytosine 
4-OHE2-NO-thymine 
Thymine 
Poly (dA) 
Poly (dT) 
Poly (dC) 
4-OHE2-NO mtDNA 
Mitochondrial DNA 
91.3 
35.0 
65.3 
38.5 
62.0 
38.2 
46.7 
26.4 
75.3 
27.8 
41.7 
38.9 
62.9 
42.2 
34.0 
33.7 
25.7 
38.0 
37.6 
15 18 
9.0 30 
7.5 36 
7.9 34.2 
ELISA plate was coated with 4-OHE2-NO-DNA at 2.5 ^g/ml. 
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Fig. 32. Inhibition of anti-4-OHE2-Cu(II)-DNA IgG binding to 4-OHE2-Cu(II)-DNA. 
Microtitre plates were coated with 4-OHE2-Cu(II)-DNA (2.5 |ig/ml). The 
competitors were (a) 4-OHE2-Cu(II)-DNA (•), native plasmid DNA (n), (b) 4-
0HE2-Cu(II) human DNA (•), native human DNA (n), 4-OHE2-Cu(II) ctDNA 
(•), native ctDNA (o). 
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4-OHE2-Cu(II)-adenine, adenine and guanine showed lower inhibitions of 
39.3%, 34% and 30.7%, respectively (Fig. 33a,b). In contrast, 4-OHE2-Cu(n)-guanine 
was a potent inhibitor, showing a maximum inhibition of 87.8%. The amount of 4-
0HE2-Cu(II)-guanine required for 50% inhibition in antibody activity was 7.5 |ig/ml 
(Table 5). Similarly 4-OHE2-Cu(II)-cytosine, cytosine and thymine showed moderate 
inhibition of 43.5%, 36.1%) and 45.6%, respectively. Competition assays with 4-
0HE2-Cu(II)-thymine showed a considerable inhibition of antibody activity (68%). 
Fifty percent inhibition was achieved with 15 f^ g/ml of the inhibitor. 
Synthetic homopolymers such as poly(dA), poly(dT) and poly(dC) caused an 
inhibition of 31.7%, 36.5% and 29.7%, respectively at 20 i^g/ml inhibitor 
concentration (Fig. 34a). 4-OHE2-Cu(II) modified mt DNA and the native analogue, 
respectively at 20 ^g/ml showed 48.6% and 36.6% inhibition (Fig. 34b). 
Detection of antibodies reactive to native and modified DNA in 
cancer sera 
Sera from patients with various types of cancer were tested for autoantibodies 
binding to native and modified DNA (4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA) 
which was evaluated by direct binding and competitive enzyme immunoassay. The 
study comparised 64 active sera from patients suffering from cancer of different 
organs/organ systems. Sera from normal, healthy individuals served as controls (Fig. 
35). Sera were obtained clinically diagnosed cancer patients with proven 
histopathoiogical diagnosis attending the Jawaharlal Nehru Medical College Hospital of 
the Univerisity. Competition ELISA was carried out to analyze the reactivity of 
circulating autoantibodies in cancer patients for native and modified DNA. The specific 
binding of the autoantibodies was remarkably higher for modified DNA than the native 
in all the sera tested (Fig. 35). In the case often sera from breast cancer, the observed 
maximum inhibition with 4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA was in the range 
of 51.6% to 67.1% and 48% to 74.8%, while with nDNA, it was, 25.3% to 48.8% (Figs. 
36-38). Mean inhibition for all the sample tested with nDNA was 34.3±7.9%, while for 
4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA, it was 59.7+5.1% and 61.9±6.8%. 
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Fig. 33. Inhibition of anti-4-OHE2-Cu(II)-DNA IgG binding to 4-OHE2-Cu(II)-DNA. 
Microtitre plates were coated with 4-OHE2-Cu(II)-DNA (2.5 |ig/ml).The 
competitors were (a) 4-OHE2-Cu(II)-adenine (•), adenine (o), 4-OHE2-Cu(II)-
guanine (•), and guanine (D), (b) 4-OHE2-Cu(II)-cytosine (a), cytosine (D), 4-
0HE2-Cu(II)- thymine (•) and thymine (o). 
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Fig. 34. Inhibition of anti-4-OHE2-Cu(II)-DNA IgG binding to 4-OHE2-Cu(II)-DNA. 
Microtitre plates were coated with 4-OHE2-Cu(II)-DNA (2.5 ^g/nii).The 
competitors were (a) polydA(A), polydT(»), polydC (•) and (b) native 
mtDNA (A), 4-OHE2-Cu(II) mtDNA (•). 
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TABLE 5 
Inhibition of Anti-4-OHE2-Cu(II)-DNA Antibody Binding to 4-OHE2-
Cu(II)-DNA by a Variety of Nucleic Acid Polymers 
Inhibitors Maximum % inhibition Concentration for Percent relative 
at 20 ]ig/m\ 50% inhibition (fig/ml) affinity 
4-OHE2-Cu(II)-DNA 92.3 3.75 100 
Native plasmid DNA 30.2 
4-OHE2-Cu(II)-human DNA 67.7 8.5 44.1 
Human DNA 
4-OHE2-Cu(II) ctDNA 
Calf thymus DNA 
4-OHE2-Cu(II)-adenine 
Adenine 
4-OHE2-Cu(II)-guanine 
Guanine 
4-OHE2-Cu(II)-cytosine 
Cytosine 
4-OHE2-Cu(II)-thymine 
Thymine 
Poly (dA) 
Poly (dT) 
Poly (dC) 
4-OHE2-Cu(II) mtDNA 
Mitochondrial DNA 
34.4 
68.7 
42.2 
39.3 
34.0 
87.8 
30.7 
43.5 
36.1 
68.0 
45.6 
31.7 
36.5 
29.7 
48.6 
36.6 
ELISA plate was coated with 4-OHE2-Cu(II)-DNA at 2.5 i^g/ml. 
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Fig. 35. Binding of various cancer sera to native (n), 4-OHE2-NO-DNA (0) and 4-OHE2-
Cu(II)-DNA (•). Normal human sera (NHS) served as negative control. The 
histogram shows mean absorbance values for binding of NHS and sera from patients 
with various types of cancer. 
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Fig. 36. Detection of autoantibodies against native DNA, 4-OHE2-NO-DNA and 4-
OHE2- Cu(II)-DNA in the sera of patients with breast cancer, (a) Cancer sera 
1 and 2 by native DNA (o, n), 4-OHE2-NO-DNA (•, •) and 4-OHE2-Cu(II)-
DNA (•, A), (b) Cancer sera 3 and 4 by native DNA (o, n), 4-OHE2-NO-
DNA (A, T) and 4-OHE2-Cu(I!)-DNA (•, •). The microtitre plates were 
coated with the respective antigen (2.5 ^g/ml). 
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Fig. 37. Detection of autoantibodies against native DNA, 4-OHE2-NO-DNA and 4-
0HE2-Cu(II)-DNA in the sera of patients with breast cancer, (a) Cancer sera 5 
and 6 by native DNA (D, o), 4-OHE2-NO-DNA (A, T) and 4-OHE2-Cu(II)-
DNA (•, • ) , (b) Cancer sera 7 and 8 by native DNA (D, o), 4-OHE2-NO-
DNA (•, •) and 4-OHE2-Cu(II)-DNA (•, A). The microtitre plates were 
coated with the respective antigen (2.5 ^ g/ml). 
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Fig. 38. Detection of autoantibodies against native DNA, 4-OHE2-NO-DNA and 4-
0HE2-Cu(Ii)-DNA in the sera of patients with cancer of (a) Breast, sera 9 and 
10 by native DNA (D, o), 4-OHE2-NO-DNA (• , T ) and 4-OHE2-Cu(II)-
DNA (•, • ) , (b) Ovary, sera I and 2 by native DNA (D, o), 4-OHE2-NO-
DNA (A, •) and 4-OHE2-Cu(II)-DNA (•, T). The microtitre plates were 
coated with the respective antigen (2.5 ug/ml). 
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In the case of ovarian cancer autoantibodies, the observed mean inhibition with 
4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA was found to be 55.1±5.9% and 
56.3±6.7%, while for nDNA, it was 33.6±10.4%. Inhibitions in the range of 47.6% to 
63.9% were obtained with 4-OHE2-NO-DNA and with 4-OHE2-Cu(II)-DNA, sera 
showed inhibitions of 48.8%) to 65.2% whereas with nDNA sera showed lower 
inhibition {\1.6Vo to 49.7%) (Figs. 38-40). Sera from uterus cancer showed an 
inhibition of 34.6±10.1%, 57.6±10.1% and 59.5±6.7% with nDNA, 4-OHE2-NO-DNA 
and 4-OHE2-Cu(II)-DNA, respectively (Figs. 40-42). 
Eight sera were collected from patients suffering from cancer of prostate. 
Inhibitions ranging from 30.5%i to 69.3%) were obtained in case of 4-OHE2-NO-DNA 
and 37.6% to 65% with 4-OHE2-Cu(II)-DNA. With nDNA, inhibitions ranging from 
19% to 42.7% were obtained (Figs. 43, 44). The mean inhibition with all the prostate 
cancer sample tested was 51.2±12.6% with 4-OHE2-NO-DNA, 54.5±10.6% with 4-
0HE2-Cu(II)-DNA and 29.5±8.4% with nDNA, respectively. 
Seven sera were from patients suffering from lung cancer. Sera of lung cancer 
showed inhibition of 48.1%) to 68.5%) with 4-OHE2-NO-DNA and an inhibition of 
47.9% to 74.5% with 4-OHE2-Cu(II)-DNA. While for nDNA it was 19.9% to 45.6% 
(Figs. 45,46). The mean percent inhibition for 4-OHE2-NO-DNA, 4-OHE2-Cu(II)-DNA 
and nDNA was 56.5±8%, 57.7±10.7% and 33.6±8.9%, respectively. 
Seven sera samples from patients with hepatocellular carcinoma showed 
inhibitions from 41.8% to 65.8% with 4-OHE2-NO-DNA and from 40.5% to 69.8% 
with 4-OHE2-Cu(II)-DNA. However for nDNA, inhibition ranged from 19.7% to 
40.9%) (Figs. 46-48). Mean percent inhibition for nDNA was 29.9±7.6%) while, it was 
54±9.2% for 4-OHE2-NO-DNA and 55.4±10% for 4-OHE2-Cu(II)-DNA. 
Seven sera, each from gall bladder and urinary bladder cancer, were collected. 
Maximum inhibition of 69.6% with 4-OHE2-NO-DNA, 61.9% with 4-OHE2-Cu(II)-
DNA was obtained in case of gall bladder cancer. However, with nDNA, maximum 
inhibition of 43.3% was obtained (Fig. 48-50). 
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Fig. 39. Detection of autoantibodies against native DNA, 4-OHE2-NO-DNA and 4-
0PIE2-Cu(II)-DNA in the sera of patients with ovarian cancer, (a) Cancer 
sera 3 and 4 by native DNA (D, o), 4-OHE2-NO-DNA (•, • ) and 4-OHE2-
Cu(II)-DNA (•, A), (b) Cancer sera 5 and 6 by native DNA (D, o), 4-
OHE2-NO-DNA (•, A) and 4-OHE2-Cu(II)-DNA ( • , • ) . The microtitre 
plates were coated with the respective antigen (2.5 |ig/ml). 
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Fig. 40. Detection of autoantibodies against native DNA, 4-OHE2-NO-DNA and 4-
0HE2-Cu(II)-DNA in the sera of patients with cancer of (a) Ovary, sera 7 and 
8 by native DNA (n,o), 4-OHE2-NO-DNA (A, •) and 4-OHE2-Cu(II)-DNA 
(•, T), (b) sera 9 (ovary) and uterus, sera 1 by native DNA (n, o), 4-OHE2-
NO-DNA (•, • ) and 4-OHE2-Cu(II)-DNA (•, A). The microtitre plates 
were coated with the respective antigen (2.5 ug/ml). 
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Fig. 41. Detection of autoantibodies against native DNA, 4-OHE2-NO-DNA and 4-
0HE2-Cu(II)-DNA in the sera of patients with uterus cancer, (a) Cancer sera 2 
and 3 by native DNA (D, o) 4-OHE2-NO-DNA (A, T) and 4-OHE2-Cu(II)-
DNA (•, • ) , (b) Cancer sera 4 and 5 by native DNA (D, o), 4-OHE2-NO-
DNA (A, T) and 4-OHE2-Cu(II)-DNA (•, • ) . The microtitre plates were 
coated with the respective antigen (2.5 ^g/ml). 
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Fig. 42. Detection of autoantibodies against native DNA, 4-OHE2-NO-DNA and 4-
0HE2-Cu(II)-DNA in trie sera of patients with uterus cancer, (a) Cancer sera 6 
and 7 by native DNA (n, o), 4-OHE2-NO-DNA (A, •) and 4-OHE2-Cu(II)-
DNA (•, T), (b) Cancer sera 8 and 9 by native DNA (a, o), 4-OHE2-NO-
DNA (A, •) and 4-OHE2-Cu(n)-DNA (•, T). The microtitre plates were 
coated with the respective antigen (2.5 i^g/ml). 
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Fig. 43. Detection of autoantibodies against native DNA, 4-OHE2-NO-DNA and 4-
0HE2-Cu(II)-DNA in the sera of patients with prostate cancer, (a) Cancer sera 
1 and 2 by native DNA (D, o), 4-OHE2-NO-DNA (•, T) and 4-OHE2-
Cu(II)-DNA (•, A), (b) Cancer sera 3 and 4 by native DNA (a, o), 4-OHE2-
NO-DNA (•, •) and 4-OHE2-Cu(II)-DNA (T, A). The microtitre plates 
were coated with the respective antigen (2.5 |ig/ml). 
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Fig. 44. Detection of autoantibodies against native DNA, 4-OHE2-NO-DNA and 4-
0HE2-Cu(II)-DNA in the sera of patients with prostate cancer, (a) Cancer sera 5 
and 6 by native DNA (a, o), 4-OHE2-NO-DNA (A, •) and 4-OHE2-Cu(II)-
DNA (•, T), (b) Cancer sera 7 and 8 by native DNA (D, o), 4-OHE2-NO-
DNA (A, •) and 4-OHE2-Cu(n)-DNA (•, T). The microtitre plates were 
coated with the respective antigen (2.5 \ig/ml). 
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Fig. 45. Detection of autoantibodies against native DNA, 4-OHE2-NO-DNA and 4-OHE2-
Cu(II)-DNA in the sera of patients with lung cancer, (a) Cancer sera 1 and 2 by 
native DNA (a, o), 4-OHE2-NO-DNA (A, T) and 4-OHE2-Cu(II)-DNA (•, • ) , 
(b) Cancer sera 3 and 4 by native DNA (D, o), 4-OHE2-NO-DNA (•, T) and 4-
0HE2-Cu(II)-DNA (•, A). The microtitre plates were coated with the respective 
antigen (2.5 fxg/ml). 
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Fig. 46. Detection of autoantibodies against native DNA, 4-OHE2-NO-DNA and 4-
0HE2-Cu(II)-DNA in the sera of patients with cancer of (a) Lung, sera 5 and 6 
by native DNA (D, o), 4-OHE2-NO-DNA (A, T) and 4-OHE2-Cu(II)-DNA 
(• , • ) , (b) sera 7 (lung) and hepatocellular, sera 1 by native DNA (D, o), 4-
OHE2-NO-DNA (A, T) and 4-OHE2-Cu(II)-DNA (•, 
plates were coated with the respective antigen (2.5 p.g/ml). 
»). The microtitre 
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Fig. 47. Detection of autoantibodies against native DNA, 4-OHE2-NO-DNA and 4-
0HE2-Cu(II)-DNA in the sera of patients with hepatocellular cancer, (a) 
Cancer sera 2 and 3 by native DNA (D, o), 4-OHE2-NO-DNA (•, T) and 4-
0HE2-Cu(II)-DNA (A, •), (b) Cancer sera 4 and 5 by native DNA (D, o), 4-
OHE2-NO-DNA (A, T) and 4-OHE2-Cu(II)-DNA (•, • ) . The microtitre 
plates were coated with the respective antigen (2.5 jig/ml). 
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Fig. 48. Detection of autoantibodies against native DNA, 4-OHE2-NO-DNA and 4-
0HE2-Cu(II)-DNA in the sera of patients with cancer of (a) Hepatocellular, 
sera 6 and 7 by native DNA (D, o), 4-OHE2-NO-DNA (•, T) and 4-OHE2-
Cu(II)-DNA (•, A), (b) Gall bladder, sera 1 and 2 by native DNA (n, o), 4-
OHE2-NO-DNA (A, T) and 4-OHE2-Cu(II)-DNA (•, •) . The microtitre plates 
were coated with the respective antigen (2.5 ^g/ml). 
107 
2 0 
4 0 -
O 
— 60 H 
8 0 -
0.01 100 
Inhibitor Concentration (|jg/ml) 
Fig. 49. Detection of autoantibodies against native DNA, 4-OHE2-NO-DNA and 4-OHE2-
Cu(II)-DNA in the sera of patients with gall bladder cancer, (a) Cancer sera 3 
and 4 by native DNA (D, o), 4-OHE2-NO-DNA (A, • ) and 4-OHE2-Cu(II)-
DNA (• , T), (b) Cancer sera 5 and 6 by native DNA (n, o), 4-OHE2-NO-DNA 
(A, T) and 4-OHE2-Cu(II)-DNA (•, • ) . The microtitre plates were coated with 
the respective antigen (2.5 iig/ml). 
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Fig. 50. Detection of autoantibodies against native DNA, 4-OHE2-NO-DNA and 4-OHE2-
Cu(II)-DNA in the sera of patients with cancer of (a) Gall bladder, sera 7 and 
urinary bladder, sera 1 by native DNA (D, o), 4-OHE2-NO-DNA (A, T) and 4-
0HE2-Cu(II)-DNA (•, • ) , (b) urinary bladder sera 2 and 3 by native DNA (D, 
o), and 4-OHE2-NO-DNA (A, • ) 4-OHE2-Cu(II)-DNA (• , • ) . The microtitre 
plates were coated with the respective antigen (2.5 ^g/'mi). 
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In case of urinary bladder cancer, sera showed a maximum inhibition of 66.9% 
with 4-OHE2-NO-DNA and 65.7% with 4-OHE2-Cu(II)-DNA. With nDNA, 
maximum inhibition of 41.5% was obtained (Fig. 50, 51). Mean percent inhibition in 
urinary bladder cancer was found to be 52.7±10.3, 49.3±12.3% and 31.7±10.8% with 
4-OHE2-NO-DNA, 4-OHE2-Cu(II)-DNA and nDNA, respectively. The binding data 
of cancer sera with native and modified DNA are shown in Table 6. 
Purification of cancer IgG 
Cancer IgG was purified by affinity cliromatography on Protein-A Agarose 
column (Fig. 52). Purified IgG migrated as a single homogenous band on SDS-PAGE 
under non-reducing conditions (Fig. 52inset). 
Band shift assay 
The binding of native and mouified DNA to cancer IgG was detected by band 
shift assay. Constant amount of antigens were incubated with varying amounts of 
cancer IgG for 2 hr at 37°C and overnight at 4°C.The resulting immune complexes 
were electrophoresed on 1% agarose for 2 hr at 30 mA. Figures 53 and 54 show the 
binding of cancer IgG to native and 4-OHE2-NO and 4-OHE2-Cu(II) modified DNA. 
With increasing concentration of IgG, the formation of high molecular weight immune 
complexes increased as judged by their fluorescence intensity, whereas, the amount of 
unbound DNA showed a proportional decrease in intensity. No appreciable change 
was observed with native DNA. 
Probing oxidative DNA damage in cancer patients using anti-4-
OHE2-NO-DNA antibody 
Genomic DNA was isolated fi-om lymphocytes of cancer patients. The purity 
and concentration of the DNA preparations were ascertained by A260 and A2go 
measurements. Anti-4-OHE2-NO-DNA antibody was used as a probe to detect 
oxidative damage in isolated DNA of cancer patients. DNA isolated from normal, 
healthy individuals served as controls. Microtitre plates were coated with 4-OHE2-
NO-DNA. 
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Fig. 51. Detection of autoantibodies against native DNA, 4-OHE2-NO-DNA and 4-
0HE2-Cu(n)-DNA in the sera of patients witli urinary bladder cancer, (a) 
Cancer sera 4 and 5 by native DNA (D, o), 4-OHE2-NO-DNA (T, •) and 4-
0HE2-Cu(n)-DNA (•, A), (b) Cancer sera 6 and 7 by native DNA (D, o), 4-
OHE2-NO-DNA (A, T) and 4-OHE2-Cu(II)-DNA (•, • ) . The microtitre 
plates were coated with the respective antigen (2.5 |ig/ml). 
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TABLE 6 
Antibodies Against Native, 4-OHE2-NO-DNA and 4-OHE2-Cu(II)-
DNA in Cancer Sera 
Types of 
Cancer 
Breast (n= 10) 
Ovarian (n=9) 
Uterus (n=9) 
Prostate (n=8) 
Lungs (n=7) 
Hepatocellular 
(n=7) 
Gall bladder 
(n=7) 
Urinary 
bladder (n=7) 
NHS(n=15) 
Maximum % inhibition at 20 pg/ml 
by 
Native DNA" 
35, 31.6, 36.4, 48.8, 47, 
25.3, 28.3, 29.6,27.3, 34.4 
36.1, 32.4, 38.2, 46.5, 
49.7,17.6,23.1,26.6,32.2 
36.1, 37.6, 28.2, 30.2, 49, 
43.1,28.3,43.8,15.8) 
24.8, 25.6, 19, 20.7, 36.7, 
36.2,42.7, 30.7 
19.9, 24.8, 35.8, 36, 45.6, 
33.1,40.5 
32.8,28.5,21, 19.7,35.5, 
31.2,40.9 
38.5, 24.6, 36.4, 43.3, 
14.9,18.9,21.5 
22.6, 38.7, 12.9, 38.4, 
39.6,41.5,28.2 
8.5±1.1 
4-OHE2-NO-DNA'' 
51.6,57.1,59.3,64,61.7, 
55.5,66.8,59.9,54.8,67.1 
52.8,47.9,61.5,63.9,50.6, 
58.2,47.6,54.1,59.6 
55.9,41.8,66.5,68.8,63.4, 
43.3,64.7,51,63 
40.7,30.5,50.2,54.9,43.3, 
58.9, 62.3, 69.3 
51.7,48.1,49.4,65.6,53, 
59.2, 68.5 
41.8,65.8,48.7,43.7,59.1, 
60.2, 58.7 
47.7,59.1,56.7,58.9,51, 
69.5, 69.2 
41.2,48.2,40.6,51.8,56.3, 
64.1,66.9 
10.1±1.5 
4-OHE2-Cu(II)-DNA'^ 
65.4,64,61.9,58.6,48,63.1, 
62, 74.8, 57.2, 64.6 
51.1,50,48.8,65.2,63.2,64.8, 
54.9, 58.2, 50.6 
63, 62.5, 52,49.8, 64.3, 54.7, 
71.4,58,60.4 
40.9,37.6,63,58.6,50.1,65.7, 
63.8, 56.4 
49.9,47.9, 66.9,48.8, 64.8, 
51.1,74.5 
51.2,60.4,46.8,62.9,56.5, 
69.8, 40.5 
49.2, 58.4,49.3,60.4, 45.2, 
61.9,55.1 
51.1,40.5,27.3,49.7,65.7,56, 
55.3 
11.5±1.2 
The microtiter plates were coated with the respective antigen (2.5 |ag/ml), n denotes the 
number of sera. The values indicate maximum percent inhibition at 20 \xg/ml of competitor, 
'n DNA as inhibitor, ^4-OHE2-NO-DNA,' 4-OHE2-Cu(II)-DNA as inhibitor. Each group of 
cancer patients has significantly high inhibition than NHS (''p<0.001, '^ p<0.001). 
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Fig. 52. Elution profile of cancer IgG on Protein-A Agarose affinity column. 
Inset: SDS-PAGE of purified IgG on 7.5% polyacrylamide gel. 
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Fig. 53. (a) Band shift assay of breast cancer IgG binding to 4-OHE2-NO-DNA and 
(b) native plasmid DNA. DNA (0.5 jig each) was incubated with buffer (lane 
2) and 20, 40, 60, 80, 100 and 120 ^ g IgG through lanes 3 to 8 respectively, 
for 2 hr at 37° C and overnight at 4° C. Electrophoresis was performed on 
1% agarose for two hr at 30 mA. Lane 1 contains 100 base pair ladder. 
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Fig. 54. (a) Band shift assay of breast cancer IgG binding to 4-OHE2-Cu(II)-DNA 
and (b) native plasmid DNA. DNA (0.5 ^g each) was incubated with buffer 
(lane 2) and 20, 40, 60, 80, 100 and 120 ng IgG through lanes 3 to 8 
respectively, for 2 hrs at 37° C and overnight at 4° C. Electrophoresis was 
performed on 1% agarose for two hrs at 30 mA. Lane 1 contains 100 base 
pair ladder. 
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DNA was isolated from the sera of five patients with breast cancer. DNA 
samples induced inhibition ranging from 51.3% to 73.9% in the anti-4-OHE2-NO-
DNA antibodies binding to immunogen (mean inhibition being 60.8±9%) (Fig. 55a). 
Samples of DNA from four patients with ovarian cancer produced maximum 
inhibition of 44.5% to 64.2% with mean percent inhibition of 56.7±9.2% (Fig. 55b). 
Another four DNA samples, from sera of patients suffering from uterus cancer and 
prostate cancer were isolated. Maximum inhibition of 65% in the antibody activity 
was obtained in case of uterus cancer DNA (Fig. 56a). DNA samples from prostate 
cancer showed maximum inhibition of 68.1% in the anti-4-OHE2-NO-DNA antibodies 
binding (Fig. 56b). The mean percent inhibition for the former was 57.9±6.9% while 
for later, it was 54.4±11.2%. 
Similarly, DNA samples were isolated from patients suffering from lung and 
hepatocellular carcinoma showed a maximum inhibition of 65.5% and 62.6% in the 
anti-4-OHE2-NO-DNA antibody activity (Fig. 57). The mean percent inhibition in 
both case were found to be 52.2±16.9% and 48.6±15.4%, respectively. 
Four DNA samples each from the sera of gall bladder and urinary bladder 
cancer patients were isolated. Maximum inhibitions in the range of 40.7% to 65.5% 
were obtained in case of DNA from gall bladder cancer, while DNA samples from 
cancer of urinary bladder showed inhibitions of 30.4% to 60.7% (Fig. 58). The binding 
data of the anti-4-OHE2-NO-DNA antibody to DNA isolated from cancer patients is 
summarized in Table 7. 
Probing oxidative DNA damage in cancer patients using anti-4-
OHE2-Cu(II)-DNA antibody 
DNA samples from breast cancer patients showed a maximum inhibition of 
71.6% in the activity of anti-4-OHE2-Cu(II)-DNA antibodies (mean inhibition being 
57.6±11.2%) (Fig. 59a). Samples of DNA from patients with ovarian cancer produced 
a maximum inhibition of 67.4%, mean being 50.6±\7.2% (Fig. 59b). 
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Fig. 55. Inhibition of anti-4-OHE2-NO-DNA antibody binding to 4-OHE2-NO-DNA 
by DNA isolated from lymphocytes of (a) breast cancer patients (•, •, • , 
A, T) and (b) patients ovarian carcinoma (A, •, T, • ) . (o) represents 
normal human DNA. Microtitre plates were coated with 4-OHE2-NO-DNA 
(2.5 ng/ml). 
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Fig. 56. Inhibition of anti-4-OHE2-NO-DNA antibody binding to 4-OHE2-NO-DNA 
by DNA isolated from lymphocytes of (a) uterus cancer patients (A, • , T, 
•) and (b) patients with cancer of prostate (•, T, •, A), (o) represents 
normal human DNA. Microtitre plates were coated with 4-OHE2-NO-DNA 
(2.5 [ig/ml). 
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Fig. 57. Inhibition of anti-4-OHE2-NO-DNA antibody binding to 4-OHE2-NO-DNA 
by DNA isolated from lymphocytes of (a) lung cancer patients ( • , • , • , 
A) and (b) patients with hepatocellular carcinoma (•, T, • , A), (o) 
represents normal human DNA. Microtitre plates were coated with 4-OHE2-
NO-DNA (2.5 ng/ml). 
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Fig. 58. Inhibition of anti-4-OHE2-NO-DNA antibody binding to 4-OHE2-NO-DNA 
by DNA isolated from lymphocytes of (a) gall bladder cancer (A, •, • , • ) 
and (b) urinary bladder cancer (A, •, • , T). (o) represents normal human 
DNA. Microtitre plates were coated with 4-OHE2-NO-DNA (2.5 |ig/ml). 
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TABLE 7 
Binding of Anti-4-OHE2-NO-DNA antibodies to DNA isolated from 
lymphocytes of cancer patients 
Type of cancer 
Breast 
Ovarian 
Uterus 
Prostate 
Lung 
Hepatocellular 
Gall bladder 
Urinary bladder 
Normal human DNA 
Number of 
samples 
5 
4 
4 
4 
4 
4 
4 
4 
19 
Max. percent inhibition 
at 20 fig/ml 
55.2,57.8,66,73.9,51.3 
63.7, 64.2, 44.5, 54.6 
65,53.1,51,62.7 
68.1,57.5,41.5,50.8 
65.5,31.1,66.3,46.1 
60.2,41.7,62.6,30.1 
65.5,39.5,40.7,42.2 
60.7,41.6,32.4,30.4 
— 
Mean ±SD 
60.8±9 
56.719.2 
57.9±6.9 
54.4±11.2 
52.2±16.9 
48.6±15.4 
46.9+23.3 
41.2+13.8 
9.9±1.5 
The microtitre plates were coated with 4-OHE2-NO-DNA (2.5 ^g/ml). 
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Fig. 59. Inhibition of anti-4-OHE2-Cu(II)-DNA antibody binding to 4-OHE2-Cu(II)-
DNA by DNA isolated from lymphocytes of (a) breast cancer (•, A, •, •, 
T) and (b) ovarian carcinoma (T, •, • , A), (o) represents normal human 
DNA. Microtitre plates were coated with 4-OHE2-Cu(n)-DNA (2.5 pg/ml). 
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DNA isolated from equal number of patients with lung cancer, hepatocellular 
carcinoma, gall bladder cancer, and urinary bladder showed maximum inhibition of 
67%, 63.1%, 67.8%) and 57.8%, respectively (Figs. 60-62). The mean percent inhibitions 
of the antibody binding are summarized in Table 8. 
Reactivity of SLE sera with native and modifiedl DNA 
Sera from twenty patients with systemic lupus eiyihematosus were tested for 
binding to native, 4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA. The binding affinity of 
serum antibodies to native and modified DNA was determined by direct binding ELISA. 
^^ [early all the twenty SLE sera showed stronger binding to 4-OHE2-NO-DNA and 4-
0HE2-Cu(II)-DNA. No appreciable binding was observed with the sera of normal 
subjects (Fig. 63). The specificity of SLE sera for native and modified DNA was 
evaluated by inhibition ELISA (Figs. 64-68). 
Native DNA showed maximum inhibitions in the range of 18.4% to 53.1% in 
twenty SLE sera, 4-OHE2-NO-DNA showed high percent inhibition ranging from 
36.9% to 66.4%. Similarly 4-OHE2-Cu(II)-DNA showed high percent inhibition ranging 
from 39% to 72.4%. The inhibition data of native DNA, 4-OHE2-NO-DNA and 4-
0HE2-Cu(II)-DNA with SLE autoantibodies are summarized in Table 9. 
Purification of SLE IgG 
SLE IgG was purified by affinity chromatography on Protein-A Agarose column 
(Fig. 69). SDS-PAGE of purified IgG under non-reducing conditions showed a single 
homogenous band (Fig. 69 inset). 
Band shift assay 
Band shift assay was employed to ftirther confirm and visualize the interaction 
of native and modified DNA with SLE autoantibodies. A constant amount of the 
antigen was incubated with increasing amount (0-80 jag) of SLE IgG for 2 hr at 37°C 
and overnight at 4°C. These immune complexes were then electrophoresed on 1% 
agarose for 2 hr at 30 mA. Figure 70 show the binding of SLE autoantibodies to native 
and 4-0HE/-N0-DNA, while Figure 71 shows the binding to native and 4-OHE2-
Cu(II)-DNA. 
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With increasing concentrations of IgG there is corresponding increase in the 
formation of high molecular weight immune complexes which resulted in retarded 
mobility and corresponding decrease in the fluorescence intensity of the unbound 
antigen. Native DNA under identical conditions did not show appreciable binding. 
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Fig. 60. Inhibition of anti-4-OHE2-Cu(II)-DNA antibody binding to 4-OHE2-Cu(II)-DNA by 
DNA isolated from lymphocytes of (a) uterus cancer (•, • , A, T) and (b) prostate 
cancer ( • , • , A, • ) . (o) represents normal human DNA. Microtitre plates were 
coated with 4-OHE2-Cu(II)-DNA (2.5 ^ig/ml). 
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Fig. 61. Inhibition of anti-4-OHE2-Cu(II)-DNA antibody binding to 4-OHE2-Cu(II)-DNA 
by DNA isolated from lymphocytes of (a) lung cancer (•, • , A, T) and (b) 
hepatocellular cancer ( • , • , A, • ) . (o) represents normal human DNA. 
Microtitre plates were coated with 4-OHE2-Cu(II)-DNA (2.5 ^ g/ml). 
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Fig. 62. Inhibition of anti-4-OHE2-Cu(II)-DNA antibody binding to 4-OHE2-Cu(II)-
DNA by DNA isolated from lymphocytes of (a) gall bladder cancer (•, • , 
• , • ) and (b) urinary bladder cancer (•, • , A, T). (o) represents normal 
human DNA. Microtitre plates were coated with 4-OHE2-Cu(II)-DNA (2.5 
|ag/ml). 
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TABLE 8 
Binding of Anti-4-OHE2-Cu(II)-DNA Antibody to DNA Isolated from 
Lymphocytes of Cancer Patients 
Type of cancer 
Breast 
Ovarian 
Uterus 
Prostrate 
Lungs 
Hepatocellular 
Gall bladder 
Urinary bladder 
Normal human DNA 
Number of 
samples 
5 
4 
5 
4 
4 
4 
4 
4 
19 
Max. percent inhibition 
at 20ng/ml 
41.6,53.7,63.9,71.6, 
57.4 
45.8, 60.8, 67.4,28.7 
61.3,54.1,61.4,69.5, 
28.1 
37.4, 60, 59, 48.8 
32.8, 39.2, 67, 56.3 
43.3,63.1,58.6,28.2 
11.2,52.8,67.8,45 
38.8,37.7,41.8,57.8 
— 
Mean ±SD 
57.6+11.2 
50.6+17.2 
54.8+15.9 
51.3±10.5 
48.8±15.9 
48.2+15.8 
44.2123.9 
43.9±9.3 
9.9±1.5 
The microtitre plates were coated with 4-OHE2-Cu(II)-DNA (2.5 jag/ml). 
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Fig. 63 (a). Direct binding ELISA of SLE anti-DNA autoantibodies to native (n), 4-OHE2-
NO-DNA (0) and 4-OHE2-Cu(II)-DNA (•). Microtitre plates were coated with 2.5 
\ig/m\ of respective antigen. 
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Fig. 63 (b). Direct binding ELISA of SLE anti-DNA autoantibodies to native (D), 4-OHE2-
NO-DNA (0 ) and 4-OHE2-Cu(II)-DNA (•). Microtitre plates were coated with 
2.5 |ig/ml of respective antigen. 
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Fig. 64. Inhibition of SLE autoantibodies binding by native DNA, 4-OHE2-NO-DNA 
and 4-OHE2-Cu(II)-DNA. (a) SLE sera 1 and 2 by native DNA (n, o), 4-
OHE2-NO-DNA (•, • ) and 4-OHE2-Cu(II)-DNA ( T , A) (b) SLE sera 3 
and 4 by native DNA (o, D),4-OHE2-NO-DNA (•, A) and 4-OHE2-Cu(II)-
DNA ( T , • ) . The microtitre plates were coated with the respective antigen 
(2.5 ^ig/ml). 
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Fig. 65. Detection of autoantibodies against native DNA, 4-OHE2-NO-DNA and 4-OHE2-
Cu(II)-DNA in the sera of patients with urinary bladder cancer, (a) SLE sera 5 
and 6 by native DNA (D, o), 4-OHE2-NO-DNA (V, • ) and 4-OHE2-Cu(II)-
DNA (•, A), (b) SLE sera 7 and 8 by native DNA (D, o), 4-OHE2-NO-DNA 
(A, T ) and 4-OHE2-Cu(II)-DNA (•, • ) . The microtitre plates were coated with 
the respective antigen (2.5 |ag/m]). 
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Fig. 66. Inhibition of SLE autoantibodies binding by native DNA, 4-OHE2-NO-DNA 
and 4-OHE2-Cu(II)DNA. (a) SLE sera 9 and 10 by native DNA (o, n), 4-
OHE2-NO-DNA (A, • ) and 4-OHE2-Cu(II)-DNA ( T , • ) , (b) SLE sera 11 
and 12 by native DNA (D, o), 4-OHE2-NO-DNA ( • , A) and 4-OHE2-
Cu(II)-DNA (B, • ) . The microtitre plates were coated with the respective 
antigen (2.5 iig/ml). 
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Fig. 67. Inhibition of SLE autoantibodies binding by native DNA, 4-OHE2-NO-DNA 
and 4-OHE2-Cu(II)-DNA. (a) SLE sera 13 and 14 by native DNA (o, D), 4-
OHE2-NO-DNA ( T , • ) and 4-OHE2-Cu(II)-DNA (A, • ) , (b) SLE sera 15 
and 16 by native DNA (D, o), 4-OHE2-NO-DNA (•, • ) and 4-OHE2-
Cu(II)-DNA (A, • ) . The microtitre plates were coated with respective 
antigen (2.5 fJ.g/ml). 
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Fig. 68. Inhibition of SLE autoantibodies binding by native DNA, 4-OHE2-NO-DNA and 
4-OHE2-Cu(II)-DNA. (a) SLE sera 17 and 18 by native DNA (D, o), 4-OHE2-
NO-DNA (A, •) and 4-OHE2-Cu(II)-DNA (•, • ) , (b) SLE sera 19 and 20 by 
native DNA (D, O), 4-OHE2-NO-DNA (•, T) and 4-OHE2-Cu(II)-DNA (•, A). 
The microtitre plates were coated with respective antigen (2.5 i^g/ml). 
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TABLE 9 
Autoantibodies Against nDNA, 4-OHE2-NO-DNA and 4-OHE2-Cu(II)-
DNA in SLE Sera 
Maximum % inhibition at 20 |ug/ml 
SLE Serum Native DNA 4-OHE2-NO-DNA 4-OHE2-Cu(II)-DNA 
60.2 70.5 
52.9 59.8 
36.9 39.0 
57.7 67.5 
61.0 54.0 
40.2 50.4 
62.8 49.8 
48.3 50.6 
63.7 67.1 
56.4 64.4 
52.9 51.0 
54.1 57.7 
65.0 59.4 
56.8 61.9 
57.1 57.4 
60.9 60.1 
58.3 59.5 
56.3 69.2 
66.4 57.3 
57.4 72.4 
The microtitie plate was coated with the respective antigen (2.5 |ig/ml). 
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Fig. 69. Elution profile of SLE IgG on Protein-A Agarose affinity column. 
Inset: SDS-PAGE of purified IgG on 7.5% polyacrylamide gel. 
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Fig. 70. Band shift assay of SLE IgG with (a) 4-OHE2-NO-DNA and (b) native plasmid 
DNA. (a) Lanes 2-8 contained 4-OHE2-NO-DNA (0.5 ng) with 0, 10, 20, 30, 
40, 60 and 80 ng SLE IgG. (b) Lanes 2-7 contained native plasmid DNA (0.5 
|ig) with 0, 10, 20, 40, 60 and 80 |ig SLE IgG. Lane 1 contains 100 base pair 
ladder in each case. 
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(a) (b) 
Fig. 71. Band shift assay of SLE IgG with (a) 4-OHE2-Cu(II)-DNA and (b) native 
plasmid DNA. (a) Lanes 2-8 contained 4-OHE2-Cu(II)-DNA (0.5 p.g) with 
0, 10, 20, 30, 40, 60 and 80 ^g SLE IgG. (b) Lanes 2-7 contained native 
plasmid DNA (0.5 ^g) with 0, 10, 20, 40, 60 and 80 ^g SLE IgG. Lane 1 
contains 100 base pair ladder in each case. 
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DISCUSSION 
Estrogens are a group of steroid hormone that have been implicated to be 
complete carcinogens in breast (Mobley and Brueggemeier, 2004) and possible 
mechanisms of carcinogenesis may also be similar for other types of cancers e.g. 
renal, brain, endometrial, ovarian and prostate. Estrogens, including the natural 
hormones estradiol and estrone, induce tumors in various organs of experimental 
animal (Cavalieri et al., 2000). Estrogen-induced cell transformation and tumor 
development are mediated by estrogen receptor-based proliferation of cells carrying 
spontaneous replication errors (Li and Li, 1990; Feigelson and Hederson, 1996) and 
disruption of spindle formation and subsequent numeric chromosomal changes 
(Barrett and Tsutsui, 1996). 
Estrogen mediated carcinogenesis involves oxidative stress. There are several 
reports, which correlate estrogen-induced breast cancer and oxidative stress (Liehr, 
1999; Cavalieri et al., 2000; Yager, 2000; Chen et al, 2000; Jefcoate et al., 2000). In 
various animal models, a variety of estrogens are capable of acting as complete 
carcinogens through a mechanism that involves oxidative stress in kidney, liver and 
breast tissue (Yager and Liehr, 1996). Serum markers for DNA damage have also been 
shown to increase in women diagnosed with breast cancer (Cavalieri, 2000). 
Furthermore, oxidative DNA damage is reportedly increased in breast cancer tissues 
relative to normal breast (Musarrat et al, 1996). The enzyme 8-oxo-2-deoxyguanosine 
(8-oxo-dG) triphosphatase has also been found to be induced in the tumor tissues of 
patients with breast cancer and the base excision repair products of 8-oxo-dG have 
been reported to increase in the urine of cancer patients (Taggesson et al., 1995; Wani 
et al., 1998). Therefore, estrogen play a major role in breast cancer initiation and 
progression and one of the mechanisms include an oxidative stress-mediated pathway. 
Estrogen may be oxidized by extra hepatic cytochrome P450 enzyme to 
hydroxy-catecholestrogens and further oxidized to the semiquinone and quinone 
forms. Redox cycling between the quinone and unstable semiquinone form cause 
hydroxyl radical formation that can lead to hydroxylated nucleotide bases and 
permanent mutation (Liehr, 1997; Liehr, 2000). The main metabolites of estradiol, 2-
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and 4-hyhroxylated catechols contain the hydroxy! groups, which predispose them to 
further oxidation (Liehr, 1997). The catechols are inactivated by 0-methylation 
mediated by catechol-0-methyltransferase as well as by glucuronidation and 
sulphation (Liehr, 2000; Roftogianis et al., 2000). The metabolic clearance of 4-
hydroxyestradiol is slower than that of 2-hydroxyestradiol (Roy et al., 1990). 
In estrogen-induced carcinogenesis, estrogen metabolites particularly catechol 
estrogens, are involved in the initiation process through oxidative DNA damage and 
estrogens themselves enhance cell proliferation, leading to tumor prom^otion (Hiraku et 
al., 2001). Estrogen-induced direct or indirect DNA damage in vitro or in vivo 
includes single-strand breaks, 8-hydroxylation of guanine bases, bulky DNA adducts 
and estrogen-DNA adducts (Liehr, 2000). The 4-catecholestrogen that forms 
predominantly depurinating adducts, is carcinogenic, whereas the non-carcinogenic 2-
catecholestrogen exclusively forms stable DNA adducts (Cavalieri, 2000). 
Estrogen and their metabolites have been implicated in systemic lupus 
erythematosus (SLE) and other autoimmune diseases (Weidler et al., 2004). Abnormal 
estrogen metabolism has been demonstrated in patients with SLE of both sexes, with 
an increase in 16a-hydroxyestrone concentration (Lahita, 1979). SLE is a prototype 
autoimmune disease characterized by a marked diversity of organ involvement and 
fluctuation in disease activity. The exact etiology of SLE is unknown, presence of 
anti-DNA antibodies are strongly correlated with the SLE (Tan, 1989). Estradiol has 
been reported to increase IgG and IgM pioduction by peripheral blood mononuclear 
cell in SLE patients, which lead to elevated levels of polyclonal IgG, including IgG 
anti-ds DNA, by enhancing B cell activity (Kanda et al., 1999). 
In the present study pUC 18 plasmid DNA was isolated from E. coli and was 
modified by synergistic action of catechol estrogen (4-OHE2) and nitric oxide (HO) 
releasing compound (SNP). The treatment induces single strand breaks in the plasmid 
DNA as depicted by digestion studies by single strand specific nuclease SI. However, 
negligible single strand breaks were observed on treatment with either NO or a 
cetechol estrogen alone. The results are consistent with the observations that single 
strand are generated on treatment with catecholestrogen and NO (Yoshic and Oshima, 
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1998; Muzandu et al, 2005). Similarly, treatment of DNA with 4-OHE2 and Cu(II) 
(CuCh) results in extensive modification of DNA, leading to strand breaks. No 
perceptible change in DNA on incubation with either 4-OHE2 or Cu(II) alone clearly 
proves that the modifications are produced upon synergestic action of Cu(II) and 
catecholestrogen. 
The UV absorption spectra of 4-OHE2-NO-DNA showed hyperchromicity of 
26.9% at 260 nm. This could be attributed to the generation of single strand breaks aiid 
modification of bases in DNA. The results are indicative of the loss of the double 
helical structure of plasmid DNA and subsequent destabilization of the double helix 
due to the generation of single strand regions in the DNA as a result of 4-OHE2-NO 
induced modification. 
UV absorption spectra of 4-OHE2-Cu(II)-DNA shows increase in absorbance at 
260 nm. This could also be attributed to the generation of strand breaks, modification 
of bases and loss in the double helical structure of plasmid DNA. 
Fluorescence spectra of both native and 4-OHE2-NO-DNA were taken in 
presence of ethidium bromide. An increase in the fluorescence intensity was seen in 
case of 4-OHE2-NO-DNA indicating exposure of fluorophoric group(s) on DNA upon 
modification. A decrease in the fluorescence intensity of the 4-OHE2-Cu(II)-DNA 
compared to nDNA confirms the destruction of structural integrity of DNA upon 
modification. CD spectra of modified DNA showed decrease in ellipticity indicating 
reduced stacking as the molecule open up due to single or double strand breaks. 
Thermal denaturation of 4-OHE2-NO modified DNA showed a net decrease of 
6.5 °C in Tm value as compared to its unmodified native form. Similarly thermal 
denaturation profile of native and 4-OHE2-Cu(II) modified DNA showed a net 
decrease of 7.5 °C in the Tm value. This, along with early onset of melting upon 
modification is a result of the presence of single strand regions in the modified DNA 
and partial destruction in its secondary structure. Base stacking as well as hydrogen 
binding is involved in stabilizing the native structure of DNA and their disruption by 
high temperature favors denaturafion (Casperson and Voss, 1983; Thomas, 1993). The 
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decresed Tm of modified DNA, therefore points towards destabilization of these 
interactions and consequently helix destabilization. 
Digestion of native and 4-OHE2-NO-DNA with restriction enzymes such as 
Pvu I, Pvu II and Ssp I shows that modification induced by 4-OHE2-NO is GC or TA 
specific. Similarly digestion of native and 4-OHE2-Cu(II)-DNA with different 
restriction enzymes show that TC and GC sites have been modified extensively after 
treatment with 4-OHE2-Cu(II). 
Estrogen-induced direct and indirect DNA damage include not only single-
strand breaks and bulky DNA adducts but also modification of bases (Liehr, 2000; 
Cavalieri, 2000). In case of both, 4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA, 
maximum modification was achieved for thymine, followed by guanine. The cytosine 
was modified minimally in both the modified DNA. 
Studies by various radical scavenging species indicate that single strand breaks 
and modification in DNA induced by 4-OHE2 and NO can be inhibited by NO-
trapping agent (carboxy-PTIO) and sodium azide, suggesting that concurrent 
generation of NO and O2 is necessary for DNA modification. Uric acid, which may 
scavenge peroxynitrite by forming a nitrated uric acid product (Skirmer et al., 1998), 
also inhibit the modification of DNA induced by 4-OHE2-NO. It has been reported 
that NO and 0'2~ react rapidly to form peroxynitrite, which induce DNA strand breaks 
in vitro (Dixit et al., 2005). The inhibitory effects of catalase and bathocuproine on 
modification of DNA by 4-OHE2-Cu(II) suggest that H2O2 and Cu(I) participate in 
DNA modification through formation of the Cu(I)-hydroperoxo complex. Scavengers 
of 'OH have no effect on DNA modification indicating free hydroxyl radical is not 
involve during reaction. Our results are consistent with the observations that Cu(I)-
hydroperoxo complex, rather than "OH is responsible for DNA breakage (Hiraku et 
al.,2001). 
Native DNA is a proven poor immunogen (Isenberg et al., 1994), whereas double 
stranded RNA, RNA-DNA hybrids, double helical polydeoxyribonucleotides, 
ribohomopolymers, DNA modified with drugs, hormones, DNA in complexes with 
DNA binding proteins are highly immunogenic (Stollar, 1975; Anderson et ai., 1988a; 
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Desai et al., 1993; Moinuddin and Ali, 1994; Hasan et al., 1995; Theofilopoulos, 
1995; Aijumand et al., 1997). The immunogenicity of DNA in vivo may therefore, 
depend upon structure or processes that render DNA immunogenic (Rekvig et al., 
1997). Bacterial DNA has potent immunomodulatory properties that is mitogenic for 
murine B cells and can induce both proliferation and antibody production (Pisetsky, 
2000). The mitogenic activity of DNA was dependent on sequence specific 
determinants that can be presented by synthetic DNA duplexes (GC rich region) as 
well as bacterial DNA, suggesting that DNA regions enriched in GC content have 
enhanced immunological activity. 
Modified DNA species, 4-OHE2-NO-DNA and 4-OHE2-Cu(Il)-DNA were 
found to be highly immunogenic in rabbits, inducing high titre antibodies as detected 
in ELISA. Antigenic specificity of purified IgG was confirmed by inhibition ELISA. 
A maximum of 91.3% inhibition of anti-4-OHE2-NO-DNA antibody with immunogen 
as inhibitor was observed at 20 |ig/ml. A maximum of 92.3% inhibition in the binding 
of anti-4-OHE2-Cu(II)-DNA antibody with immunogen as an inhibitor at 20 ^g/ml 
was observed and 3.73 pg/ml of immunogen was required for 50% inhibition. In 
addition, the induced antibodies in both case showed lesser binding of < 40% to the 
native DNA. Specific recognition of induced antibodies for their respective 
immunogen was also evaluated by band shift assay. Increased immune complex 
deposition in the well with decreased residual band fluorescence as a fraction of IgG 
concentration demoiistrate the highly immunogen specific nature of the induced 
antibodies. The data clearly shows that DNA modified with 4-OHE2-NO and 4-OHE2-
Cu(ll) was highly immunogenic inducing immunogen specific high titre anfibody 
activity response. 
Native human and calf thymus DNA showed inhibitions of 38.5% and 38.2% 
respectively, whereas their modified forms showed higher inhibifion of 65.3% and 
62% respectively. These results demonstrate the preferential recognition of 4-OHE2-
NO modified epitopes on the nucleic acid by immune IgG. Similar results were 
obtained with guanine, thymine and their 4-OHE2-NO modified forms. 4-OHE2-NO-
guanine showed maximum inhibifion of 75.3% in the antibody activity. Estrogen 
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induced DNA damage include single strand breaks, estrogen-DNA adducts, oxidation 
of guanine (8-OHdG) (Liehr, 2000). Among the oxidatively modified bases, 8-OHdG 
is apparently the most abundant and frequently formed during oxidative DNA damage 
(Higuchi and Linn, 1995; Spencer et al., 1996). It might be possible that 4-OHE2-NO-
guanine may cause changes in the DNA molecule consequently rendering it 
immunogenic resulting in antibody response. Similar results were obtained with anti-
4-OHE2-Cu(II)-DNA antibody indicating preferential recognition of 4-OHE2-Cu(II) 
modified epitopes by immune IgG especially with 4-OHE2-Cu(II)-guanine. 
Lymphorecticular malignancies and autoimmune rheumatic disease are closely 
related (Shoenfeld and Gershwin, 2000). There is a close association of a specific 
autoantibody response with distinct disease phenotypes in both cancer and 
autoimmune disease (Utanet et al., 2003). Increased levels of circulating antibodies 
and autoantibodies have been reported in sera of patients with cancer (Anderson et al., 
1988b; Chagnaud et al., 1992; Faiderbe et al., 1992; Becker et al., 1994; Soussi, 2000; 
Conrad, 2000). In addition anti-alpha-enolase antibodies have been detected in cancer 
associated retinopathy with small cell carcinoma of the lung (Dot et al., 2005). 
Elevated levels of anti-nuclear antibodies upto 27% have been reported in cancer 
(Bunham, 1972; Zeronski et al., 1972). The presence of autoantibodies reactive 
towards native and modified DNA in sera of patients with cancer was investigated in 
this study. The study consisted of sixty four sera from patients with various types of 
malignancies. 
Sera from breast cancer patients showed a higher binding to modified DNA in 
comparison to nDNA. Estrogen-mediated oxidative DNA damage in mammary gland 
epithelia includes the induction of 8-oxo-2'-deoxyguanosine, both in vitro and in vivo, 
thereby suggesting a role for oxidative stress in the initiation and progression of breast 
cancer (Mobley and Brueggemeier, 2004). Therefore estrogen modification of plasmid 
DNA might be the contributory factor in the induction and elevated levels of the 
circulating antibodies primarily against modified DNA, cross-reacting with native 
DNA, in sera of cancer patients. 
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Reactivity of serum auotantibodies from ovarian cancer patient was also 
greater towards modified DNA. It has been well established that oxidized purines were 
also increased even at sites distal to the cancerous tissue, such as ovary (Malins et al, 
1998). Therefore, the increased levels of oxidized bases in human DNA precede 
cancer development and may serve as biomarker of cancer risk (Djuric et al., 1996; 
Malins et al, 1998). The binding of autoantibodies to modified DNA substantiates 
these observations. 
A high proportion of sera from uterus cancer patients showed reactivity to 
nDNA and modified DNA. Earlier studies showed that 4-OHE2 was more 
carcinogenic than 2-OHE2 in the mouse uterus (Newbold and liehr, 2000). 
Predominant 4-hydroxylase activity has also been found in human microsomes of 
uterine myometrium and benign uterine leiomyomas (Liehr et al., 1995). Increased 
formation of 4-hydroxylated catechol estrogen, which react with DNA to form the 
depurinating adducts, suggests that the 4-hydroxyestrogen pathway producing catechol 
estrogen quinone is responsible for the genotoxic effects leading to estrogen-induced 
initiation of cancer. Our findings are therefore, consistent with the earlier observation. 
Similarly, sera of patients with prostate cancer also showed high reactivity toward 
modified DNA over nDNA. There is an accumulating evidence for the possible 
involvement of estrogen in initiation and progression of prostate tumorigenesis 
(Cavalieri et al., 2002; Chang et al., 2003; Maggiolini et al, 2004; Muzandu et al, 
2005). 
The reactivity of sera from lung cancer patients, who had a history of smoking 
for over two decades, was also greater toward modified DNA. Cigarette smoking 
contains many carcinogens and radicals that induce oxidative damage in human (Fryor 
et al , 1998). Similar activity has been shown by autoantibodies from hepatocellular 
carcinoma patients. This cancer has been strongly correlated with a high incidence of 
oxidative DNA damage (Peng et al., 2003), similar to estrogen. Hepatitis infection is 
well knovm risk factor causing ROS generation and oxidative DNA damage (Moriya 
et al., 2001). Sera from cancer of gall and urinary bladder also show greater 
recognition to modified DNA as compared to its native form. 
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Presence of autoantibodies in cancer sera reactive towards modified and native 
DNA may be attributed to 4-OHE2-NO and 4-OHE2-Cu(II) induced damage to DNA 
rendering it immunogenic. The above statement is supported by the observation that 
circulating antibodies bind preferentially to modified DNA over native DNA. In fact, 
the preferential recognition of modified epitopes by circulating antibodies clearly 
establish the immimogenicity of DNA as a result of modification 
DNA was isolated from lymphocytes of patients with various types of cancer. 
The anti-4-OHE2-NO-DNA and anti-4-OHE2-Cu(II)-DNA antibodies was used as an 
immunochemical probe to detect oxidative damage in these DNA isolates by 
competitive ELISA. Our study show that DNA samples from different cancer patients 
appreciable inhibited the binding of induced antibodies to their respective immunogen, 
indicating the presence of oxidatively altered epitopes on DNA isolated from various 
cancer patients. The DNA damage could be directly correlated to radical/estrogen 
mediated oxidative stress. 8-OHdG is kiiown to represent one of the major forms of 
oxidative DNA damage (major mutagenic lesions) that is elevated in DNA in most 
cancer patients and increases the risk of cancer (Musarrat et al., 1996). DNA samples 
from breast cancer patients showed high binding with anti-4-OHE2-NO-DNA antibody 
and anti-4-OHE2-Cu(II)-DNA antibody. Serum markers for oxidative DNA damage 
have been shown to increase in women diagnosed with breast cancer. Estrogen 
mediated oxidative DNA damage in mammary gland epithelia play an important role 
in the initiation and progression of breast cancer (Mobly and Brueggemeier, 2004). 
DNA samples isolated from uterus and ovarian cancer patients also showed binding to 
the antibody. These cancers also related to high oxidative stress and DNA damage due 
to estrogen. Similarly, oxidative lesions in DNA of lungs, hepatocellular, gall and 
urinary bladder cancer was confirmed by binding to antibodies due to oxidative stress, 
aging or smoking (Mizushima et al., 2001). 
Data obtained from our studies on serum antibodies and lymphocytes DNA 
isolates has a direct correlation as the isolates fi-om the blood of these cancer patients, 
whose antibodies were extensively inhibited by the modified DNA, produced 
appreciable inhibition in the anti-4-OHE2-NO-DNA and anti-4-OHE2-Cu(II)-DNA 
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induced antibodies. These results on serum autoantibodies and oxidative DNA lesions 
demonstrated that patients have oxidative lesions in their genomic DNA which may 
lead to altered antigenicity, generating antibodies against modified antigenic DNA. 
SLE is an autoimmune disease characterized by diverse array of clinical 
manifestations and production of aiitibodies to components of the cell nucleus. The 
presence of large amounts of serum antibodies to double-stranded DNA is specific for 
SLE (Hahn, 1998) and serve as immunochemical marker for the diagnosis of disease. 
SLE is predominantly a female disease (Carvera et al., 1993) and endogenous estrogen 
concentration may influence disease activity and prognosis in human SLE (Mok and 
Lau, 2003). Estrogen and its metabolites might play role in SLE and other 
autoimmune disease. Patients with SLE have increased renal excretion of mitogenic 
estrogens in relation to endogenous antiestrogens (Weidler et al., 2004). In addition, 
elevated serum concentrations of estrogen have been described in patients with SLE 
(Lahita et al., 1979). 
In the present study, autoantibodies from twenty SLE patients were screened 
by direct binding and inhibition ELISA. Sera were found to show a higher binding 
with the modified DNA as compared to native plasmid DNA. When reactivity of 
native and modified DNA with SLE sera was probed, competition ELISA results 
showed the preferential binding of modified DNA over native DNA. The results 
indicate substantial difference in recognition of 4-OHE2-NO-DNA and 4-OHE2-
Cu(Il)-DNA over native DNA. Band shift assay further substantiated the enhanced 
binding of modified DNA with SLE autoantibodies. The strong binding of anti-DNA 
IgG toward 4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA demonstrates the possible 
role of modified nucleotides in SLE pathogenesis. These are numerous reports that 
native form of DNA is non-immunogenic and the possibility of some modified form of 
native DNA acting as antigens trigger is gaining ground day by day. The present v/ork 
is also an effort in the direction which points towards the role of female sex hormone 
in DNA modification making a non-immunogenic molecule to an immunogen. 
Based on the above studies, the following conclusion can be drawn; 
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1. Treatment of DNA with 4-OHE2 and nitric oxide resulted in the formation of 
single strand breaks, base modification and consequent helix destabilization. 
2. Modification of DNA with 4-OHE2 and copper resulting in the formation of single 
and double strand breaks, modification of DNA bases and disruption of hydrogen 
bonds. 
3. Thermal transition shows that the modified polymers are less stable as compared 
to native form. 
4. 4-OHE2-NO-DNA and 4-OHE2-Cu(II)-DNA were highly immunogenic in 
experimental animals in contrast to nDNA. 
5. Induced antibodies were highly specific for respective immunogens. 
6. Antibodies in the sera of various cancer patients recognized 4-OHE2-NO-DNA and 
4-OHE2-Cu(II)-DNA to a greater extent as compared to nDNA. 
7. Anti-4-OHE2-NO-DNA and anti-4-OHE2-Cu(II)-DNA antibodies were used as an 
immunochemical probe to detect oxidative DNA damage in cancer patients. 
8. SLE autoantibodies showed preferential binding to 4-OHE2-NO-DNA and 4-OHE2-
Cu(II)-DNA over native DNA. The data once again point out the conversion of a 
non-immunogenic molecule to a potent immunogen, inducing antibodies cross 
reactive with nDNA. 
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